WO2007013671A2 - Method of diagnosing esophageal cancer - Google Patents

Abstract

In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45, S. cerevisiae, homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.

Description

DESCRIPTION METHOD OF DIAGNOSING ESOPHAGEAL CANCER

CROSS-REFERENCE TO RELATED APPLICATIONS

The present invention claims the benefit of U.S. Provisional Patent Application No. 60/703,263, filed on July 27, 2005, the disclosure of which is hereby incorporated herein by reference in its entirety for all purposes.

FIELD OF THE INVENTION

The present invention relates to methods for detecting, diagnosing, and providing a prognosis of esophageal cancer, for example esophageal squamous-cell carcinoma (ESCC), and lung cancer, as well as methods of treating and preventing esophageal cancer, esophageal cancer metastasis, esophageal cancer recurrence. Alternatively, the present invention further relates to methods for detecting, diagnosing, and providing a prognosis of cancer, including esophageal cancer, or lung cancer.

BACKGROUND OF THE INVENTION Lung cancer is the leading cause of cancer-related death in the world. Despite some advances in early detection and recent improvements in its treatment, the prognosis of the patients with lung cancer remains poor (Parkin et al, Lancet Oncol. 2001 Sep;2(9):533-43). On the other hand, esophageal squamous-cell carcinoma (ESCC) is one of the most lethal malignant tumors in the gastrointestinal carcinoma family. The majority of esophageal cancers are advanced at the time of presentation and diagnosis, rendering cure unlikely, especially by surgery alone (Shimada et ah, Surgery. 2003;133(5):486-94). In spite of the use of modern surgical techniques combined with multi-treatment modalities, such as radiotherapy and chemotherapy, the over all 5-year survival rate remains 40-60% (Tamoto et al., Clin Cancer Res. 2004;10(l l):3629-38) while that of lung cancer is only 15 % (Parkin et al, Lancet Oncol. 2001 Sep;2(9):533-43). In fact, it is reported that recurrent ESCC had developed in almost half of the patients who underwent an apparently curative resection, at a median follow up of 37.3 months (Mariette et al, Cancer. 2003; 97(7): 1616-23). Consequently, much research effort has been directed towards studies of adjuvant chemotherapy and chemoradiation, particularly in defining the best regimens from the standpoint of efficacy and minimal toxicity and in an attempt to predict response. However, developments in neoadjuvant and adjuvant therapies have led to mixed conclusions. Collectively, past studies have not shown an optimal neoadjuvant or adjuvant regimen in terms of survival benefit. Therefore, there is an urgent need for novel diagnostic tools for early detection of cancer and molecular-targeted therapies involving small- molecule and antibody-based approaches.

In that vein, several tumor markers are used for diagnosis and follow-up of patients with ESCC₅ for example, SCC (squamous-cell carcinoma antigen), CEA (carcinoembryonic antigen), and CYFRA 21-1. Recently, serum MK (midkine), CD 147, MMP-2 (matrix metalloproteinase- 2), MMP-26 and MMP-9 in patients with ESCC was reported to be associated with poor prognosis (Shimada et al, Cancer Sci. 2003;94(7):628-32; Kawaguchi et al, Cancer. 2000;89(7):1413-7; Ishibashi et al, Cancer. 2004;101(9): 1994-2000; Yamamoto et al., Carcinogenesis. 2004;25(12):2353-60). However, at present, no specific tumor marker is clinically useful for detection of ESCC at an early and potentially curative stage. Therefore, new diagnostic and therapeutic strategies such as development of molecular-targeted agents and antibodies as well as cancer vaccines, are urgently needed. Several tumor markers, such as proGPP, NSE, cytokeratin 19-fragment (CYFRA 21-1), squamous-cell carcinoma antigen (SCC), and carcinoembryonic antigen (CEA) have been increased in the circulation of lung cancer patients (Castaldo G, et al, J Clin Oncol. 1997 Nov;15(l l):3388-93.; Peck et al, Cancer Res. 1998 JuI l;58(13):2761-5.; Salerno et al, Chest. 1998 Jun;113(6):1526-32.), while SCC, CEA, and CYFRA 21-1 for ESCC, are used in clinic for diagnosis as well as in follow-up of the patients (Shimada et al, Surgery. 2003 May;133(5):486-94, Kawaguchi et al, Cancer. 2000 Oct 1 ;89(7): 1413-7). In NSCLC patients, the sensitivity of CEA was 25% in squamous-cell carcinoma and 50% in adenocarcinoma, whereas, the sensitivity of SCC was 30% in squamous- cell carcinoma (Rastel et al, Eur J Cancer. 1994;30A(5):601-6). The sensitivity of CYFRA 21-1 was 57% in squamous-cell carcinoma and 27% in adenocarcinoma (Rastel et al, Eur J Cancer. 1994;30A(5):601-6). Reportedly, the positive rate of serum SCC in patients with ESCC was 18% in stage I, 22% in stage II, 34% in stage III, and 37% in stage IV. The incidence of CEA positivity in patients with stage IV ESCC was only 16%. Although CEA was not a prognostic factor, SCC was shown to be an independent prognostic factor to pTNM factors by using multivariate analysis (Shimada et al, Surgery. 2003 May;133(5):486-94). These facts indicate that no tumor marker has been proven to be useful for detection of lung cancer and ESCC at potentially curative stage, and a limited number of practical prognostic marker is presently available for selection of treatment modalities for individual patients.

Analysis of gene-expression profiles on cDNA microarray enables the comprehensive analysis of gene expression profiles in cancer cells, and some studies describing such transcription profiles have been reported. For example, with regard to ESCC, several studies reported gene expression profiles of human ESCC that are candidates as diagnostic markers or therapeutic targets (Luo et al, Oncogene. 2004 ;23(6):1291-9; Kihara et al, Cancer Res. 2001;61(17):6474-9;. Tamoto et al, Clin Cancer Res. 2004;10(l l):3629-38). However, all of the previous studies in human ESCC involved bulk tumor tissues and, since ESCC contains various types of cells, such as mesenchymal cells and inflammatory cells, fail to reflect accurate expressional changes during esophageal carcinogenesis (Nishida et al, Cancer Res. 2005;65(2):401-9). Accordingly, more accurate studies are needed.

The present invention addresses these needs. Specifically, in an effort to understand the carcinogenic mechanisms associated with cancer and identify targets for developing novel anticancer agents, the present inventors performed large scale, genome-wide analyses of gene expression profiles found in purified populations of esophageal cancer cells, including 19 ESCC samples purified by laser microbeam microdissection (LMM), using a cDNA microarray consisting of 32,256 transcribed genes.

To isolate potential molecular targets for diagnosis, treatment, and/or prevention of lung and esophageal carcinomas, the present inventors performed a genome-wide analysis of gene expression profiles of cancer cells from 101 lung cancer and 19 ESCC patients, all of which had been purified by laser microbeam microdissection (LMM) using a cDNA microarray (Kikuchi et al, Oncogene. 2003 Apr 10;22(14):2192-205, Int J Oncol. 2006 Apr;28(4):799-805; Kakiuchi et al, MoI Cancer Res. 2003 May;l(7):485-99, Hum MoI Genet. 2004 Dec 15;13(24):3029-43. Epub 2004 Oct 20; Yamabuki T, et al, Int J Oncol. 2006 Jun;28(6): 1375-84). To verify the biological and clinicopathological significance of the respective gene products, the present inventors have established a screening system by a combination of the tumor-tissue microarray analysis of clinical lung-cancer materials with RNA interference (RNAi) technique (Suzuki et ah, Cancer Res. 2003 Nov l;63(21):7038-41, Cancer Res. 2005 Dec 15;65(24):11314-25; Ishikawa et al, Clin Cancer Res. 2004 Dec 15;10(24):8363-70, Cancer Res. 2005 Oct 15;65(20):9176-84; Kato et al, Cancer Res. 2005 JuI l;65(13):5638-46; Furukawa et al, Cancer Res. 2005 Aug 15;65(16):7102-10). In the process, the present inventors identified Dikkopf-1 (DKKl) as a novel serological and histochemical biomarker and as a therapeutic target for lung and esophageal cancers.

DKKl is reported to be a secreted protein which plays a crucial role in head formation in vertebrate development, and is known as a negative regulator of Wnt signaling (Niida et al, Oncogene. 2004 Nov 4;23(52):8520-6). Dkkl binds to LRP5/6 and Kremen proteins, thus inducing LRP endocytosis which prevents the formation of Wnt-Frizzled-LRP5/6 receptor complexes (Gonzalez et ah, Oncogene. 2005 Feb 3;24(6):1098-103). In spite of these biological studies, there has been no report describing the significance of activation of DKKl in human cancer and its potential as a diagnostic and therapeutic target.

The present inventors report here the identification of DKKl as a novel diagnostic and prognostic biomarker and a potential target for therapeutic agents/antibodies, and also provide evidence for its possible role in human pulmonary and esophageal carcinogenesis.

SUMMARY OF THE INVENTION Accordingly, the present invention involves the discovery of unique patterns of gene expression that correlate with esophageal cancer as well as the discovery of targets for the development of signal-suppressing strategies in human esophageal cancer. Genes that are differentially expressed in esophageal cancer (EC), for example, esophageal squamous-cell carcinoma (ESCC), are collectively referred to herein as "EC nucleic acids" or "EC polynucleotides" and the corresponding encoded polypeptides are referred to herein as "EC polypeptides" or "EC proteins".

Thus, it is an objective of the present invention is to provide a method for detecting, diagnosing, providing a prognosis, or determining a predisposition to esophageal cancer in a subject by determining an expression level of an EC-associated gene in a biological sample from a patient, for example, a solid tissue or bodily fluid sample. The term "EC-associated gene" refers to a gene that is characterized by an expression level which differs in an EC cell as compared to a normal cell. A normal cell is one obtained from esophageal tissue from an individual known not to have EC. In the context of the present invention, an EC-associated gene is a gene listed in tables 1-2 and 4-7 {i.e., genes of EC Nos. 1-1716), or a gene having at least 90%, 95%, 96%, 97% 98%, or 99% sequence identity to a gene listed in tables 1-2 and 4-7 and the same function {e.g., homologs, genetic variants and polymorphisms). Algorithms known in the art can be used to determine the sequence identity of two or more nucleic acid sequences {e.g., BLAST, see below). An alteration, e.g., an increase or decrease in the level of expression of a gene as compared to a normal control level of the gene, indicates that the subject suffers from or is at risk of developing EC.

In the context of the present invention, the phrase "control level" refers to a mRNA or protein expression level detected in a control sample and includes both a normal control level and an esophageal cancer control level. A control level can be a single expression pattern from a single reference population or from a plurality of expression patterns. For example, the control level can be a database of expression patterns from previously tested cells. A "normal control level" refers to a level of gene expression detected in a normal, healthy individual or in a population of individuals known not to be suffering from esophageal cancer. A normal individual is one with no clinical symptoms of esophageal cancer. On the other hand, an "EC control level" refers to an expression profile of EC-associated genes found in a population suffering from esophageal cancer.

An increase in the expression level of one^" or more EC-associated genes listed in tables 2, 5, and 7 (i.e., genes of EC Nos. 728-1543, 1603-1679, and 1689-1716) detected in a test sample as compared to the expression level from a normal control sample indicates that the subject (from which the test sample was obtained) suffers from or is at risk of developing EC. In contrast, a decrease in the expression level of one or more EC-associated genes listed in tables 1,

4, and 6 (i.e., genes of EC Nos. 1-727, 1544-1602, and 1680-1688) detected in a test sample compared to the expression level from a normal control sample indicates that the subject (from which the test sample was obtained) suffers from or is at risk of developing EC.

Alternatively, expression levels of a panel of EC-associated genes in a test sample can be compared to expression levels of an EC control panel of the same genes. A similarity in expression levels between genes in the test sample panel and genes in the EC control panel indicates that the subject (from which the test sample was obtained) suffers from or is at risk of developing EC.

According to the present invention, gene expression level is deemed to "altered" or "differ" when gene expression is increased or decreased 10%, 25%, or 50% as compared to the control level. Alternatively, an expression level is deemed "increased" or "decreased" when gene expression is increased or decreased by at least 0.1, at least 0.2, at least 1, at least 2, at least

5, or at least 10 or more fold as compared to a control level. Expression is determined by detecting hybridization, e.g., on an array, of an EC-associated gene probe to a gene transcript in a tissue sample from a patient.

In the context of the present invention, the tissue sample from a patient is any tissue obtained from a test subject, e.g. , a patient known to or suspected of having EC. For example, the tissue can contain epithelial cells. More particularly, the tissue can be epithelial cells from esophageal squamous-cell carcinoma. The present invention also provides an EC reference expression profile, comprising a gene expression level of two or more of EC-associated genes listed in tables 1-2 and 4-7.

The present invention further provides methods of identifying an agent that inhibits or enhances the expression or activity of an EC-associated gene, e.g. an EC-associated gene listed in tables 1-2 and 4-7, by contacting a test cell expressing an EC-associated gene with a test compound and determining the expression level of the EC-associated gene or the activity of its gene product. The test cell can be an epithelial cell, for example, an epithelial cell obtained from an esophageal squamous-cell carcinoma. A decrease in the expression level of an up-regulated EC-associated gene or the activity of its gene product as compared to a normal control expression level or activity of the gene or gene product indicates that the test agent is an inhibitor of the EC-associated gene and can be used to reduce a symptom of EC₅ e.g. the expression of one or more EC-associated genes listed in tables 2, 5, and 7. Alternatively, an increase in the expression level of a down-regulated EC-associated gene or the activity of its gene product as compared to a normal control expression level or activity of the gene or gene product indicates that the test agent is an enhancer of expression or function of the EC-associated gene and can be used to reduce a symptom of EC, e.g., the under-expression of one or more EC-associated genes listed in tables 1, 4, and 6.

The present invention also provides a kit comprising a detection reagent which binds to one or more EC nucleic acids or EC polypeptides. Also provided is an array of nucleic acids that binds to one or more EC nucleic acids.

Therapeutic methods of the present invention include methods of treating or preventing EC in a subject including the step of administering to the subject a composition comprising one or more antisense oligonucleotides. In the context of the present invention, the antisense composition reduces the expression of one or more specific target genes. For example, the antisense composition can contain one or more nucleotides which are complementary to one or more up-regulated EC-associated gene sequences selected from the group consisting of the EC- associated genes listed in tables 2, 5, and 7. Alternatively, the present methods can include the steps of administering to a subject a composition comprising one or more small interfering RNA (siRNA) oligonucleotides. In the context of the present invention, the siRNA composition reduces the expression of one or more EC nucleic acids selected from the group consisting of the up-regulated EC-associated genes listed in tables 2, 5, and 7. In yet another method, the treatment or prevention of EC in a subject can be carried out by administering to a subject a composition comprising one or more ribozyme oligonucleotides. In the context of the present invention, the nucleic acid-specific ribozyme composition reduces the expression of one or more EC nucleic acids selected from the group consisting of the up-regulated EC-associated genes listed in tables 2, 5, and 7. The inhibition effect of the siRNA for selected EC-associated genes listed in the tables is confirmed herein. Specifically, siRKA a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) (SEQ ID NO; 30, 31) and a cell division cycle 45, S. Cerevisiae, homolog-like (CDC45L) (SEQ ID NO; 32, 33) are demonstrated herein to inhibit proliferation and viability of esophageal cancer cells. Thus, in some embodiments of the present invention, EC-associated genes listed in tables 2, 5, and 7, including ECT2 and CDC45L, are therapeutic targets of esophageal cancer.

Other therapeutic methods include those in which a subject is administered a compound that increases the expression of one or more of the down-regulated EC-associated genes listed in tables 1, 4, and 6 or the activity of a polypeptide encoded by one or more of the EC-associated genes listed in tables I₅ 4, and 6.

The present invention also includes vaccines and vaccination methods. For example, methods of treating or preventing EC in a subject can involve administering to the subject a vaccine composition comprising one or more polypeptides encoded by one or more nucleic acids selected from the group consisting of an up-regulated EC-associated genes listed in tables 2, 5, and 7 or immunologically active fragments of such polypeptides. In the context of the present invention, an immunologically active fragment is a polypeptide that is shorter in length than the full-length naturally-occurring protein yet which induces an immune response analogous to that induced by the full-length protein. For example, an immunologically active fragment is least 8 residues in length and capable of stimulating an immune cell including, a T cell or a B cell. Immune cell stimulation can be measured by detecting cell proliferation, elaboration of cytokines (e.g., IL-2), or production of an antibody. See, for example, Harlow and Lane, Using Antibodies: A Laboratory Manual, 1998, Cold Spring Harbor Laboratory Press; and Coligan, et ah, Current Protocols in Immunology, 1991-2006, John Wiley & Sons.

It is a further objective of the present invention to provide novel molecular targets and expression patterns unique to EC. Identified genes serve as candidates in the development of novel therapeutic drugs or immunotherapy. For example, ECT2 and CDC45L are characterized herein as two representative candidates identified by the promising screening system of the present invention. Additionally, the present invention provides target molecules for treating or preventing malignant esophageal cancer, more particularly for treating or preventing metastasis or post-surgery recurrence of esophageal cancer. According to the present invention, genes listed in tables 4-5 (i.e., genes of EC Nos. 1544-1679) were identified as genes having unique altered expression patterns in esophageal cancer cells with lymph-node metastasis and genes listed in tables 6-7 (/. e. , genes of EC Nos. 1680- 1716) were identified as genes having unique altered expression patterns in esophageal cancers associated with post-surgery recurrence. Thus, metastasis and/or recurrence of esophageal cancer can be treated or prevented via the suppression of the expression or activity of the up-regulated genes of tables 5 and 7 or their gene products. Alternatively, metastasis and/or recurrence of esophageal cancer can be treated or prevented by enhancing the expression or activity in cancerous cells of the down-regulated genes of tables 4 and 6 or their gene products.

The present invention also provides methods for predicting esophageal cancer metastasis. Specifically, the present method comprises the step of measuring the expression level of one or more marker genes selected from the group consisting of genes listed in tables 4 and 5. These marker genes are identified herein as genes having unique altered expression patterns in the esophageal cancer cells isolated from patients with lymph node metastasis. Therefore, metastasis of the esophageal cancer in a subject can be predicted by determining whether the expression level detected in a sample from the subject is closer to the mean expression level of lymph node metastasis positive cases or negative cases in reference samples.

The present invention also provides methods for predicting post-surgery recurrence of esophageal cancer. Specifically, the present method comprises the step of measuring the expression level of one or more marker genes selected from the group consisting of genes listed in tables 6 and 7. These marker genes are identified herein as genes having unique altered expression patterns in the esophageal cancer cells isolated from patients with recurrence after surgery. Therefore, recurrence of the esophageal cancer in a subject can be predicted by determining whether the expression level detected in a sample from the subject is closer to the mean expression level of recurrence positive cases or negative cases in reference samples.

One advantage of the methods described herein is that esophageal cancer is identified prior to detection of overt clinical symptoms. These and other objects and features of the invention will become more fully apparent when the following detailed description is read in conjunction with the accompanying figures and examples. However, it is to be understood that both the foregoing summary of the invention and the following detailed description are of a preferred embodiment, and not restrictive of the invention or other alternate embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates laser-microbeam microdissection (LMM) of a representative ESCC. The upper row (A) shows the samples before dissection; the lower row (B), the same sections after microdissection (H.E. stain XlOO). The microdissected cancer cells captured on the collecting cap were also shown (C).

Figure 2 Expressions of 38 candidate gene in tumors, cell lines, and normal tissues. Figure 2A depicts the results of semi-quantitative RT-PCR of 38 candidate genes. ACTB is aninternal control. Figure 2B depicts expression of DKKl in a normal lung tissue and 15 clinical lung cancer samples. Figure 2C depicts 25 lung cancer cell lines, detected by semi-quantitative RT-PCR analysis. Figure 2D depicts expression of DKKl protein in 5 representative pairs of NSCLC samples, detected by western-blot analysis.

Figure 3 depicts the results of a northern blot analysis. Figure 3 A depicts the expression of ECT2 in normal organs using multiple tissue northern blot (MTN). A transcript of about 4.3- kb was expressed only in testis. Figure 3B depicts the expression of CDC45L in normal organs using multiple tissue northern blot (MTN). A transcript of about 2.2-kb was expressed only in testis. Figure 3 C depicts Northern blot analysis of the DKKl transcript in normal adult human tissues. A strong signal was observed in placenta and a very weak signal in prostate. Figure 3D depicts subcellular localization of endogenous DKKl protein in TE8 cells. DKKl was stained at the cytoplasm of the cell.

Figure 4 depicts the results of a small interfering RNA (siRNA) experiment against ECT2. In part (A), the knockdown effect of si-_5CT2-l and U-ECT2-2 was confirmed by RT-PCR. MTT assay (C) and colony formation assay (B) revealed inhibition of cell growth in cells transfected with si-£CT2-l and si-ECT2-2.

Figure 5 depicts the results of a small interfering RNA (siRNA) experiment against CDC45L. In part (A), the knockdown effect of ή-CDC45LA and si-CDC45L-2 was confirmed by RT-PCR. MTT assay (C) and colony formation assay (B) revealed inhibition of cell growth in cells transfected with si-CDC45L-l and U-CDC45L-2. Figure 6 depicts the results of a supervised two-dimensional hierarchical clustering analysis using 136 genes associated with lymph-node metastasis that were selected by random permutation test.

Figure 7 depicts the results of a supervised two-dimensional hierarchical clustering analysis using 37 genes associated with recurrence after surgery that were selected by random permutation test.

Figure 8 Association of DKKl over-expression with poor prognosis of NSCLC and ESCC patients. Figure 8 A, C depicts examples are shown of strong, weak, and absent DKKl expression in cancer and of no expression in normal tissue (original magnification xlOO); (A) esophageal cancer, (C) lung cancer. Figure 8B, D depicts Kaplan-Meier analysis of survival of ESCC (B) and NSCLC (D) patients according to expressions of DKKl.

Figure 9 Serologic concentration of DKKl determined by ELISA in patients with ESCC, lung cancers and in healthy controls. Figure 9 A depicts distribution of DKKl in sera from patients with ESCC₉ lung ADC, lung SCC, or SCLC. Differences were significant between ESCC patients and healthy individuals (P < 0.001, Mann- Whitney U test), ADC patients and healthy individuals (P < 0.001, Mann- Whitney U test), between SCC patients and healthy individuals (P < 0.001) and between SCLC patients and healthy individuals (P < 0.001). Figure 9B, Receiver-operating characteristic (ROC) curve analysis of DKKl (black) as serum markers for lung and esophageal cancer (X-axis, 1 -specificity; Y-axis, sensitivity).

Figure 10 Figure 1OA depicts post-translational modification of secreted DKKl in cancer cells. Alanine-replacement mutant of DKKl appeared as immunoreactive bands with similar molecular weight to the deglycosylated form of wild type DKKl . Treatment with N- glycosidase F did not cause any shift of a band of the mutant DKKl in the conditioned medium as well as that in the cell pellet, suggesting that DKKl is N-glycosylated at only asparagine-256. Promotion of invasiveness of mammalian cells transfected with DKKl -expressing plasmids. Figure 1OB depicts an assay demonstrating the invasive nature of NIH3T3 and COS-7 cells in Matrigel matrix after transfection with expression plasmids for human DKKl . Upper panels, Transient expression of DKKl inNIH3T3 and COS-7 cells, detected by western-blot analysis. Middle panels and lower panels, Giemsa staining (x200) and the number of cells migrating through the Matrigel-coated filters. Assays were performed three times, and in triplicate wells.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS I. Overview

The words "a", "an", and "the" as used herein mean "at least one" unless otherwise specifically indicated.

Generally, esophageal cancer cells exist as a solid mass having a highly inflammatory reaction and containing various cellular components, including non-cancerous cells such as mesenchymal cells and inflammatory cells,. Therefore, previously published gene expression data reflect heterogeneous profiles and do not necessarily reflect accurate expressional changes during esophageal carcinogenesis.

Accordingly, to avoid the contamination of these normal cells, the present invention utilized a laser microbeam microdissection (LMM) system to purify the populations of cancerous cells and normal epithelial cells from surgical specimens (Gjerdrum et al, J MoI Diagn. 2001;3(3):105-10; Kitahara et al , Cancer Res. 2001;61(9):3544-9; Kakiuchi et al, Hum MoI Genet. 2004;13(24):3029-43). This is believed to be the first study for gene expression profiles of human ESCC on cDNA microarray combined with an LMM system.

Specifically, herein, a detailed genome-wide database is established for sets of genes that are differentially expressed in ESCCs. The data on all 32,256 genes was linked to their expression in ESCCs and their distribution determined by the cDNA microarray in 34 normal human tissues (30 adult and 4 fetal organs). The data herein not only provide important information about esophageal carcinogenesis, but also facilitates the identification of candidate genes whose products serve as diagnostic markers and/or as molecular targets for treatment of patients with esophageal cancer and providing clinically relevant information.

To date, 816 candidate genes have been identified as tumor markers or therapeutic targets {see Table 2) specifically up-regulated in cancer. The up-regulated genes represent a variety of functions, including genes encoding cancer-testis or onco-fetal antigens as well as ones important for cell growth, proliferation, survival, motility/invasion and transformation. These targets find utility as diagnostic/prognostic markers as well as therapeutic targets for the development of new molecular-targeted agents or immunotherapy in esophageal-cancer treatment. The up-regulated genes also represent tumor-specific transmembrane/secretory proteins that have significant advantages, because they are presented on the cell surface or within the extracellular space, and/or in serum, making them easily accessible as molecular markers and therapeutic targets. Some tumor-specific markers already available, such as CYFRA or Pro- GRP, are transmembrane/secretory proteins (Pujol JL, et al, Cancer Res. 1993;53(l):61-6; Miyake Y, et al, Cancer Res. 1994 Apr 15;54(8):2136-40); the example of rituximab (Rituxan), a humanized monoclonal antibody against CD20-positive lymphomas, provides proof that targeting specific cell-surface proteins can result in significant clinical benefits (Hennessy BT, et al, Lancet Oncol. 2004;5(6):341-53). Among the up-regulated genes, 38 genes were selected for validation by semi-quantitative RT-PCR experiments and confirmed their cancer-specific expression (Figure 2).

Next, expression profiles of lymph-node-metastasis (node-positive) cases were compared with expression profiles of node-negative cases, because lymph-node metastasis is a key step in tumor progression and a risk factor for poor prognosis. Accordingly, 136 genes were identified that are associated with lymph-node metastasis. Additionally, 37 genes were identified that are associated with recurrence after surgery. The patterns of recurrence during the observation period of 32 months included local recurrence, regional lymph-node, and distant metastasis (lung). Mean (SD) time to recurrence after operation was 21.8±11.1 month (range, 2-32). These genes are key molecules in the process of EC tumor progression. Accordingly, this data enables the identification and selection of patients who can take adjuvant therapy after surgery.

From the cDNA microarray system of the present invention, containing 32,256 genes, ECT2 (GenBank Accession NO. AY376439; SEQ ID NO; 30, 31) was identified as gene up- regulated in esophageal cancer. This molecule, discovered to be a cancer-testis antigen activated in the great majority of ESCCs, is believed to play a pivotal role in cell growth/survival, as demonstrated by northern-blot analysis and siRNA experiments discussed below. The ECT2 gene encodes a protein of 882 amino acids with a pair of BRCT domains, a RhoGEF domain, and a PH domain. It is reported to be a nucleotide exchange factor, and is involved in the regulation of cytokinesis (Tatsumoto et al, J Cell Biol. 1999;147(5):921-8;, Saito et al, J Cell Biochem. 2003;90(4):819-36, Liu et al, MoI Cell Biol. 2004;24(15):6665-75).

In addition, CDC45L (GenBank Accession NO. AJ223728; SEQ ID NO; 32, 33) was isolated as an up-regulated gene. This molecule was discovered to be a cancer-testis antigen activated in the most of ESCCs. As demonstrated by northern-blot analysis and siRNA experiments, CDC45L was suggested to be associated with cell growth and survival. The CDC45L gene encodes a protein of 566 amino acids. The protein was identified by its strong similarity with Saccharomyces cerevisiae Cdc45, an essential protein required to the initiation of DNA replication (Saha et al, J Biol Chem. 1998;273(29): 18205-9). Among tumor antigens identified to date, cancer-testis antigens have been recognized as a group of highly attractive targets for cancer vaccine (Li et al, Clin Cancer Res. 2005; 11 (5) : 1809- 14). Although other factors, including the in vivo immunogenicity of the protein, are also important (Wang et al, Clin Cancer Res. 2004;10(19):6544-50), ECT2 and CDC45L both appear to be good targets for immunotherapy as well as for the development of new anti-cancer drugs.

In sum, the cDNA microarray combined with a LMM system described herein revealed characteristic gene expression profiles of ESCC that were associated with carcinogenesis; lymph- node metastasis, and recurrence after surgery. The use of the integrated gene-expression database of human ESCC offers a powerful strategy for rapid identification and further evaluation of target molecules like ECT2 and CDC45L for a personalized therapy of esophageal cancer.

Gene-expression profiles of lung and esophageal carcinomas and subsequent analyses revealed that Dikkopf-1 (DKKl; Accession No. NM_012242; SEQ ID NO: 109, 110) was transactivated in the great majority of various types of lung cancers and esophageal squamous- cell carcinomas (ESCCs). Northern-blot analysis detected expression of DKKl gene only in placenta and prostate among the normal tissues. Immunohistochemical staining using tumor tissue microarrays consisting of 279 archived non-small cell lung cancers (NSCLCs) and 220 ESCC specimens confirmed that DKKl protein was frequently over-expressed in these tumors; its positive staining was observed in 227 of 279 (81.4%) NSCLCs and in 135 of 220 (61.4%) ESCCs examined. In addition, a high level of DKKl expression was associated with poor prognosis of patients with NSCLC as well as ESCC, and multivariate analysis confirmed its independent prognostic value. Serum levels of DKKl were significantly higher in lung and esophageal cancer patients than in healthy controls. The proportion of the serum DKKl -positive cases defined by our criteria was 101 of 162 (62.3%) NSCLC, 47 of 71 (66.2%) SCLC₅ and 45 of 67 (67.2%) ESCC patients, while only 11 of 220 (5.0%) healthy volunteers were falsely diagnosed as positive. A combined assay using both DKKl and CEA increased sensitivity, as 78.6% of the NSCLC patients were then diagnosed as positive while only 8.2% of healthy volunteers were falsely diagnosed as positive. The use of both DKKl and proGRP increased sensitivity to detect SCLCs up to 84.8%, while false positive rate in healthy donors were only 6.2%. In addition, exogenous expression of DKKl increased the migratory and invasive activity of mammalian cells, an indication that DKKl may play a significant role in progression of certain types of cancer. Our data imply that DKKl should be useful as a novel diagnostic/prognostic marker and probably as a therapeutic target for lung and esophageal cancer.

II. Diagnosing Esophageal Cancer

The differentially expressed genes identified herein find diagnostic and prognostic utility as markers of EC and as EC gene targets, the expression of which can be altered to treat or alleviate a symptom of EC. The genes whose expression level is modulated (i.e., increased or decreased) in EC patients are summarized in tables 1 , 2, and 4-7 and are collectively referred to herein as "EC-associated genes," "EC nucleic acids" or "EC polynucleotides" and the ' corresponding encoded polypeptides are referred to as "EC polypeptides" or "EC proteins;" Unless indicated otherwise, "EC" refers to any of the sequences disclosed herein (e.g., EC- associated genes listed in tables 1 , 2, and 4-7) and sequences sharing the same function and having at least 90%, 95%, 96%, 97%, 98%, 99% sequence identity (i.e., homologs, variants and polymorphisms). Genes that have been previously described are presented along with a database accession number.

By measuring expression of the various genes in a sample of cells, EC can be diagnosed.

Similarly, measuring the expression of these genes in response to various agents can identify agents for treating EC.

The present invention involves determining (e.g., measuring) the expression of at least one, and up to all the EC-associated genes listed in tables 1, 2, and 4-7. Using sequence information provided by the GenBank™ database entries for known sequences, the EC- associated genes can be detected and measured using techniques well known to one of ordinary skill in the art. For example, sequences within the sequence database entries corresponding to EC-associated genes, can be used to construct probes for detecting RNA sequences corresponding to EC-associated genes in, e.g., Northern blot hybridization analyses. Probes typically include at least 10, at least 20, at least 50, at least 100, or at least 200 nucleotides of a reference sequence. As another example, the sequences can be used to construct primers for specifically amplifying the EC nucleic acid in, e.g., amplification-based detection methods, for example, reverse-transcription based polymerase chain reaction.

Expression level of one or more of EC-associated genes in a test cell population, e.g., a tissue sample from a patient, is then compared to the expression level (s) of the same gene(s) in a reference cell population. The reference cell population includes one or more cells for which the compared parameter is known, i.e., esophageal squamous-cell carcinoma cells (e.g., EC cells) or normal esophageal epithelial cells (e.g., non-EC cells).

Whether or not a pattern of gene expression in a test cell population as compared to a reference cell population indicates EC or a predisposition thereto depends upon the composition of the reference cell population. For example, if the reference cell population is composed of non-EC cells, a similarity in gene expression pattern between the test cell population and the reference cell population indicates the test cell population is non-EC. Conversely, if the reference cell population is made up of EC cells, a similarity in gene expression profile between the test cell population and the reference cell population indicates that the test cell population includes EC cells.

A level of expression of an EC marker gene in a test cell population is considered "altered" or "to differ" if it varies from the expression level of the corresponding EC marker gene in a reference cell population by more than 1.1, more than 1.5, more than 2.0, more than 5.0, more than 10.0 or more fold.

Differential gene expression between a test cell population and a reference cell population can be normalized to a control nucleic acid, e.g. a housekeeping gene. For example, a control nucleic acid is one which is known not to differ depending on the cancerous or noncancerous state of the cell. The expression level of a control nucleic acid can be used to normalize signal levels in the test and reference cell populations. Exemplary control genes include, but are not limited to, e.g., β-actin, glyceraldehyde 3- phosphate dehydrogenase and ribosomal protein Pl.

The test cell population can be compared to multiple reference cell populations. Each of the multiple reference cell populations can differ in the known parameter. Thus, a test cell population can be compared to a first reference cell population known to contain, e.g., EC cells, as well as a second reference cell population known to contain, e.g., non-EC cells (normal cells). The test cell population can be included in a tissue or cell sample from a subject known to contain, or suspected of containing, EC cells.

The test cell population can be obtained from a bodily tissue or a bodily fluid, e.g., biological fluid (for example, blood, sputum, saliva). For example, the test cell population can be purified from esophageal tissue. Preferably, the test cell population comprises an epithelial cell. The epithelial cell is preferably from a tissue known to be or suspected to be an esophageal squamous-cell carcinoma. Cells in the reference cell population are from- a tissue type similar to that of the test cell population. Optionally, the reference cell population is a cell line, e.g. an EC cell line (i.e. , a positive control) or a normal non-EC cell line (i.e. , a negative control). Alternatively, the control cell population can be from a database of molecular information from cells for which the assayed parameter or condition is known.

The subject is preferably a mammal. Exemplary mammals include, but are not limited to, e.g., a human, non-human primate, mouse, rat, dog, cat, horse, or cow.

Expression of the genes disclosed herein can be determined at the protein or nucleic acid level, using methods known in the art. For example, Northern hybridization analysis, using probes which specifically recognize one or more of these nucleic acid sequences can be used to determine gene expression. Alternatively, gene expression can be measured using reverse- transcription-based PCR assays, e.g., using primers specific for the differentially expressed gene sequences. Expression can also be determined at the protein level, i.e., by measuring the level of a polypeptides encoded by a gene described herein, or the biological activity thereof. Such methods are well known in the art and include, but are not limited to, e.g., immunoassays that utilize antibodies to proteins encoded by the genes. The biological activities of the proteins encoded by the genes are generally well known. See, Sambrook and Russell, Molecular Cloning: A Laboratory Manual, 3^rd Edition, 2001, Cold Spring Harbor Laboratory Press; Ausubel, Current Protocols in Molecular Biology, 1987-2006, John Wiley and Sons; and Harlow and Lane, Using Antibodies: A Laboratory Manual, 1998, Cold Spring Harbor Laboratory Press.

In the context of the present invention, EC is diagnosed by measuring the expression level of one or more EC nucleic acids from a test population of cells, (i. e. , a biological sample from a patient). Preferably, the test cell population contains an epithelial cell, e.g., a cell obtained from esophageal tissue. Gene expression can also be measured from blood or other bodily fluids, for example, saliva or sputum. Other biological samples can be used for measuring protein levels. For example, the protein level in blood or serum from a subject to be diagnosed can be measured by immunoassay or other conventional biological assay.

Expression of one or more EC-associated genes, e.g., genes listed in tables 1, 2, and 4-7, is determined in the test cell population or biological sample and compared to the normal control expression level associated with the one or more EC-associated gene(s) assayed. A normal control level is an expression profile of an EC-associated gene typically found in a cell population from a subject known not to be suffering from EC. An alteration or difference (e.g. , an increase or decrease) in the level of expression of one or more EC-associated genes in a tissue sample from a patient in comparison to expression from a normal control sample indicates that the subject is suffering from or is at risk of developing EC. For example, an increase in the expression of one or more up-regulated EC-associated genes listed in tables 2, 5, and 7 in the test cell population as compared to the expression in a normal control cell population indicates that the subject is suffering from or is at risk of developing EC. Conversely, a decrease in expression of one or more down-regulated EC-associated genes listed in tables 1 , 4, and 6 in the test cell population as compared to the expression in a normal control cell population indicates that the subject is suffering from or is at risk of developing EC.

Alteration in expression levels of one or more of the EC-associated genes in the test cell population as compared to normal control expression levels indicates that the subject suffers from or is at risk of developing EC. For example, alteration in expression levels of at least 1%, at least 5%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more of the panel of EC-associated genes (genes listed in tables 1, 2, and 4-7) indicates that the subject suffers from or is at risk of developing EC.

III. Screening Assays

Identifying agents that inhibit or enhance EC-associated sene expression: An agent that inhibits the expression of an EC-associated gene or the activity of its gene product can be identified by contacting a test cell population expressing an EC-associated up- regulated gene with a test agent and then determining the expression level of the EC-associated gene or the activity of its gene product. A decrease in the level of expression of the EC- associated gene or in the level of activity of its gene product in the presence of the agent as compared to the expression or activity level in the absence of the test agent indicates that the agent is an inhibitor of an EC-associated up-regulated gene and useful in inhibiting EC.

Alternatively, an agent that enhances the expression of an EC-associated down-regulated gene or the activity of its gene product can be identified by contacting a test cell population expressing an EC-associated gene with a test agent and then determining the expression level or activity of the EC-associated down-regulated gene. An increase in the level of expression of the EC-associated gene or in the level of activity of its gene product in the presence of the test agent as compared to the expression or activity level in the absence of the test agent indicates that the test agent augments expression of the EC-associated down-regulated gene or the activity of its gene product. The test cell population can be any cells expressing the EC-associated genes. For example, the test cell population can contain epithelial cells, for example, cells from esophageal tissue. Furthermore, the test cell population can be an immortalized cell line from an esophageal squamous-cell carcinoma cell. Alternatively, the test cell population can be comprised of cells which have been transfected with an EC-associated gene or which have been transfected with a regulatory sequence (e.g. promoter sequence) from an EC-associated gene operably linked to a reporter gene.

The agent can be, for example, an inhibitory oligonucleotide (e.g., an antisense ^■ oligonucleotide, an siRNA, a ribozyme), an antibody, a polypeptide, a small organic molecule. Screening for agents can be carried out using high throughput methods, by simultaneously screening a plurality of agents using multiwell plates (e.g., 96-well, 192-well, 384-well, 768-well, 1536-well). Automated systems for high throughput screening are commercially available from, for example, Caliper Life Sciences, Hopkinton, MA. Small organic molecule libraries available for screening can be purchased, for example, from Reaction Biology Corp., Malvern, PA; TimTec, Newark, DE.

Identifying therapeutic agents:

The differentially expressed EC-associated genes disclosed herein can also be used to identify candidate therapeutic agents for treating EC. The methods of the present invention involve screening a candidate therapeutic agent to determine if the test agent can convert an expression profile of one or more EC-associated genes listed in tables 1, 2, and 4-7 characteristic of an EC state to a gene expression pattern characteristic of a non-EC state.

In the instant method, a test cell population is exposed to a test agent or a plurality of test agents (sequentially or in combination) and the expression of one or more of the EC-associated genes listed in tables I₅ 2, and 4-7 in the cells is measured. The expression profile of the EC- associated gene(s) assayed in the test cell population is compared to the expression level of the same EC-associated gene(s) in a reference cell population that is not exposed to the test agent.

An agent capable of stimulating the expression of an under-expressed gene or suppressing the expression of an over-expressed gene has clinical benefit. Such agents can be further tested for the ability to prevent esophageal carcinomal growth in animals or test subjects.

In a further embodiment, the present invention provides methods for screening candidate agents which act on the targets in the treatment of EC. As discussed in detail above, by controlling the expression levels of marker genes or the activities of their gene products, one can control the onset and progression of EC. Thus, candidate agents, which act on the targets in the treatment of EC₅ can be identified through screening methods that use such expression levels and activities as indices of the cancerous or non-cancerous state. In the context of the present invention, such screening can comprise, for example, the following steps:

(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes listed in table I₅ 2, 4, 5, 6 or 7

(b) detecting the binding activity between the polypeptide and the test compound; and

(c) selecting the test compound that binds to the polypeptide.

Alternatively, the screening methods of the present invention can comprise the following steps:

(a) contacting a candidate compound with a cell expressing one or more marker genes, wherein the one or more marker genes are selected from the group consisting of the genes listed in table 1, 2, 4, 5, 6 or 7; and

(b) selecting the candidate compound that reduces the expression level of one or more marker genes selected from the group consisting of the genes listed in table 2, 5, and 7, or elevates the expression level of one or more marker genes selected from the group consisting of the genes listed in table 1, 4, and 6, as compared to the expression level detected in the absence of the candidate compound.

Cells expressing a marker gene include, for example, cell lines established from EC; such cells can be used for the above screening of the present invention.

Alternatively, the screening methods of the present invention can comprise the following steps:

(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes listed in table 1, 2, 4, 5, 6 or 7; (b) detecting the biological activity of the polypeptide of step (a); and

(c) selecting a compound that suppresses the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes listed in table 2, 5 and 7, or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes listed in table 1, 4, and 6, as compared to the biological activity detected in the absence of the test compound.

A protein for use in the screening methods of the present invention can be obtained as a recombinant protein using the nucleotide sequence of the marker gene. Based on the information regarding the marker gene and its encoded protein, one skilled in the art can select any biological activity of the protein as an index for screening and any suitable measurement method to assay for the selected biological activity.

Alternatively, the screening methods of the present invention can comprise the following steps:

(a) contacting a candidate compound with a cell into which a vector, comprising the transcriptional regulatory region of one or more marker genes and a reporter gene that is expressed under the control of the transcriptional regulatory region, has been introduced, wherein the one or more marker genes are selected from the group consisting of the genes listed in table 1, 2, 4, 5, 6 or 7;

(b) measuring the expression or activity of said reporter gene; and

(c) selecting the candidate compound that reduces the expression or activity level of said reporter gene when said marker gene is an up-regulated marker gene selected from the group consisting of the genes listed in table 2, 5 and 7, or that enhances the expression or activity level of said reporter gene when said marker gene is a down-regulated marker gene selected from the group consisting of the genes listed in table 1, 4 and 6, as compared to the expression or activity level detected in the absence of the candidate compound.

Suitable reporter genes and host cells are well known in the art. A reporter construct suitable for the screening methods of the present invention can be prepared by using the transcriptional regulatory region of a marker gene. When the transcriptional regulatory region of the marker gene is known to those skilled in the art, a reporter construct can be prepared by using the previous sequence information. When the transcriptional regulatory region of the marker gene remains unidentified, a nucleotide segment containing the transcriptional regulatory region can be isolated from a genome library based on the nucleotide sequence information of the marker gene.

Selecting a therapeutic agent for treating EC:

Differences in the genetic makeup of individuals can result in differences in their relative abilities to metabolize various drugs. An agent that is metabolized in a subject to act as an anti-EC agent can manifest itself by inducing a change in a gene expression pattern in the subject's cells from that characteristic of a cancerous state to a gene expression pattern characteristic of a non-cancerous state. Accordingly, the differentially expressed EC^:associated genes disclosed herein allow for a putative therapeutic or prophylactic inhibitor of EC to be tested in a test cell population from a selected subject in order to determine if the agent is a suitable inhibitor of EC in the subject.

To identify an inhibitor of EC that is appropriate for a specific subject, a test cell population from the subject is exposed to a therapeutic agent, and the expression of one or more of EC-associated genes listed in table I₅ 2, and 4-7 is determined.

In the context of the methods of the present invention, the test cell population contains EC cells expressing one or more EC-associated genes. Preferably, the test cell population comprises epithelial cells. For example, a test cell population can be incubated in the presence of a candidate agent and the pattern of gene expression of the test cell population can be measured and compared to one or more reference expression profiles, e.g., an EC reference expression profile or a non-EC reference expression profile.

A decrease in expression of one or more of the EC-associated genes listed in tables 2, 5, and 7 or an increase in expression of one or more of the EC-associated genes listed in tables 1, 4, and 6 in a test cell population relative to a reference cell population containing EC indicates that the agent has therapeutic use.

In the context of the present invention, the test agent can be any compound or composition. Exemplary test agents include, but are not limited to, immunomodulatory agents (e.g., antibodies), inhibitory oligonuceotides (e.g., antisense oligonucleodies, short-inhibitory oligonucleotides and ribozymes) and small organic compounds.

Identifying therapeutic agents for metastatic esophageal cancer:

The present invention provides target molecules for treating or preventing metastasis esophageal cancer. Screening assays for EC metastasis of the present invention can be performed according to the method for EC described above, using marker genes associated with EC metastasis.

In the present invention, marker genes selected from the group consisting of genes listed in tables 4 and 5 are useful for the screening. An agent that suppresses the expression of one or more of up-regulated genes or the activity of their gene products obtained by the present invention are useful for treating or preventing EC with lymph-node metastasis. Alternatively, an agent that enhances the expression of one or more down-regulated genes or the activity of their gene products obtained by the present invention is also useful for treating or preventing EC with lymph-node metastasis. In the present invention, the agent regulating an expression level of genes listed in tables 4 and 5 can be identified by the same manner for identifying agents that inhibit or enhance EC- associated gene expression. Alternatively, the agent regulating the activity of their gene products can be also identified by the same manner for identifying agents that inhibit or enhance EC- associated gene product.

Identifying therapeutic agents for recurrent esophageal cancer: The present invention provides target molecules for treating or preventing recurrent esophageal cancer. Screening assays for EC metastasis of the present invention can be ^• performed according to the method for EC described above, using marker genes associated with EC metastasis.

In the present invention, marker genes selected from the group consisting of genes listed in tables 6 and 7 are useful for the screening. An agent that suppresses the expression of one or more of up-regulated genes or the activity of their gene products obtained by the present invention are useful for treating or preventing EC with post-surgery recurrence. Alternatively, an agent that enhances the expression of one or more down-regulated genes or the activity of their gene products obtained by the present invention is also useful for treating or preventing EC with post-surgery recurrence.

In the present invention, the agent regulating an expression level of genes listed in tables 6 and 7 can be identified by the same manner for identifying agents that inhibit or enhance EC- associated gene expression. Alternatively, the agent regulating the activity of their gene products can be also identified by the same manner for identifying agents that inhibit or enhance EC- associated gene product.

Kits: The present invention also includes an EC-detection reagent, e.g., a nucleic acid that specifically binds to or identifies one or more EC nucleic acids, including oligonucleotide sequences which are complementary to a portion of an EC nucleic acid, or an antibody that bind to one or more proteins encoded by an EC nucleic acid. The detection reagents can be packaged together in the form of a kit. For example, the detection reagents can be packaged in separate containers, e.g., a nucleic acid or antibody (either bound to a solid matrix or packaged separately with reagents for binding them to the matrix), a control reagent (positive and/or negative), and/or a detectable label. Instructions (e.g., written, tape, VCR, CD-ROM₃ etc.) for carrying out the assay can also be included in the kit. The assay format of the kit can be a Northern hybridization or a sandwich ELISA, both of which are known in the art. See, for example, Sambrook and Russell, Molecular Cloning: A Laboratory Manual, 3^rd Edition, 2001, Cold Spring Harbor Laboratory Press; and Using Antibodies, supra.

For example, an EC detection reagent can be immobilized on a solid matrix, for example a porous strip, to form at least one EC detection site. The measurement or detection region of the porous strip can include a plurality of sites, each containing a nucleic acid. A test strip can also contain sites for negative and/or positive controls. Alternatively, control sites can be located on a separate strip from the test strip. Optionally, the different detection sites can contain different amounts of immobilized nucleic acids, i.e., a higher amount in the first detection site and lesser amounts in subsequent sites. Upon the addition of test sample, the number of sites displaying a detectable signal provides a quantitative indication of the amount of EC present in the sample. The detection sites can be configured in any suitably detectable shape and are typically in the shape of a bar or dot spanning the width of a test strip.

Alternatively, the kit can contain a nucleic acid substrate array comprising one or more nucleic acids. The nucleic acids on the array specifically identify one or more nucleic acid sequences represented by the EC-associated genes listed in tables 1, 2, and 4-7. The expression of 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 40 or 50 or more of the nucleic acids represented by the EC-associated genes listed in tables 1, 2, and 4-7 can be identified by virtue of the level of binding to an array test strip or chip. The substrate array can be on, e.g., a solid substrate, for example a "chip" described in U.S. Patent No. 5,744,305, the contents of which are incorporated by reference herein in its entirety. Array substrates of use in the present methods are commercially available, for example, from Affymetrix, Santa Clara, CA.

Arrays and pluralities:

The present invention also includes a nucleic acid substrate array comprising one or more nucleic acids. The nucleic acids on the array specifically correspond to one or more nucleic acid sequences represented by the EC-associated genes listed in tables I₅ 2, and 4-7. The level of expression of 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 40 or 50 or more of the nucleic acids represented by the EC-associated genes listed in tables I₅ 2, and 4-7 can be identified by detecting nucleic acid binding to the array.

The present invention also includes an isolated plurality (z. e., a mixture of two or more nucleic acids) of nucleic acids. The nucleic acids can be in a liquid phase or a solid phase, e.g., immobilized on a solid support, for example, a nitrocellulose membrane. The plurality includes one or more of the nucleic acids represented by the EC-associated genes listed in tables 1, 2, and 4-7. In various embodiments, the plurality includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 40 or 50 or more of the nucleic acids represented by the EC-associated genes listed in tables 1, 2, and 4-7.

Candidate compounds: A compound isolated by the screening serves as a candidate for the development of drugs that inhibit the expression of the marker gene or the activity of the protein encoded by the marker gene and can be applied to the treatment or prevention of esophageal cancer.

Moreover, compounds in which a part of the structure of the compound inhibiting the activity of proteins encoded by marker genes is converted by addition, deletion and/or replacement are also included as the compounds obtainable by the screening methods of the present invention.

When administrating a compound isolated by the methods of the present invention as a pharmaceutical for humans and other mammals, including without limitation, mice, rats, hamsters, guinea-pigs, rabbits, cats, dogs, sheep, pigs, cattle, monkeys, baboons, and chimpanzees, the isolated compound can be directly administered or can be formulated into a dosage form using known pharmaceutical preparation methods. For example, according to the needs of the patient, the drugs can be taken orally, as sugar-coated tablets, capsules, elixirs and microcapsules, or non-orally, in the form of injections of sterile solutions or suspensions with water or any other pharmaceutically acceptable liquid. For example, the compounds can be mixed with pharmaceutically acceptable carriers or media, specifically, sterilized water, physiological saline, plant-oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binders, and such, in a unit dose form required for generally accepted drug implementation. The amount of active ingredient contained in such a preparation makes a suitable dosage within the indicated range acquirable.

Examples of additives that can be admixed into tablets and capsules include, but are not limited to, binders, including gelatin, corn starch, tragacanth gum and arabic gum; excipients, including crystalline cellulose; swelling agents, including corn starch, gelatin and alginic acid; lubricants, including magnesium stearate; sweeteners, including sucrose, lactose or saccharin; and flavoring agents, including peppermint, spearmint, Gaultheria adenothrix oil and cherry. When the unit-dose form is a capsule, a liquid carrier, including an oil, can be further included in the above ingredients. Sterile composites for injection can be formulated following normal drug implementations using vehicles, for example, distilled water or saline solution, suitable for injection.

Physiological saline, glucose, and other isotonic liquids, including adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride, can be used as aqueous solutions for injection. These can be used in conjunction with suitable solubilizers, for example, alcohols including ethanol; polyalcohols, including propylene glycol and polyethylene glycol; and non- ionic surfactants, including Polysorbate 80 (TM) and HCO-50.

Sesame oil or soy-bean oil can be used as an oleaginous liquid, can be used in conjunction with benzyl benzoate or benzyl alcohol as a solubilizer, and can be formulated with a buffer, including phosphate buffer and sodium acetate buffer; a pain-killer, including procaine hydrochloride; a stabilizer, including benzyl alcohol and phenol; and/or an anti-oxidant. A prepared injection can be filled into a suitable ampoule.

Methods well known to those skilled in the art can be used to administer the pharmaceutical composition of the present invention to patients, for example as an intra-arterial, intravenous, or percutaneous injection or as an intranasal, transbronchial, intramuscular or oral administration. The dosage and method of administration vary according to the body- weight and age of a patient and the administration method; however, one skilled in the art can routinely select a suitable method of administration. If said compound is encodable by a DNA, the DNA can be inserted into a vector for gene therapy and the vector administered to a patient to perform the therapy. The dosage and method of administration vary according to the body- weight, age, and symptoms of the patient; however, one skilled in the art can suitably select them.

For example, although the dose of a compound that binds to a protein of the present invention and regulates its activity depends on the symptoms, the dose is generally about 0.1 mg to about 100 mg per day, preferably about 1.0 mg to about 50 mg per day and more preferably about 1.0 mg to about 20 mg per day, when administered orally to a normal adult human (weighing about 60 kg).

When administering the compound parenterally, in the form of an injection to a normal adult human (weighing about 60 kg), although there are some differences according to the patient, target organ, symptoms and method of administration, it is convenient to intravenously inject a dose of about 0.01 mg to about 30 mg per day, preferably about 0.1 to about 20 mg per day and more preferably about 0.1 to about 10 mg per day. In the case of other animals, the appropriate dosage amount can be routinely calculated by converting to 60 kg of body- weight. IV. Monitoring and Prognosing Esophageal Cancer

Assessing the efficacy of treatment:

The differentially expressed EC-associated genes identified herein also allow for the course of treatment of EC to be monitored. In this method, a test cell population is provided from a subject undergoing treatment for EC. If desired, test cell populations are obtained from the subject at various time points, before, during, and/or after treatment. Expression of one or more of the EC-associated genes in the test cell population is then determined and compared to expression of the same genes in a reference cell population which includes cells whose EC state is known. In the context of the present invention, the reference cells have not been exposed to the treatment of interest.

If the reference cell population contains no EC cells, a similarity in the expression of an EC-associated gene in the test cell population and the reference cell population indicates that the treatment of interest is efficacious. However, a difference in the expression of an EC-associated gene in the test cell population and a normal control reference cell population indicates a less favorable clinical outcome or prognosis. Similarly, if the reference cell population contains EC cells, a difference between the expression of an EC-associated gene in the test cell population and the reference cell population indicates that the treatment of interest is efficacious, while a similarity in the expression of an EC-associated gene in the test population and a EC control reference cell population indicates a less favorable clinical outcome or prognosis.

Additionally, the expression level of one or more EC-associated genes determined in a biological sample from a subject obtained after treatment {i.e., post-treatment levels) can be compared to the expression level of the one or more EC-associated genes determined in a biological sample from a subject obtained prior to treatment onset (i.e., pre-treatment levels). If the EC-associated gene is an up-regulated gene, a decrease in the expression level in a post- treatment sample indicates that the treatment of interest is efficacious while an increase or maintenance in the expression level in the post-treatment sample indicates a less favorable clinical outcome or prognosis. Conversely, if the EC-associated gene is a down-regulated gene, an increase in the expression level in a post-treatment sample can indicate that the treatment of interest is efficacious while a decrease or maintenance in the expression level in the post- treatment sample indicates a less favorable clinical outcome or prognosis.

As used herein, the term "efficacious" indicates that the treatment leads to a reduction in the expression of a pathologically up-regulated gene, an increase in the expression of a pathologically down-regulated gene or a decrease in size, prevalence, or metastatic potential of esophageal ductal carcinoma in a subject. When a treatment of interest is applied prophylactically, the term "efficacious" means that the treatment retards or prevents an esophageal tumor from forming or retards, prevents, or alleviates a symptom of clinical EC. Assessment of esophageal tumors can be made using standard clinical protocols.

In addition, efficaciousness can be determined in association with any known method for diagnosing or treating EC. EC can be diagnosed, for example, by identifying symptomatic anomalies, e.g., weight loss, abdominal pain, back pain, anorexia, nausea, vomiting and- generalized malaise, weakness, and jaundice.

Assessing the prognosis of a subject with esophageal cancer:

The present invention also provides methods of assessing the prognosis of a subject with EC including the step of comparing the expression of one or more EC-associated genes in a test cell population to the expression of the same EC-associated genes in a reference cell population from patients over a spectrum of disease stages. By comparing the gene expression of one or more EC-associated genes in the test cell population and the reference cell population(s), or by comparing the pattern of gene expression, over time in test cell populations from the subject, the prognosis of the subject can be assessed.

For example, an increase in the expression of one or more of up-regulated EC-associated genes, including those listed in table 2, 5 or 7, in a test sample as compared to a normal control sample, or a decrease in the expression of one or more of down-regulated EC-associated genes, including those listed in tables 1, 4, or 6, in a test sample as compared to a normal control sample, indicates a less favorable prognosis. Conversely, a similarity in the expression of one or more of EC-associated genes listed in tables 1, 2, and 4-7, in a test sample as compared to normal control sample, indicates a more favorable prognosis for the subject. Preferably, the prognosis of a subject can be assessed by comparing the expression profile of the genes selected from the group consisting of genes listed in tables 1, 2, and 4-7.

Furthermore, the present invention also provides a method for predicting metastasis of esophageal cancer in a subject, the method comprising the steps of:

(a) detecting an expression level of one or more marker genes in a specimen collected from said subject, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1544-1679 (tables 4-5);

(b) comparing the expression level of the one or more marker genes in said specimen to that of a metastasis positive case and metastasis negative case; and (c) wherein a specimen expression level similar to that of a metastasis positive case indicates a high risk of metastasis of esophageal cancer, and wherein specimen expression level similar to that of a metastasis negative case indicates a low risk of metastasis of esophageal cancer.

Alternatively, the present invention provides a method for predicting recurrence of esophageal cancer in a subject, the method comprising the steps of:

(a) detecting an expression level of one or more marker genes in a specimen collected from said subject, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1680-1716 (tables 6-7);

(b) comparing the expression level of the one or more marker genes in said specimen to that of a recurrence positive case and recurrence negative case; and

(c) wherein a specimen expression level similar to that of a recurrence positive case indicates a high risk of recurrence of esophageal cancer, and wherein specimen expression level similar to that of a recurrence negative case indicates a low risk of recurrence of esophageal cancer.

The differentially expressed EC Nos. 1544-1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7) identified herein can also allow for predicting metastasis and recurrence of esophageal cancer in a subject respectively. In this method, a test biological sample is provided from a subject undergoing treatment for esophageal cancer. If desired, multiple test biological samples are obtained from the subject at various time points before, during or after the treatment e.g. surgery. The expression of one or more genes selected from EC Nos. 1544-1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7) in the sample is then determined and compared expression of the same genes in a reference sample with and/or without a metastasis and recurrence of esophageal cancer.

In the present invention, esophageal cancer cells obtained from metastasis negative patients can be used as the reference sample of metastasis negative case. For example, generally, when no lymph-node metastasis was observed in surgically-resected tumors by pathological diagnosis, the patient is metastasis negative. Accordingly, in some preferred embodiments, metastasis of esophageal cancer can be predicted by the method comprising the steps of: (i) detecting an expression level of one or more marker genes selected from the group consisting of EC Nos. 1544-1679 (tables 4-5) in a specimen collected from a subject whose metastasis of esophageal cancer is to be predicted,

(ii) comparing the expression level of the one or more marker genes in said specimen to the expression level of the same one or more marker genes from a metastasis negative specimen; and

(iii) wherein a decrease in the expression level of one or more genes selected from the group consisting of EC Nos. 1544-1602 (table 4) in step (i), or an increase in the expression level of one or more genes selected from the group consisting of EC Nos. 1603-1679 (table 5) in step (i) as compared to the expression levels of the same genes from the metastasis negative specimen indicates that said subject suffers from or is at risk of metastasis of esophageal cancer.

Similarly, in the present invention, esophageal cancer cells obtained from recurrence negative patients can be used as the reference sample of recurrence negative case. For example, generally, when no recurrence was observed within 32 months after the surgery, the patient is recurrence negative. Accordingly, in some preferred embodiments, recurrence of esophageal cancer can be predicted by the method comprising the steps of:

(i) detecting an expression level of one or more marker genes selected from the group consisting of EC Nos. 1680-1716 (tables 6-7) in a specimen collected from a subject whose recurrence of esophageal cancer is to be predicted,

(ii) comparing the expression level of the one or more marker genes in said specimen to the expression levels of the same one or more marker genes from a recurrence negative specimen; and

(iii) wherein a decrease in the expression level of one or more genes selected from the group consisting of EC Nos. 1680-1688 (table 6) step (i), or an increase in the expression level of one or more genes selected from the group consisting of EC Nos. 1689-1716 (table 7) step (i) as compared to expression levels of the same genes in recurrence negative specimen indicates that said subject suffers from or is at risk of recurrence of esophageal cancer. In the present methods, the expression level of EC Nos. 1544- 1679 (tables 4-5) or EC

Nos. 1680-1716 (tables 6-7) can be detected by any one of the following methods:

(a) detecting the mRNA of EC Nos. 1544-1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7), (b) detecting the protein of EC Nos. 1544-1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7), and .

(c) detecting the biological activity of the protein of EC Nos. 1544-1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7). The present invention also provides kits for predicting a metastasis or recurrence, wherein the kit comprising any one component select from the group consisting of:

(a) reagent for detecting the mRNA of EC Nos. 1544- 1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7),

(b) reagent for detecting the protein of EC Nos. 1544- 1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7), and

(c) reagent for detecting the biological activity of the protein of EC Nos. 1544- 1679 (tables 4-5) or EC Nos. 1680-1716 (tables 6-7).

V. Treating and Preventing Esophageal Cancer

Methods of inhibiting esophageal cancer: The present invention further provides a method for preventing, treating or alleviating one or more symptoms of EC in a subject by decreasing the expression of one or more of the EC- associated genes listed in tables 2, 5, and 7 (or the activity of its gene product) or increasing the expression of one or more of the EC-associated genes listed in tables 1, 4, and 6 (or the activity of its gene product). Suitable therapeutic compounds can be administered prophylactically or therapeutically to a subject suffering from or at risk of (or susceptible to) developing EC. Such subjects can be identified using standard clinical methods or by detecting an aberrant level of expression of one or more of the EC-associated genes listed in tables 1, 2, and 4-7 or aberrant activity of its gene product. In the context of the present invention, suitable therapeutic agents include, for example, inhibitors of cell cycle regulation, cell proliferation, and protein kinase activity.

The therapeutic methods of the present invention can include the step of increasing the expression, function, or both of one or more gene products of genes whose expression is decreased ("down-regulated" or "under-expressed" genes) in an EC cell relative to normal cells of the same tissue type from which the EC cells are retrieved. In these methods, the subject is treated with an effective amount of a compound that increases the amount of one or more of the under-expressed (down-regulated) genes in the subject. Administration can be systemic or local. Suitable therapeutic compounds include a polypeptide product of an under-expressed gene, a biologically active fragment thereof, and a nucleic acid encoding an under-expressed gene and having expression control elements permitting expression in the EC cells; for example, an agent that increases the level of expression of such a gene endogenous to the EC cells (i. e. , which up- regulates the expression of the under-expressed gene or genes). Administration of such compounds counters the effects of aberrantly under-expressed gene or genes in the subject's esophageal cells and improves the clinical condition of the subject.

Alternatively, the therapeutic methods of the present invention can include the step of decreasing the expression, function, or both, of one or more gene products of genes whose expression is aberrantly increased ("up-regulated" or "over-expressed" gene) in esophageal cells. Expression can be inhibited in any of several ways known in the art. For example, expression can be inhibited by administering to the subject a compound, e.g., a. nucleic acid that inhibits, or antagonizes the expression of the over-expressed gene or genes, e.g., an antisense oligonucleotide or small interfering RNA which disrupts expression of the over-expressed gene or genes.

Inhibitory Nucleic Acids:

As noted above, inhibitory nucleic acids (e.g. , antisense oligonucleotides, siRNA, ribozymes) complementary to the nucleotide sequence of the EC-associated genes listed in tables 2, 5, and 7 can be used to reduce the expression level of the genes. For example, inhibitory nucleic acids complementary to the EC-associated genes listed in tables 2, 5, and 7 that are up- regulated in esophageal cancer are useful for the treatment of esophageal cancer. Specifically, the inhibitory nucleic acids of the present invention can act by binding to the EC-associated genes listed in tables 2, 5, and 7, or mRNAs corresponding thereto, thereby inhibiting the transcription or translation of the genes, promoting the degradation of the mRNAs, and/or inhibiting the expression of proteins encoded by the EC-associated genes listed in tables 2, 5, and 7, thereby, inhibiting the function of the proteins.

The term "inhibitory nucleic acids" as used herein encompasses both nucleotides that are entirely complementary to the target sequence and those having a mismatch of one or more nucleotides, so long as the inhibitory nucleic acids can specifically hybridize to the target sequences. The inhibitory nucleic acids of the present invention include polynucleotides that have a sequence identity of at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or higher over a span of at least 15 continuous nucleotides. Algorithms known in the art can be used to determine the sequence identity. One useful algorithm is BLAST 2.0, originally described in Altschul et ah, (1990) J. MoI Biol. 215: 403-10. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (available on the World Wide Web at ncbi.nlm.nih.gov). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et ah, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix {see, Henikoff & Henikoff (1989) Proc. Natl. Acad. ScI USA 89: 10915-9).

An additional example of a useful sequence alignment algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, (1987) J. MoI. Evol. 35: 351-60. The method used is similar to the method described by Higgins & Sharp, (1989) CABIOS 5:151-3. The program can align, e.g., up to 300 sequences of a maximum length of 5,000 letters. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster can then be aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences can be aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program can also be used to plot a dendogram or tree representation of clustering relationships. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison. For example, in order to determine conserved amino acids in a monomer domain family or to compare the sequences of monomer domains in a family, the sequence of the invention, or coding nucleic acids, are aligned to provide structure-function information.

The antisense nucleic acids of the present invention act on cells producing the proteins encoded by EC-associated marker genes by binding to the DNAs or mRNAs encoding the proteins, inhibiting their transcription or translation, promoting the degradation of the mRNAs, and inhibiting the expression of the proteins, thereby resulting in the inhibition of the protein function.

An antisense nucleic acid of the present invention can be made into an external preparation, for example, a liniment or a poultice, by admixing it with a suitable base material which is inactive against the nucleic acid.

Also, as needed, the antisense nucleic acids of the present invention can be formulated into tablets, powders, granules, capsules, liposome capsules, injections, solutions, nose-drops and freeze-drying agents by adding excipients, isotonic agents, solubilizers, stabilizers, preservatives, pain-killers, and such. These can be prepared by following known methods.

The antisense nucleic acids of the present invention can be given to the patient by direct application onto the ailing site or by injection into a blood vessel so that it will reach the site of ailment. An antisense-mounting medium can also be used to increase durability and membrane- permeability. Examples include, but are not limited to, liposomes, poly-L-lysine, lipids, cholesterol, lipofectin or derivatives of these.

The dosage of the inhibitory nucleic acids of the present invention can be adjusted suitably according to the patient's condition and used in desired amounts. For example, a dose range of 0.1 to 100 mg/kg, preferably 0.1 to 50 mg/kg can be administered.

The antisense nucleic acids of the present invention inhibit the expression of a protein of the present invention and are thereby useful for suppressing the biological activity of the protein of the invention. In addition, expression-inhibitors, comprising antisense nucleic acids of the present invention, are useful in that they can inhibit the biological activity of a protein of the present invention. The methods of the present invention can be used to alter the expression in a cell of an up-regulated EC-associated gene, e.g. , up-regulation resulting from the malignant transformation of the cells. Binding of the siRNA to a transcript complementary to one of the EC-associated genes listed in tables 2, 5, and 7 in the target cell results in a reduction in the protein production by the cell. The length of the oligonucleotide is at least 10 nucleotides and can be as long as the naturally-occurring transcript. Preferably, the oligonucleotide is less than 75, 50, 25 nucleotides in length. Most preferably, the oligonucleotide is 19-25 nucleotides in length.

The antisense nucleic acids of present invention include modified oligonucleotides. For example, thioated oligonucleotides can be used to confer nuclease resistance to an oligonucleotide.

Also, an siRNA against a marker gene can be used to reduce the expression level of the marker gene. Herein, term "siRNA" refers to a double stranded RNA molecule which prevents translation of a target mRNA. Standard techniques for introducing siRNA into the cell can be used, including those in which DNA is a template from which RNA is transcribed. In the context of the present invention, the siRNA comprises a sense nucleic acid sequence and an anti- sense nucleic acid sequence against an up-regulated marker gene, such as an EC-associated gene listed in tables 2, 5, and 7. The siRNA is constructed such that a single transcript has both the sense and complementary antisense sequences from the target gene, e.g., a. hairpin.

An siRNA of an EC-associated gene, including those listed in tables 2, 5, and 7, hybridizes to target mRNA and thereby decreases or inhibits production of the polypeptides encoded by EC-associated gene listed in tables 2, 5, and 7 by associating with the normally single-stranded mRNA transcript, thereby interfering with translation and thus, expression of the protein. In the context of the present invention, an siRNA is preferably less than 500, 200, 100, 50, or 25 nucleotides in length. More preferably an siRNA is 19-25 nucleotides in length. Exemplary nucleic acid sequence for the production of ECT2 siRNA includes the sequences of nucleotides of SEQ ID NOs: 8 and 9 as the target sequence. Exemplary nucleic acid sequence for the production of CDC45L siRNA includes the sequences of nucleotides of SEQ ID NOs: 10 and 11 as the target sequence. In order to enhance the inhibition activity of the siRNA, one or more uridine ("u") nucleotides can be added to 3 'end of the antisense strand of the target sequence. The number of "u's" to be added is at least 2, generally 2 to 10, preferably 2 to 5. The added "u's" form a single strand at the 3 'end of the antisense strand of the siRNA.

An siRNA of an EC-associated gene, including those listed in tables 2, 5, and 7, can be directly introduced into the cells in a form that is capable of binding to the mRNA transcripts. Alternatively, a DNA encoding the siRNA can be carried in a vector.

Vectors can be produced, for example, by cloning an EC-associated gene target sequence into an expression vector having operatively-linked regulatory sequences flanking the sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands (Lee, N.S., et al, (2002) Nature Biotechnology 20: 500-5). An RNA molecule that is antisense to mRNA of an EC-associated gene is transcribed by a first promoter (e.g., a promoter sequence 3' of the cloned DNA) and an RNA molecule that is the sense strand for the mRNA of an EC- associated gene is transcribed by a second promoter (e.g., a promoter sequence 5' of the cloned DNA). The sense and antisense strands hybridize in vivo to generate siRNA constructs for silencing of the EC-associated gene. Alternatively, the two constructs can be utilized to create the sense and anti-sense strands of a siRNA construct. Cloned EC-associated genes can encode a construct having secondary structure, e.g., hairpins, wherein a single transcript has both the sense and complementary antisense sequences from the target gene.

A loop sequence consisting of an arbitrary nucleotide sequence can be located between the sense and antisense sequence in order to form the hairpin loop structure. Thus, the present invention also provides siRNA having the general formula 5'-[A]-[B]-[A']-3', wherein [A] is a ribonucleotide sequence corresponding to a sequence of a gene selected from table 2, 5 or 7,

[B] is a ribonucleotide sequence consisting of 3 to 23 nucleotides, and [A'] is a ribonucleotide sequence consisting of the complementary sequence of [A].

The region [A] hybridizes to [A'], and then a loop consisting of region [B] is formed. The loop sequence can be 3 to 23 nucleotides in length. The loop sequence, for example, can be selected from the following sequences (found on the worldwide web at ambion.com/techlib/tb/tb_506.html). Furthermore, a loop sequence consisting of 23 nucleotides also provides active siRNA (Jacque, J. M., et al, (2002) Nature 418 : 435-

8.)-

CCC₅ CCACC or CCACACC: Jacque, J. M, et al, (2002) Nature, Vol. 418: 435-8. UUCG: Lee, N.S., et al, (2002) Nature Biotechnology 20: 500-5.; Fruscoloni, P., et al, (2003) Proc. Natl. Acad. Sci. USA 100(4): 1639-44. UUCAAGAGA: Dykxhoorn, D. M., et al, (2003) Nature Reviews Molecular Cell

Biology 4: 457-67. Accordingly, in some embodiments, the loop sequence can be selected from group consisting of, CCC, UUCG, CCACC, CCACACC, and UUCAAGAGA. A preferable loop sequence is UUCAAGAGA ("ttcaagaga" in DNA). Exemplary hairpin siRNA suitable for use in the context of the present invention include:

for ECT2-siRNA gaugcacucaccuuguagu-[b]-acuacaaggugagugcauc(for target sequence of SEQ ID NO: 8) ggcaaauacuccugagcuc-[b]-gagcucaggaguauuugcc(for target sequence of SEQ ID NO: 9) for CDC45L-siRNA gagacauccucuuugacua-[b]-uagucaaagaggaugucuc(for target sequence of SEQ ID NO: 10) cagaccagugggugcaaga-[b]-ucuugcacccacuggucug(for target sequence of SEQ ID NO: 11)

The nucleotide sequence of suitable siRNAs can be designed using an siRNA design computer program available from the Ambion website on the worldwide web at ambion.com/techlib/misc/siRNAjEmder.html. The computer program selects nucleotide sequences for siRNA synthesis based on the following protocol.

Selection of siRNA TarRet Sites:

1. Beginning with the AUG start codon of the object transcript, scan downstream for AA dinucleotide sequences. Record the occurrence of each AA and the 3' adjacent 19 nucleotides as siRNA target sites. Tuschl, et al. Genes Dev 13(24):3191-7(1999) don't recommend against designing siRNA to the 5' and 3' untranslated regions (UTRs) and regions near the start codon (within 75 bases) as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes can interfere with binding of the siRNA endonuclease complex.

2. Compare the target sites to the human genome database and eliminate from consideration any target sequences with significant sequence identity to other coding sequences. The sequence identity search can be performed using BLAST 2.0 (Altschul SF, et al, Nucleic Acids Res. 1997;25(17):3389-402; Altschul SF, J MoI Biol. 1990;215(3):403- 10.), which can be found on the NCBI server at ncbi.nlm.nih.gov/BLAST/.

3. Select qualifying target sequences for synthesis. Using the Ambion algorithm, preferably several target sequences can be selected along the length of the gene to evaluate. The regulatory sequences flanking the EC-associated gene sequences can be identical or different, such that their expression can be modulated independently, or in a temporal or spatial manner. siRNAs are transcribed intracellularly by cloning the EC-associated gene templates, respectively, into a vector containing, e.g., a RNA polymerase III transcription unit from the small nuclear RNA (snRNA) U6 or the human Hl RNA promoter. For introducing the vector into the cell, transfection-enhancing agent can be used. FuGENE (Roche diagnostics), Lipofectamine 2000 (Invitrogen), Oligofectamine (Invitrogen), and Nucleofector (Wako pure Chemical) are useful as the transfection-enhancing agent.

The antisense oligonucleotide or siRNA of the present invention inhibits the expression of a polypeptide of the present invention and is thereby useful for suppressing the biological activity of a polypeptide of the invention. Also, expression-inhibitors, comprising the antisense oligonucleotide or siRNA of the invention, are useful in the point that they can inhibit the biological activity of the polypeptide of the invention. Therefore, a composition comprising one or more antisense oligonucleotides or siRNAs of the present invention is useful for treating an esophageal cancer.

Antibodies:

Alternatively, the function of one or more gene products of the genes over-expressed in EC can be inhibited by administering a compound that binds to or otherwise inhibits the function of the gene products. For example, the compound can be an antibody which binds to the over- expressed gene product or gene products.

The present invention refers to the use of antibodies, particularly antibodies against a protein encoded by an up-regulated marker gene, or a fragment of such an antibody. As used herein, the term "antibody" refers to an immunoglobulin molecule having a specific structure, that interacts (i. e. , binds) only with the antigen that was used for synthesizing the antibody ( i. e. , the gene product of an up-regulated marker) or with an antigen closely related thereto. Furthermore, an antibody can be a fragment of an antibody or a modified antibody, so long as it binds to one or more of the proteins encoded by the marker genes. For instance, the antibody fragment can be Fab, F(ab')₂, Fv, or single chain Fv (scFv), in which Fv fragments from H and L chains are ligated by an appropriate linker (Huston J. S. et al. Proc. Natl. Acad. Sci. U.S.A. 85:5879-83 (1988)). More specifically, an antibody fragment can be generated by treating an antibody with an enzyme, including papain or pepsin. Alternatively, a gene encoding the antibody fragment can be constructed, inserted into an expression vector, and expressed in an appropriate host cell {see, for example, Co M. S. et al. J. Immunol. 152:2968-76 (1994); Better M. and Horwitz A. H. Methods Enzymol. 178:476-96 (1989); Pluckthun A. and Skerra A. Methods Enzymol. 178:497-515 (1989); Lamoyi E. Methods Enzymol. 121 :652-63 (1986); Rousseaux J. et al. Methods Enzymol. 121:663-9 (1986); Bird R. E. and Walker B. W. Trends Biotechnol. 9:132-7 (1991)).

An antibody can be modified by conjugation with a variety of molecules, including polyethylene glycol.(PEG). The present invention provides such modified antibodies. The modified antibody can be obtained by chemically modifying an antibody. Such modification methods are conventional in the field.

Alternatively, an antibody can comprise a chimeric antibody having a variable region from a nonhuman antibody and a constant region from a human antibody, or a humanized antibody, comprising a complementarity determining region (CDR) from a nonhuman antibody, a frame work region (FR) and a constant region from a human antibody. Such antibodies can be prepared by using known technologies.

Cancer therapies directed at specific molecular alterations that occur in cancer cells have been validated through clinical development and regulatory approval of anti-cancer drugs including trastuzumab (Herceptin) for the treatment of advanced breast cancer, imatinib methylate (Gleevec) for chronic myeloid leukemia, gefitinib (Iressa) for non-small cell lung cancer (NSCLC), and rituximab (anti-CD20 mAb) for B-cell lymphoma and mantle cell lymphoma (Ciardiello F and Tortora G. Clin Cancer Res. 2001;7(10):2958-70. Review.; Slamon DJ, et al, N Engl J Med. 2001;344(l l):783-92.; Rehwald U, et al, Blood. 2003;101(2):420-4.; Fang G, et al, (2000). Blood, 96, 2246-53.). These drugs are clinically effective and better tolerated than traditional anti-cancer agents because they target only transformed cells. Hence, such drugs not only improve survival and quality of life for cancer patients, but also validate the concept of molecularly targeted cancer therapy. Furthermore, targeted drugs can enhance the efficacy of standard chemotherapy when used in combination with it (Gianni L. (2002). Oncology, 63 Suppl 1, 47-56.; Klejman A, et al, (2002). Oncogene, 21, 5868-76.). Therefore, future cancer treatments will involve combining conventional drugs with target-specific agents aimed at different characteristics of tumor cells, for example, angiogenesis and invasiveness.

These modulatory methods can be performed ex vivo or in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). The methods involve administering a protein or combination of proteins or a nucleic acid molecule or combination of nucleic acid molecules as therapy to counteract aberrant expression of the differentially expressed genes or aberrant activity of their gene products.

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) expression levels or biological activities of genes and gene products, respectively, can be treated with therapeutics that antagonize (i.e., reduce or inhibit) activity of the over-expressed gene or genes. Therapeutics that antagonize activity can be administered therapeutically or prophylactically.

Accordingly, therapeutics that can be utilized in the context of the present invention include, e.g., (i) a polypeptide of the over-expressed or under-expressed gene or genes, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to the over-expressed gene or gene products; (iii) nucleic acids encoding the over-expressed or under-expressed gene or genes; (iv) antisense nucleic acids or nucleic acids that are "dysfunctional" (i.e., due to a heterologous insertion within the nucleic acids of one or more over-expressed gene or genes); (v) small interfering RNA (siRNA); or (vi) modulators (i.e., inhibitors, agonists and antagonists that alter the interaction between an over-expressed or under-expressed polypeptide and its binding partner). The dysfunctional antisense molecules are utilized to "knockout" endogenous function of a polypeptide by homologous recombination (see, e.g., Capecchi, Science 244: 1288-92 1989).

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) biological activity can be treated with therapeutics that increase (i.e., are agonists to) activity. Therapeutics that up-regulate activity can be administered in a therapeutic or prophylactic manner. Therapeutics that can be utilized include, but are not limited to, a polypeptide (or analogs, derivatives, fragments or homologs thereof) or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of a gene whose expression is altered). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, etc.).

Prophylactic administration occurs prior to the manifestation of overt clinical symptoms of disease or disorder, such that a disease or disorder is prevented or, alternatively, delayed in its progression.

Therapeutic methods of the present invention can include the step of contacting a cell with an agent that modulates one or more of the activities of the gene products of the differentially expressed genes. Examples of agents that modulates protein activity include, but are not limited to, nucleic acids, proteins, naturally-occurring cognate ligands of such proteins, peptides, peptidomimetics, and other small molecule. For example, a suitable agent can stimulate one or more protein activities of one or more differentially under-expressed genes.

Vaccinating against esophageal cancer:

The present invention also relates to methods of treating or preventing esophageal cancer in a subject comprising the step of administering to said subject a vaccine comprising one or more polypeptides encoded by one or more nucleic acid selected from the group consisting of the EC-associated genes listed in tables 2, 5, and 7 (i.e., up-regulated genes), an immunologically active fragment of said polypeptide (i. e. , an epitope), or a polynucleotide encoding such a polypeptide or fragment thereof. Administration of the polypeptide induces an anti-tumor immunity in a subject. To induce anti-tumor immunity, one or more polypeptides encoded by one or more nucleic acids selected from the group consisting of the EC-associated genes listed in tables 2, 5, and 7, an immunologically active fragment(s) of said polypeptides, or polynucleotide(s) encoding such polypeptide(s) or fragment(s) thereof is administered to subject in need thereof. Furthermore, the one or more polypeptides encoded by the one or more nucleic acids selected from the group consisting of the EC-associated genes listed in tables 5 and 7 can induce anti-tumor immunity against metastatic and recurrent esophageal cancer, respectively. The polypeptide or the immunologically active fragments thereof are useful as vaccines against EC. In some cases, the proteins or fragments thereof can be administered in a form bound to the T cell receptor (TCR) or presented by an antigen presenting cell (APC), including macrophages, dendritic cells (DC), or B-cells. Due to the strong antigen presenting ability of DC, the use of DC is most preferable among the APCs.

Identification of immunologically active fragments (i.e., epitopes) is well known in the art. B-cell epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding (i. e. , conformational^ determined) are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996). Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen (e.g. , a competitive ELISA or solid phase radioimmunoassay (SPRIA)). T-cells recognize continuous epitopes of about nine amino acids for CD 8 cells or about 13-15 amino acids for CD4 cells. T cells that recognize the epitope can be identified by in vitro assays that measure antigen- dependent proliferation, as determined by ³H-thymidine incorporation by primed T cells in response to an epitope (Burke et al., J. Inf. Dis. 170, 1110-19 (1994)), by antigen-dependent killing (cytotoxic T lymphocyte assay, Tigges et al, J. Immunol. (1996) 156:3901-10) or by cytokine secretion. Methods for determining immunogenic epitopes are described, for example, in Reineke, et al, Curr Top Microbiol Immunol (1999) 243:23-36; Mahler, et ah, Clin Immunol (2003) 107:65-79; Anthony and Lehmann, Methods (2003) 29:260-9; Parker and Tomer,

Methods MoI Biol (2000) 146:185-201; DeLisser, Methods MoI Biol (1999) 96:11-20; Van de Water, et al, Clin Immunol Immunopathol (1997) 85:229-35; Carter, Methods MoI Biol (1994) 36:207-23; and Pettersson, MoI Biol Rep (1992) 16:149-53.

In the present invention, a vaccine against EC refers to a substance that has the ability to induce anti-tumor immunity upon inoculation into animals. According to the present invention, polypeptides encoded by the EC-associated genes listed in tables 2, 5, and 7, or fragments thereof, are HLA- A24 or HLA-A* 0201 restricted epitopes peptides that induce potent and specific immune response against EC cells expressing the EC-associated genes listed in tables 2, 5, and 7. Thus, the present invention also encompasses methods of inducing anti-tumor immunity using the polypeptides. In general, anti-tumor immunity includes immune responses including as follows:

- induction of cytotoxic lymphocytes against tumors,

- induction of antibodies that recognize tumors, and induction of anti-tumor cytokine production. Therefore, when a certain protein induces any one of these immune responses upon inoculation into an animal, the protein is determined to have anti-tumor immunity inducing effect. The induction of the anti-tumor immunity by a protein can be detected by observing in vivo or in vitro the response of the immune system in the host against the protein.

For example, a method for detecting the induction of cytotoxic T lymphocytes is well known. Specifically, a foreign substance that enters the living body is presented to T cells and B cells by the action of antigen presenting cells (APCs). T cells that respond to the antigen presented by the APCs in an antigen specific manner differentiate into cytotoxic T cells (or cytotoxic T lymphocytes; CTLs) due to stimulation by the antigen, and then proliferate (this is referred to as activation of T cells). Therefore, CTL induction by a certain peptide can be evaluated by presenting the peptide to a T cell via an APC, and detecting the induction of CTLs. Furthermore, APCs have the effect of activating CD4+ T cells, CD8+ T cells, macrophages, eosinophils, and NK cells. Since CD4+ T cells and CD8+ T cells are also important in antitumor immunity, the anti-tumor immunity-inducing action of the peptide can be evaluated using the activation effect of these cells as indicators. See, Coligan, Current Protocols in Immunology, supra.

A method for evaluating the inducing action of CTLs using dendritic cells (DCs) as the APC is well known in the art. DCs are a representative APCs having the strongest CTL- inducing action among APCs. In this method, the test polypeptide is initially contacted with DCs, and then the DCs are contacted with T cells. Detection of T cells having cytotoxic effects against the cells of interest after the contact with DC shows that the test polypeptide has an activity of inducing the cytotoxic T cells. Activity of CTLs against tumors can be detected, for example, using the lysis of ⁵¹Cr-labeled tumor cells as the indicator. Alternatively, methods of evaluating the degree of tumor cell damage using ³H-thymidirie uptake activity or LDH (lactose dehydrogenase)-release as the indicator is also well known.

Apart from DCs, peripheral blood mononuclear cells (PBMCs) can also be used as the APC. The induction of CTLs has been reported to be enhanced by culturing PBMCs in the presence of GM-CSF and IL-4. Similarly, CTLs have been shown to be induced by culturing PBMCs in the presence of keyhole limpet hemocyanin (KLH) and IL-7.

Test polypeptides confirmed to possess CTL-inducing activity by these methods are deemed to be polypeptides having DC activation effect and subsequent CTL-inducing activity. Therefore, polypeptides that induce CTLs against tumor cells are useful as vaccines against tumors. Furthermore, APCs that have acquired the ability to induce CTLs against tumors through contact with the polypeptides are also useful as vaccines against tumors. Furthermore, CTLs that have acquired cytotoxicity due to presentation of the polypeptide antigens by APCs can be also be used as vaccines against tumors. Such therapeutic methods for tumors, using antitumor immunity due to APCs and CTLs, are referred to as cellular immunotherapy.

Generally, when using a polypeptide for cellular immunotherapy, efficiency of the CTL- induction is known to be increased by combining a plurality of polypeptides having different structures and contacting them with DCs. Therefore, when stimulating DCs with protein firagments, it is advantageous to use a mixture of multiple types of fragments.

Alternatively, the induction of anti-tumor immunity by a polypeptide can be confirmed by observing the induction of antibody production against tumors. For example, when antibodies against a polypeptide are induced in a laboratory animal immunized with the polypeptide, and when growth of tumor cells is suppressed by those antibodies, the polypeptide is deemed to have the ability to induce anti-tumor immunity.

Anti-tumor immunity is induced by administering the vaccine of this invention, and the induction of anti-tumor immunity enables treatment and prevention of EC. Therapy against cancer or prevention of the onset of cancer includes any of the following steps, including inhibition of the growth of cancerous cells, involution of cancer, and suppression of the occurrence of cancer. A decrease in mortality and morbidity of individuals having cancer, decrease in the levels of tumor markers in the blood, alleviation of detectable symptoms accompanying cancer, and such are also included in the therapy or prevention of cancer. Such therapeutic and preventive effects are preferably statistically significant. For example, in observation, at a significance level of 5% or less, wherein the therapeutic or preventive effect of a vaccine against cell proliferative diseases is compared to a control without vaccine administration. For example, Student's t-test, the Mann- Whitney U-test, or ANOVA can be used for statistical analysis.

The above-mentioned protein having immunological activity or a vector encoding the protein can be combined with an adjuvant. An adjuvant refers to a compound that enhances the immune response against the protein when administered together (or successively) with the protein having immunological activity. Exemplary adjuvants include, but are not limited to, cholera toxin, salmonella toxin, alum, and such, but are not limited thereto. Furthermore, the vaccine of this invention can be combined appropriately with a pharmaceutically acceptable carrier. Examples of such carriers include sterilized water, physiological saline, phosphate buffer, culture fluid, and such. Furthermore, the vaccine can contain as necessary, stabilizers, suspensions, preservatives, surfactants, and such. The vaccine can be administered systemically or locally, for example, through intradermal, intramuscular, subcutaneous, transdermal, buccal, or intranasal routes. Vaccine administration can be performed by single administration, or boosted by multiple administrations. Doses are as set forth below.

When using an APC or CTL as the vaccine of this invention, tumors can be treated or prevented, for example, by the ex vivo method. More specifically, PBMCs of the subject receiving treatment or prevention are collected, the cells are contacted with the polypeptide ex vivo, and following the induction of APCs or CTLs, the cells can be administered to the subject. APCs can be also induced by introducing a vector encoding the polypeptide into PBMCs ex vivo. APCs or CTLs induced in vitro can be cloned prior to administration. By cloning and growing cells having high activity of damaging target cells, cellular immunotherapy can be performed more effectively. Furthermore, APCs and CTLs isolated in this manner can be used for cellular immunotherapy not only against individuals from whom the cells are retrieved, but also against similar types of tumors from other individuals.

General methods for developing vaccines are described, for example, -in Vaccine Protocols, Robinson and Cranage, Eds., 2003, Humana Press; Marshall, Vaccine Handbook: A Practical Guide for Clinicians, 2003, Lippincott Williams & Wilkins; and Vaccine Delivery Strategies, Dietrich, et ah, Eds., 2003, Springer Verlag.

Pharmaceutical compositions:

Furthermore, a pharmaceutical composition for treating or preventing a cell proliferative disease, for example cancer, comprising a pharmaceutically effective amount of the polypeptide of the present invention is provided. The pharmaceutical composition can be used for raising anti-tumor immunity.

In the context of the present invention, suitable pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration, or for administration by inhalation or insufflation. Preferably, administration is intravenous. The formulations are optionally packaged in discrete dosage units.

Pharmaceutical formulations suitable for oral administration include capsules, cachets or tablets, each containing a predetermined amount of active ingredient. Suitable formulations also include powders, granules, solutions, suspensions and emulsions. The active ingredient is optionally administered as a bolus electuary or paste. Tablets and capsules for oral administration can contain conventional excipients, including binding agents, fillers, lubricants, disintegrant and/or wetting agents. A tablet can be made by compression or molding, optionally with one or more formulational ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form, for example, a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active and/or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets can be coated according to methods well known in the art. Oral fluid preparations can be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can contain conventional additives, for example, suspending agents, emulsifying agents, non-aqueous vehicles (which can include edible oils), and/or preservatives. The tablets can optionally be formulated so as to provide slow or controlled release of the active ingredient therein. A package of tablets can contain one tablet to be taken on each of the month.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions, optionally contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; as well as aqueous and non-aqueous sterile suspensions including suspending agents and/or thickening agents. The formulations can be presented in unit dose or multi-dose containers, for example as sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition, requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Alternatively, the formulations can be presented for continuous infusion. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the kind previously described.

Formulations suitable for rectal administration include suppositories with standard carriers for example, cocoa butter or polyethylene glycol. Formulations suitable for topical administration in the mouth, for example, buccally or sublingually, include lozenges, containing the active ingredient in a flavored base, for example, sucrose and acacia or tragacanth, and pastilles, comprising the active ingredient in a base, for example, gelatin and glycerin or sucrose and acacia. For intra-nasal administration, the compounds of the invention can be used as a liquid spray, a dispersible powder, or in the form of drops. Drops can be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents and/or suspending agents.

For administration by inhalation the compounds can be conveniently delivered from an insufflator, nebulizer, pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs can comprise a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the compounds can take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base, for example, lactose or starch. The powder composition can be presented in unit dosage form, for example, as capsules, cartridges, gelatin or blister packs, from which the powder can be administered with the aid of an inhalator or insufflators.

Other formulations include implantable devices and adhesive patches which release a therapeutic agent.

When desired, the above described formulations, adapted to give sustained release of the active ingredient, can be employed. The pharmaceutical compositions can also contain other active ingredients, including antimicrobial agents, immunosuppressants and/or preservatives.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention can include other agents conventional in the art with regard to the type of formulation in question. For example, formulations suitable for oral administration can include flavoring agents.

Preferred unit dosage formulations contain an effective dose, as recited below, or an appropriate fraction thereof, of the active ingredient.

For each of the aforementioned conditions, the compositions, e.g., polypeptides and organic compounds, can be administered orally or via injection at a dose ranging from about 0.1 to about 250 mg/kg per day. The dose range for adult humans is generally from about 5 mg to about 17.5 g/day, preferably about 5 mg to about 10 g/day, and most preferably about 100 mg to about 3 g/day. Tablets or other unit dosage forms of presentation provided in discrete units can conveniently contain an amount which is effective at such dosage or as a multiple of the same, for instance, units containing about 5 mg to about 500 mg, usually from about 100 mg to about 500 mg.

The dose employed will depend upon a number of factors, including the age and sex of the subject, the precise disorder being treated, and its severity. Also the route of administration can vary depending upon the condition and its severity. In any event, appropriate and optimum dosages can be routinely calculated by those skilled in the art, taking into consideration the above-mentioned factors.

VI. Serodiagnosing cancer: By measuring the level of DKKl in a subject-derived biological sample, the occurrence of cancer or a predisposition to develop cancer in a subject can be determined. Preferably, cancer is either of esophageal and lung cancer, or both. Accordingly, the present invention involves determining {e.g., measuring) the level of DKKl in a biological sample.

Any biological materials may be used as the biological sample for determining the level of DKKl so long as either the DKKl gene or the DKKl protein can be detected in the sample. Preferably, the biological sample comprises blood, serum or other bodily fluids such as sputum. The preferred biological sample is blood or blood derived sample. The blood derived sample includes serum, plasma, or whole blood.

The subject diagnosed for cancer according to the method is preferably a mammal and includes human, non-human primate, mouse, rat, dog, cat, horse and cow.

In one embodiment of the present invention, a gene transcript of the DKKl gene (e.g., the DKKl protein) is detected to determine the DKKl level. The DKKl gene can be detected and measured using techniques well known to one of ordinary skill in the art. The gene transcripts detected by the method include both the transcription and translation products, such as mRNA and proteins. For example, sequences corresponding to DKKl gene can be used to construct probes for detecting DKKl mRNAs by, e.g. , Northern blot hybridization analysis. The hybridization of the probe to a gene transcript in a subject biological sample can be also carried out on a DNA array. As another example, the DKKl sequence can be used to construct primers for specifically amplifying the DKKl polynucleotide in, e.g., amplification-based detection methods such as reverse-transcription based polymerase chain reaction (RT-PCR).

In an alternate embodiment, the level of DKKl is determined by measuring the quantity DKKl protein in a biological sample. A method for determining the quantity of the DKKl protein in a biological sample includes immunoassay methods. In a preferred embodiment, the immunoassay comprises an ELISA.

The DKKl level in the biological sample is then compared with an DKKl level associated with a reference sample, such as a normal control sample. The phrase "normal control level" refers to the level of DKKl typically found in a biological sample of a population not suffering from cancer. The reference sample is preferably of a similar nature to that of the test sample. For example, if the test sample comprise serum collected from a patient to be diagnosed or prognosed, the reference sample should also be serum. The DKKl level in the biological samples from control and test subjects may be determined at the same time or, altematively, the normal control level may be determined by a statistical method based on the results obtained by analyzing the level of DKKl in samples previously collected from a control group.

The DKKl level may also be used to monitor the course of treatment of cancer. In this method, a test biological sample is provided from a subject undergoing treatment for cancer. Preferably, cancer is esophageal and lung cancer. Preferably, multiple test biological samples are obtained from the subject at various time points before, during or after the treatment. The level of DKKl in the post-treatment sample may then be compared with the level of DKKl in the pre-treatment sample or, alternatively, with a reference sample (e.g., a normal control level). For example, if the post-treatment DKKl level is lower than the pre-treatment DKKl level, one can conclude that the treatment was efficacious. Likewise, if the post-treatment DKKl level is similar to the normal control DKKl level, one can also conclude that the treatment was efficacious.

An "efficacious" treatment is one that leads to a reduction in the level of DKKl or a decrease in size, prevalence or. metastatic potential of cancer in a subject. When a treatment is applied prophylactically, "efficacious" means that the treatment retards or prevents occurrence of cancer or alleviates a clinical symptom of cancer. The assessment of cancer can be made using standard clinical protocols. Furthermore, the efficaciousness of a treatment can be determined in association with any known method for diagnosing or treating cancer. For example, cancer is routinely diagnosed histopathologically or by identifying symptomatic anomalies such as chronic cough, hoarseness, coughing up blood, weight loss, loss of appetite, shortness of breath, wheezing, repeated bouts of bronchitis or pneumonia and chest pain.

Moreover, the present method for diagnosing cancer may also be applied for assessing the prognosis of a patient with the cancer by comparing the level of DKKl in a patient-derived biological sample with that of a reference sample. Preferably, cancer is esophageal and lung cancer. Alternatively, the level of DKKl in the biological sample may be measured over a spectrum of disease stages to assess the prognosis of the patient. An increase in the level of DKKl as compared to a normal control level indicates less favorable prognosis. A similarity in the level of DKKl as compared to a normal control level indicates a more favorable prognosis of the patient.

VII. Method for assessing the prognosis of cancer

According to the present invention, it was newly discovered that DKKl expression is signifϊcantly associated with poorer prognosis of patients (see Figure 2). Thus, the present invention provides a method for determining or assessing the prognosis of a patient with cancer, in particular, esophageal and lung cancer, by detecting the expression level of the DE-Kl gene in a biological sample of the patient; comparing the detected expression level to a control level; and determining a increased expression level to the control level as indicative of poor prognosis (poor survival).

Herein, the term "prognosis" refers to a forecast as to the probable outcome of the disease as well as the prospect of recovery from the disease as indicated by the nature and symptoms of the case. Accordingly, a less favorable, negative, poor prognosis is defined by a lower post- treatment survival term or survival rate. Conversely, a positive, favorable, or good prognosis is defined by an elevated post-treatment survival term or survival rate.

The terms "assessing the prognosis" refer to the ability of predicting, forecasting or correlating a given detection or measurement with a future outcome of cancer of the patient (e.g., malignancy, likelihood of curing cancer, survival, and the like). For example, a determination of the expression level of DKKl over time enables a predicting of an outcome for the patient (e.g., increase or decrease in malignancy, increase or decrease in grade of a cancer, likelihood of curing cancer, survival, and the like).

In the context of the present invention, the phrase "assessing (or determining) the prognosis" is intended to encompass predictions and likelihood analysis of cancer, progression, particularly cancer recurrence, metastatic spread and disease relapse. The present method for assessing prognosis is intended to be used clinically in making decisions concerning treatment modalities, including therapeutic intervention, diagnostic criteria such as disease staging, and disease monitoring and surveillance for metastasis or recurrence of neoplastic disease.

The patient-derived biological sample used for the method may be any sample derived from the subject to be assessed so long as the DKKl gene can be detected in the sample.

Preferably, the biological sample comprises an esophageal and lung cell (a cell obtained from the esophagus and lung). Furthermore, the biological sample includes bodily fluids such as sputum, blood, serum, or plasma. Moreover, the sample may be cells purified from a tissue. The biological samples may be obtained from a patient at various time points, including before, during, and/or after a treatment.

According to the present invention, it was shown that the higher the expression level of the DKKl gene measured in the patient-derived biological sample, the poorer the prognosis for post-treatment remission, recovery, and/or survival and the higher the likelihood of poor clinical outcome. Thus, according to the present method, the "control level" used for comparison may be, for example, the expression level of the DKKl gene detected before any kind of treatment in an individual or a population of individuals who showed good or positive prognosis of cancer, after the treatment, which herein will be referred to as "good prognosis control level".

Alternatively, the "control level" may be the expression level of the DKKl gene detected before any kind of treatment in an individual or a population of individuals who showed poor or negative prognosis of cancer, after the treatment, which herein will be referred to as "poor prognosis control level". The "control level" is a single expression pattern derived from a single reference population or from a plurality of expression patterns. Thus, the control level may be determined based on the expression level of the DKKl gene detected before any kind of treatment in a patient of cancer, or a population of the patients whose disease state (good or poor prognosis) is known. Preferably, cancer is esophageal and lung cancer. It is preferred, to use the standard value of the expression levels of the DKKl gene in a patient group with a known disease state. The standard value may be obtained by any method known in the art. For example, a range of mean ± 2 S.D. or mean ± 3 S.D. may be used as standard value.

The control level may be determined at the same time with the test biological sample by using a sample(s) previously collected and stored before any kind of treatment from cancer patient(s) (control or control group) whose disease state (good prognosis or poor prognosis) are known.

Alternatively, the control level may be determined by a statistical method based on the results obtained by analyzing the expression level of the DKKl gene in samples previously collected and stored from a control group. Furthermore, the control level can be a database of expression patterns from previously tested cells. Moreover, according to an aspect of the present invention, the expression level of the DKKl gene in a biological sample may be compared to multiple control levels, which control levels are determined from multiple reference samples. It is preferred to use a control level determined from a reference sample derived from a tissue type similar to that of the patient-derived biological sample.

According to the present invention, a similarity in the expression level of the DKKl gene to the good prognosis control level indicates a more favorable prognosis of the patient and an increase in the expression level to the good prognosis control level indicates less favorable, poorer prognosis for post-treatment remission, recovery, survival, and/or clinical outcome. On the other hand, a decrease in the expression level of the DKKl gene to the poor prognosis control level indicates a more favorable prognosis of the patient and a similarity in the expression level to the poor prognosis control level indicates less favorable, poorer prognosis for post-treatment remission, recovery, survival, and/or clinical outcome.

An expression level of the DKKl gene in a biological sample can be considered altered when the expression level differs from the control level by more than 1.0, 1.5, 2.0, 5.0, 10.0, or more fold. Alternatively, an expression level of the DKKl gene in a biological sample can be considered altered, when the expression level is increased or decreased to the control level at least 10%, 20%, 30%, 40%, 50%, 60%, 80%, 90%, or more.

The difference in the expression level between the test biological sample and the control level can be normalized to a control, e.g., housekeeping gene. For example, polynucleotides whose expression levels are known not to differ between the cancerous and non-cancerous cells, including those coding for β-actin, glyceraldehyde 3-phosphate dehydrogenase, and ribosomal protein Pl, may be used to normalize the expression levels of the DKKl gene.

The expression level may be determined by detecting the gene transcript in the patient- derived biological sample using techniques well known in the art. The gene transcripts detected by the present method include both the transcription and translation products, such as mRNA and protein.

For instance, the transcription product of the DKKl gene can be detected by hybridization, e.g. , Northern blot hybridization analyses, that use a DKKl gene probe to the gene transcript. The detection may be carried out on a chip or an array. The use of an array is preferable for detecting the expression level of a plurality of genes including the DKKl gene. As another example, amplification-based detection methods, such as reverse-transcription based polymerase chain reaction (RT-PCR) which use primers specific to the DKKl gene may be employed for the detection (see Example). The DKKl gene-specific probe or primers may be designed and prepared using conventional techniques by referring to the whole sequence of the DKKl gene (SEQ ID NO: 109). For example, the primers (SEQ ID NOs: 74 and 111, 73 and 74) used in the Example may be employed for the detection by RT-PCR, but the present invention is not restricted thereto.

Specifically, a probe or primer used for the present method hybridizes under stringent, moderately stringent, or low stringent conditions to the mRNA of the DKKl gene. As used herein, the phrase "stringent (hybridization) conditions" refers to conditions under which a probe or primer will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different under different circumstances. Specific hybridization of longer sequences is observed at higher temperatures than shorter sequences. Generally, the temperature of a stringent condition is selected to be about 5°C lower than the thermal melting point (Tm) for a specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30⁰C for short probes or primers (e.g., 10 to 50 nucleotides) and at least about 60⁰C for longer probes or primers. . Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Alternatively, the translation product may be detected for the assessment of the present invention. For example, the quantity of the DKKl protein may be determined. A method for determining the quantity of the protein as the translation product includes immunoassay methods that use an antibody specifically recognizing the DKKl protein. The antibody may be monoclonal or polyclonal. Furthermore, any fragment or modification (e.g., chimeric antibody, scFv, Fab, F(ab')2, Fv, etc.) of the antibody may be used for the detection, so long as the fragment retains the binding ability to the DKKl protein. Methods to prepare these kinds of antibodies for the detection of proteins are well known in the art, and any method may be employed in the present invention to prepare such antibodies and equivalents thereof.

As another method to detect the expression level of the DKKl gene based on its translation product, the intensity of staining may be observed via immunohistochemical analysis using an antibody against DKKl protein. Namely, the observation of strong staining indicates increased presence of the DKKl protein and at the same time high expression level of the DKKl gene.

Furthermore , the DKKl protein is known to have a cell proliferating activity. Therefore, the expression level of the DKKl gene can be determined using such cell proliferating activity as an index. For example, cells which express DKKl are prepared and cultured in the presence of a biological sample, and then by detecting the speed of proliferation, or by measuring the cell cycle or the colony forming ability the cell proliferating activity of the biological sample can be determined.

Moreover, in addition to the expression level of the DKKl gene, the expression level of other esophageal and lung cell-associated genes, for example, genes known to be differentially expressed in esophageal and lung cancer, may also be determined to improve the accuracy of the assessment. Such other lung cell-associated genes include those described in WO 2004/031413 and WO 2005/090603.

The patient to be assessed for the prognosis of cancer according to the method is preferably a mammal and includes human, non-human primate, mouse, rat, dog, cat, horse, and cow.

VIII. A kit for assessing the prognosis of cancer

The present invention provides a kit for assessing the prognosis of cancer. Preferably, cancer is esophageal and lung cancer. Specifically, the kit comprises at least one reagent for detecting the expression of the DKKl gene in a patient-derived biological sample, which reagent may be selected from the group of:

(a) a reagent for detecting mRNA of the DKKl gene;

(b) a reagent for detecting the DKKl protein; and

(c) a reagent for detecting the biological activity of the DKKl protein.

Suitable reagents for detecting mRNA of the DKKl gene include nucleic acids that specifically bind to or identify the DKKl mRNA, such as oligonucleotides which have a complementary sequence to a part of the DKKl mRNA. These kinds of oligonucleotides are exemplified by primers and probes that are specific to the DKKl mRNA. These kinds of oligonucleotides may be prepared based on methods well known in the art. If needed, the reagent for detecting the DKKl mRNA may be immobilized on a solid matrix. Moreover, more than one reagent for detecting the DKKl mRNA may be included in the kit.

On the other hand, suitable reagents for detecting the DKKl protein include antibodies to the DKKl protein. The antibody may be monoclonal or polyclonal. Furthermore, any fragment or modification (e.g., chimeric antibody, scFv, Fab, F(ab')2, Fv, etc.) of the antibody may be used as the reagent, so long as the fragment retains the binding ability to the DKKl protein. Methods to prepare these kinds of antibodies for the detection of proteins are well known in the art, and any method may be employed in the present invention to prepare such antibodies and equivalents thereof. Furthermore, the antibody may be labeled with signal generating molecules via direct linkage or an indirect labeling technique. Labels and methods for labeling antibodies and detecting the binding of antibodies to their targets are well known in the art and any labels and methods may be employed for the present invention. Moreover, more than one reagent for detecting the DKKl protein may be included in the kit.

Furthermore, when a cell expressing LRP5/6 and Kremen is used as the reagent, the biological activity can be determined by, for example, measuring the cell proliferating activity due to the expressed DKKl protein in the biological. For example, the cell is cultured in the presence of a patient-derived biological sample, and then by detecting the speed of proliferation, or by measuring the cell cycle or the colony forming ability the cell proliferating activity of the biological sample can be determined. If needed, the reagent for detecting the DKKl mRNA may be immobilized on a solid matrix. Moreover, more than one reagent for detecting the biological activity of the DKKl protein may be included in the kit.

The kit may comprise more than one of the aforementioned reagents. Furthermore, the kit may comprise a solid matrix and reagent for binding a probe against the DKKl gene or antibody against the DKKl protein, a medium and container for culturing cells, positive and negative control reagents, and a secondary antibody for detecting an antibody against the DKKl protein. For example, tissue samples obtained from patient with good prognosis or poor prognosis may serve as useful control reagents. A kit of the present invention may further include other materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts (e.g., written, tape, CD-ROM, etc.) with instructions for use. These reagents and such may be comprised in a container with a label. Suitable containers include bottles, vials, and test tubes. The containers may be formed from a variety of materials, such as glass or plastic.

As an embodiment of the present invention, when the reagent is a probe against the DKKl mRNA, the reagent may be immobilized on a solid matrix, such as a porous strip, to form at least one detection site. The measurement or detection region of the porous strip may include a plurality of sites, each containing a nucleic acid (probe). A test strip may also contain sites for negative and/or positive controls. Alternatively, control sites may be located on a strip separated from the test strip. Optionally, the different detection sites may contain different amounts of immobilized nucleic acids, i. e. , a higher amount in the first detection site and lesser amounts in subsequent sites. Upon the addition of test sample, the number of sites displaying a detectable signal provides a quantitative indication of the amount of DKKl mRNA present in the sample. The detection sites may be configured in any suitably detectable shape and are typically in the shape of a bar or dot spanning the width of a test strip.

The kit of the present invention may further comprise a positive control sample or KDDl standard sample. The positive control sample of the present invention may be prepared by collecting KDDl positive blood samples and then those KDDl level are assayed. Alternatively, purified KDDl protein or polynucleotide may be added to KDDl free serum to form the positive sample or the KDDl standard. In the present invention, purifyed KDDl may be recombinant protein. The KDDl level of the positive control sample is, for example more than cut off value.

Hereinafter, the present invention is described in more detail by reference to the Examples. However, the following materials, methods and examples only illustrate aspects of the invention and in no way are intended to limit the scope of the present invention. As such, methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.

EXAMPLES

Example 1:

Materials and Methods Cell Lines: The 10 human ESCC cell lines and a pharyngeal carcinoma cell line used herein included

10 squamous-cell carcinomas (SCCs; TEl, TE2, TE3, TE4, TE5, TE6, TE8, TE9, TElO, and FaDu), and one adenocarcinoma (ADC; TE7). The 25 human lung-cancer cell lines used in this study included nine adenocarcinomas (ADCs), A427, A549, LC319, PC-3, PC-9, PC-14, NCI- H1373, NCI-H1666, and NCI-Hl 781, two adenosquamous carcinomas (ASCs), NCI-H226, NCI-H647, seven squamous-cell carcinomas (SCCs), EBC-I, LU61, NCI-H520, NCI-H1703, NCI-H2170, RERF-LC-AI, and SK-MES-I, one large-cell carcinoma (LCC), LXl, and six small-cell lung cancers (SCLCs), DMSl 14, DMS273, SBC-3, SBC-5, NCI-H196, and NCI- H446. All cells were grown in monolayers in appropriate media supplemented with 10% fetal calf serum (FCS) and were maintained at 37⁰C in an atmosphere of humidified air with 5% CO₂.

Tissue Samples and Microdissection:

Tissue samples from ESCC (n=19) and from normal esophagus (n=5) were obtained from surgical specimens with informed consent. This study and the use of all clinical materials mentioned were approved by individual institutional Ethical Committees. All cancer tissues had been confirmed histologically as squamous-cell carcinoma of the esophagus by the pathologists. Clinical information was obtained from medical records (five female and 14 male patients; median age 66.6 with range 51-76 years). Clinical stage was judged according to the UICC TNM classification. Normal esophageal tissues were observed as a normal epithelium pathologically, and they were not dysplasia. All specimens were harvested immediately after surgical resection and were embedded in TissueTek OCT medium (Sakura, Tokyo, Japan) before storage at -8O⁰C. These frozen tissues were cut into 8 μm sections using a cryostat (Sakura, Tokyo, Japan) and then stained with hematoxylin and eosin for histological examination. ESCC cells and normal esophageal epithelial cells were collected selectively using the EZ cut system with a pulsed ultraviolet narrow beam-focus laser (SL Microtest GmbH, Germany) according to the manufacturer's protocols.

To obtain precise expression profiles of ESCC cells, LMM was employed to avoid contamination of the samples by non-cancerous cells. After microdissection, the five normal esophageal epithelial cells were mixed to make a 'universal control' for microarray hybridization. Figure 1 shows the microscopic images of representative cancers (A) before and after microdissection (B) and dissected cancer cells (C).

Human small airway epithelial cells (SAEC) used as a normal control were grown in optimized medium (SAGM) purchased from Cambrex Bio Science Inc. 15 primary lung-cancer samples, of which 5 were classified as ADCs, 5 as SCCs, and 5 as SCLCs, as well as 10 primary ESCC tissue samples had been obtained earlier with informed consent (Kikuchi et ah, Oncogene. 2003 Apr 10;22(14):2192-205, Yamabuki et al., Int J Oncol. 2006 Jun;28(6): 1375-84). Clinical stage was judged according to the UICC TNM classification (Sobin et ah, TNM Classification of Malignant Tumours, 6th edition. New York: Wiley-Liss, Inc., 2002). Formalin-fixed primary lung tumors and adjacent normal lung tissue samples used for immunostaining on tissue microarrays had been obtained from 279 patients (161 ADCs, 96 SCCs, 18 LCCs, 4 ASCs; 96 female and 183 male patients; median age 63.3 with range 26 - 84 years) undergoing surgery at Saitama Cancer Center (Saitama, Japan), and Hokkaido University and its affiliated hospitals (Sapporo, Japan). A total of 220 formalin-fixed primary ESCCs (18 female and 202 male patients; median age 61.4 with range 42 - 81 years) and adjacent normal esophageal tissue samples had also been obtained from patients undergoing surgery. This study and the use of all clinical materials mentioned were approved by individual institutional Ethical Committees. Serum Samples:

Serum samples were obtained with written informed consent from 220 healthy control individuals (179 males and 41 females; median age, 50.2 ± 6.8 SD; range, 31 - 61 years) who showed no abnormalities in complete blood cell counts, C-reactive proteins, erythrocyte sedimentation rates, liver function tests, renal function tests, urinalyses, fecal examinations, chest X-rays, or electrocardiograms. Serum samples were also obtained with informed consent from 94 lung cancer patients (72 males and 22 females; median age, 65.5 ± 12.3 SD; range, 30 - 86 years) admitted to Hiroshima University Hospital and its affiliated hospitals, 139 patients with lung cancer enrolled as a part of the Japanese Project for Personalized Medicine (BioBank Japan; 100 males and 39 females; median age, 64.5 ± 8.8 SD; range, 41 - 89 years). These 233 lung cancer cases included 106 ADCs, 56 SCCs, and 71 SCLCs. Serum samples were also obtained with informed consent from 67 ESCC patients who were registered in the same project of BioBank Japan (55 males and 12 females; median age, 63.8 ± 6.3 SD; range, 46 - 74 years). These serum samples from 300 cancer patients in total were selected for the study on the basis of the following criteria: (a) patients were newly diagnosed and previously untreated and (b) their tumors were pathologically diagnosed as lung or esophageal cancers (stages I - IV). Serum was obtained at the time of diagnosis and stored at -80°C. Clinicopathological records were fully documented.

cDNA Microarray:

A genome-wide cDNA microarray was fabricated with 32,256 cDNAs selected from the

UniGene database (build # 131) of the National Center for Biotechnology Information (NCBI). This microarray system was constructed essentially as described previously (Ono et ah, Cancer Res. 2000;60(18):5007-l 1). Briefly, the cDNAs were amplified by RT-PCR using poly (A)+ RNAs isolated from various human organs as templates; the lengths of the amplicons ranged from 200 to 1100 bp, without any repetitive or poly (A) sequences.

RNA Extraction, T7-based RNA Amplification, and Hybridization:

Total RNAs were extracted from each sample of laser-microdissected cells into 350 μl of RLT lysis buffer (QIAGEN, Hilden, Germany). The extracted RNAs were treated for 30 min at room temperature with 30 U of DNase I (Roche, Basel, Switzerland) in the presence of 1 U of RNase inhibitor (TOYOBO, Osaka, Japan) to remove any contaminating genomic DNA. After inactivation at 7O⁰C for 10 min, the RNAs were purified with an RNeasy Mini Kit (QIAGEN) according to the manufacturer's recommendations. All of the DNase I-treated RNAs were subjected to T7-based RNA amplification; two rounds of amplification yielded 50-100 μg of aRNA from each sample. Then 2.5 μg aliquots of aRNA from cancer cells or normal esophageal epithelial cells were labeled by reverse transcription with Cy5-dCTP or Cy3-dCTP (GE Healthcare/ Amersham Biosciences Corp.), respectively, as described elsewhere (Ono et al, Cancer Res. 2000;60(18):5007-l 1). Hybridization, washing, and scanning were also carried out according to methods described previously (Ono et al, Cancer Res. 2000;60(18):5007-l 1).

Data Analysis:

Signal intensities of Cy 3 and Cy5 from the 32,256 spots were quantified and analyzed by substituting backgrounds, using ArrayVision software (Imaging Research, Inc., St Catharines, Ontario, Canada). Subsequently, the fluorescent intensities of Cy5 (tumor) and Cy3 (control) for each target spot were adjusted so that the mean Cy3/Cy5 ratio of 52 housekeeping genes on the array was equal to one. Because data derived from low signal intensities are less reliable, a cutoff value was determined on each slide as described previously (Ono et al, Cancer Res. 2000;60(18):5007-l 1) and genes were excluded from further analysis when both Cy3 and Cy5 dyes yielded signal intensities lower than the cutoff (Saito-Hisaminato et al. , DNA Res.

2002;9(2):35-45). For other genes, the Cy5/Cy3 ratio was calculated using the raw data of each sample.

Semi-quantitative RT-PCR:

Highly up-regulated genes were selected and examined their expression levels by means of semi-quantitative RT-PCR experiments. A total of 3 μg aliquot of aRNA from each sample was reverse transcribed to single- stranded cDNAs using random primer (Roche) and Superscript II (Invitrogen). Each cDNA mixture was diluted for subsequent PCR amplification with the same primer sets that were prepared for the target DNA- or beta-actin (ACTB)-specific reactions. (Primer sequence shown in Table.3). Expression of ACTB served as an internal control. PCR reactions were optimized for the number of cycles to ensure product intensity within the linear phase of amplification.

Northern-blot Analysis:

For Northern analysis, Human Multiple Tissue Northern blots (BD Bioscience, Palo Alto, CA) were hybridized with an [α-³²P]-dCTP-labeled, 269-bp PCR product of ECT2 (C9098) that was prepared as a probe by reverse transcription-PCR (RT-PCR) using primers

5^I-CAATTTTCCCATGGTCTTATCC-3¹ (SEQ ID NO; 1) and 5'-GCGTTTTCAAGATCTAGCATGTG-S' (SEQ ID NO; 2). 1019-bp PCR product of CDC45L (A2466) was prepared as a probe by reverse transcription-PCR (RT-PCR) using primers 5'-ATGAGGAGAACACACTCTCCGT-S' (SEQ ID NO; 3) and

5'-GCTTCTACATCTCAAATCATGTCC-S ' (SEQ ID NO; 4). 776-bp PCR product of DKKl that was prepared as a probe using primers 5 '-CATCAGACTGTGCCTCAGGA-3 ' (SEQ ID NO : 111) and 5'-CAAAAACTATC AC AGCCTAAAGGG-3¹ (SEQ ID NO: 74).

Pre-hybridization, hybridization, and washing were performed following manufacturer's specifications. The blots were autoradiographed with intensifying screens at -80°C for 7 days.

RNA Interference Assay:

To evaluate the biological functions of ECT2 and CDC45L in cancer cells, a psiHlBX3.0 vector was used for expression of short-hairpin RNA against the target gene, as described previously (Shimokawa T, et ah, Cancer Res. 2003;63(19):6116-20). The Hl promoter was cloned into upstream of the gene-specific sequence (19-nucleotide sequence from the target transcript, separated from the reverse complement of the same sequence by a short spacer, TTCAAGAGA (SEQ ID NO; 5)), with five thymidines as a termination signal and a neo-cassette for selection by Geneticin (Sigma). The target sequences of the synthetic oligonucleotides for RNAi were as follows: control 1 (EGFP: enhanced green fluorescent protein (GFP) gene, a mutant of Aequorea victoria GFP), 5'-GAAGCAGCACGACTTCTTC-S' (SEQ ID NO; 6); control 2 (Scramble (SCR): chloroplast Euglena gracilis gene coding for 5S and 16S rRNAs), 5'- GCGCGCTTTGTAGGATTCG-3 ' (SEQ ID NO; 7);

si-ECT2-l, 5'-GATGCACTCACCTTGTAGT-S' (SEQ ID NO; 8); si-ECT2-2, 5'-GGCAAATACTCCTGAGCTC-3^I; (SEQ ID NO; 9) si-CDC45L-l, 5'-GAGACATCCTCTTTGACTA-S'; (SEQ ID NO; 10) si-CDC45L-2, 5'-CAGACCAGTGGGTGCAAGA-S' (SEQ ID NO; 11). FaDu and TE9 cells were plated onto 10-cm dishes (1.5x 10⁶ cells per dish), and transfected with psiHIBX vectors that included the target sequences for EGFP, SCR, ECT2, and CDC45L, using Lipofectamine 2000 (Invitrogen), according to the manufacturers' instructions. Cells were selected in medium containing 1 mg/ml of Geneticin (Invitrogen) for 7 days and harvested after 4 days for RT-PCR analysis of knockdown effects on individual genes. Primers for these RT-PCR experiments were the same as those described above. After 7 days of incubation, these cells were stained by Giemsa solution to assess colony formation, and cell numbers were assessed by 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Western-blotting:

Tumor tissues or cells were lysed in lysis buffer; 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% NP40, 0.5% sodium deoxycholate, and Protease Inhibitor Cocktail Set III (Calbiochem). The protein content of each lysate was determined by a Bio-Rad protein assay (Bio-Rad, Hercules, CA) with bovine serum albumin (BSA) as a standard. Ten micrograms of each lysate were resolved on a 10% to 12% denaturing polyacrylamide gel (with 3% polyacrylamide stacking gel) and transferred electrophoretically to a nitrocellulose membrane (GE Healthcare Bio-sciences). After blocking with 5% non-fat dry milk in TBST, the membrane was incubated with primary antibodies for 1 hour at room temperature. Immunoreactive proteins were incubated with horseradish peroxidase-conjugated secondary antibodies (GE Healthcare Bio-sciences) for 1 hour at room temperature. After washing with TBST, the reactants were developed using the enhanced chemiluminescence kit (GE Healthcare Bio-sciences). A commercially available rabbit polyclonal antibody to human DKKl (Catalog No. sc-25516, Santa Cruz, CA) was proved to be specific to human DKKl, by western-blot analysis using lysates of NSCLC and ESCC tissues and cell lines as well as normal tissues {see Fig. 2).

Immunocytoehemical Analysis:

Cells were plated on glass coverslips (Becton Dickinson Labware, Franklin Lakes, NJ), fixed with 4% paraformaldehyde, and permeablilized with 0.1% Triton X-100 in PBS for 3 minutes at room temperature. Nonspecific binding was blocked by CASBLOCK (ZYMED) for 10 minutes at room temperature. Cells were then incubated for 60 minutes at room temperature with primary antibodies diluted in PBS containing 3% BSA. After being washed with PBS, the cells were stained by FITC-conjugated secondary antibody (Santa Cruz) for 60 minutes at room temperature. After another wash with PBS, each specimen was mounted with Vectashield (Vector Laboratories, Inc, Burlingame, CA) containing 4',6'-diamidine-2'- phenylindolendihydrochrolide (DAPI) and visualized with Spectral Confocal Scanning Systems (TSC SP2 AOBS: Leica Microsystems, Wetzlar, Germany).

Immunohistochemistry and Tissue Microarray :

To investigate the presence of DKKl protein in clinical samples that had been embedded in paraffin blocks, the present inventors stained the sections in the following manner. Briefly, 3.3 μg/ml of a rabbit polyclonal anti-human DKKl antibody (Santa Cruz) was added to each slide after blocking of endogenous peroxidase and proteins, and the sections were incubated with horseradish peroxidase-labeled anti-rabbit IgG (Histofme Simple Stain MAX PO (G), Nichirei, Tokyo, Japan) as the secondary antibody. Substrate-chromogen was added, and the specimens were counterstained with hematoxylin. Tumor tissue microarrays were constructed with formalin-fixed 279 primary lung cancers and 220 primary esophageal cancers, as described elsewhere (Chin et al, MoI Pathol. 2003 Oct;56(5):275-9; Callagy et al, Diagn MoI Pathol. 2003 Mar;12(l):27-34, J Pathol. 2005 Feb;205(3):388-96). The tissue area for sampling was selected based on visual alignment with the corresponding H&E-stained section on a slide. Three, four, or five tissue cores (diameter, 0.6 mm; depth, 3 - 4 mm) taken from a donor tumor block were placed into a recipient paraffin block with a tissue microarrayer (Beecher Instruments, Sun Prairie, WI). A core of normal tissue was punched from each case, and 5-μm sections of the resulting microarray block were used for immunohistochemicaϊ analysis. Three independent investigators semi-quantitatively assessed DKKl positivity without prior knowledge of clinicopathological data, as reported previously (Suzuki et al, Cancer Res. 2005 Dec 15;65(24): 11314-25; Ishikawa et al, Clin Cancer Res. 2004 Dec 15;10(24):8363-70, Cancer Res. 2005 Oct 15;65(20):9176-84; Kato et al, Cancer Res. 2005 M l;65(13):5638-46; Furukawa et al, Cancer Res. 2005 Aug 15;65(16):7102-10). The intensity of DKKl staining was evaluated using following criteria: strong positive (scored as 2+), dark brown staining in more than 50% of tumor cells completely obscuring cytoplasm; weak positive (1+), any lesser degree of brown staining appreciable in tumor cell cytoplasm; absent (scored as 0), no appreciable staining in tumor cells. Cases were accepted as strongly positive only if reviewers independently defined them as such.

Statistical Analysis:

Statistical analyses were performed using the StatView statistical program (SaS, Cary, NC). Tumor-specific survival curves were calculated from the date of surgery to the time of death related to NSCLC or ESCC, or to the last follow-up observation. Kaplan-Meier curves were calculated for each relevant variable and for DKKl expression; differences in survival times among patient subgroups were analyzed using the log-rank test. Univariate and multivariate analyses were performed with the Cox proportional-hazard regression model to determine associations between clinicopathological variables and cancer-related mortality. First, the present inventors analyzed associations between death and possible prognostic factors including age, gender, histology, pT-classification, and pN-classification taking into consideration one factor at a time. Second, multivariate Cox analysis was applied on backward (stepwise) procedures that always forced strong DKKl expression into the model, along with any and all variables that satisfied an entry level of a P-value less than 0.05. As the model continued to add factors, independent factors did not exceed an exit level of P < 0.05.

ELISA:

Serum levels of DKKl were measured by ELISA system which had been originally constructed. First of all, a rabbit polyclonal antibody specific for DKKl (Santa Cruz) was added to a 96-well microplate (Apogent, Denmark) as a capture antibody and incubated for 2 hours at room temperature. After washing away any unbound antibody, 5% BSA was added to the wells and incubated for 16 hours at 4⁰C for blocking. After a wash, 3 -fold diluted sera were added to the wells and incubated for 2 hours at room temperature. After washing away any unbound substances, a biotinylated polyclonal antibody specific for DKKl using Biotin Labeling Kit-NH2 (Dojindo Molecular Technologies, Inc.) was added to the wells as a detection antibody and incubated for 2 hours at room temperature. After a wash to remove any unbound antibody- enzyme reagent, HRP-streptavisin was added to the wells and incubated for 20 minutes. After a wash, a substrate solution (R&D Systems, Inc.) was added to the wells and allowed to react for 30 minutes. The reaction was stopped by adding 100 μl of 2 N sulfuric acid. Color intensity was determined by a photometer at a wavelength of 450 run, with a reference wavelength of 570 nm. Levels of CEA in serum were measured by ELISA with a commercially available enzyme test kit (HOPE Laboratories, Belmont, CA), according to the supplier's recommendations. Levels of ProGRP in serum were measured by ELISA with a commercially available enzyme test kit (TFB, Tokyo, Japan), according to the manufacturer's protocol. Differences in the levels of DKKl, CEA, and proGRP between tumor groups and a healthy control group were analyzed by Mann- Whitney U tests. The levels of DKKl₅ CEA, and ProGRP were additionally evaluated by receiver-operating characteristic (ROC) curve analysis to determine cutoff levels with optimal diagnostic accuracy and likelihood ratios. The correlation coefficients between DKKl and CEA/proGRP were calculated with Spearman rank correlation. Significance was defined as P < 0.05.

DKKl Expression Plasmids:

Constructs of a wild-type and point mutant form of C-terminal FLAG-tagged DKKl with asparagine 256 to alanine were generated as reported elsewhere (Suzuki et ah, Cancer Res. 2005 Dec 15;65(24):11314-25). COS-7 cells transfected either with p3XFLAG-tagged plasmids expressing DKKl (wild-type or point mutant) or with mock plasmids were used for western-blot analyses.

Matrigel Invasion Assay: NIH3T3 and COS-7 cells transfected either with ρ3 XFL AG-tagged (C-terminal) plasmids expressing DKKl or with mock plasmids were grown to near confluence in DMEM containing 10% FCS. The cells were harvested by trypsinization, washed in DMEM without addition of serum or proteinase inhibitor, and suspended in DMEM at 1 x 10⁵ cells/ml. Before preparing the cell suspension, the dried layer of Matrigel matrix (Becton Dickinson Labware) was rehydrated with DMEM for 2 hours at room temperature. DMEM (0.75 ml) containing 10% FCS was added to each lower chamber in 24- well Matrigel invasion chambers, and 0.5 ml (5 x 10⁴ cells) of cell suspension was added to each insert of the upper chamber. The plates of inserts were incubated for 24 hours at 37°C. After incubation the chambers were processed; cells invading through the Matrigel were fixed and stained by Giemsa as directed by the supplier (Becton Dickinson Labware).

Example 2:

Genes Commonly Down/Up-regulated in ESCC

Genes commonly up- and down-regulated in ESCCs were identified according to the following criteria: (1) genes for which expression data was available in more than 50% (at least 10 of the 19 cases) of the cancers examined; and (2) genes whose expression ratio was more than 3.0 in ESCC cells (defined as up-regulated genes) in more than 40% of informative cases or genes whose expression ratio was less than 0.33 (defined as down-regulated genes) in more than 50% of informative cases. A total of 727 genes commonly down-regulated in ESCC are listed in Table 1, while 816 genes commonly up-regulated are in Table2.

To validate the expression data obtained by microarray analysis, semi-quantitative RT- PCR experiments were performed for the genes which were highly over-expressed in almost all informative cases. Among the candidates above, 38 genes were selected (C 1948, A9371, E0341, A3097, A2735, A5065, D9504, C6209, B3827, A4513, E0556, A8172, A3802, C8926, A9723, G3996, F5946, B7534, A7296, A8487, C9490, C9858, E0133, A7856, A7608, A7908, C9098, C9517, C9046, A8335, C9016, A6598, B4161, E2191, B6125N, D8457, B8814, and A2466) and their gene expression pattern was confirmed in tumor and normal tissues using semi-quantitative RT-PCR (Figure 2). The results of RT-PCR experiments were exclusively concordant with microarray data in the tested cases.

Example 3:

Genes Associated with Lymph-node Metastasis or Post-surgery Recurrence. To detect relations between gene expression profiles and clinico-pathological features, the present inventors searched for genes that were possibly associated with lymph-node metastasis, an important factor in determining a patient's prognosis.

Genes associated with clinico-pathological features, such as lymph-node metastasis positive (node-positive) (r) and node-negative (n), recurrence positive (r) and recurrence negative (n), were chosen according to following two criteria: (i) signal intensities are higher than the cutoff value in at least 80% of the cases; and (ii) |Medr-Medn| >0.5, where Med indicates the median derived from log-transformed relative expression ratios in two groups. Genes were selected as candidates when they met the criteria with a permutation P-value of smaller than 0.05 in each clinico-pathological status.

To begin with, expression profiles and lymph-node metastasis status were examined using 13 lymph-node-positive and six node-negative cases. A random permutation test was applied to identify genes that were expressed differently in the two groups. The mean (μ) and standard deviation (σ) were calculated from the log-transformed relative expression ratios of each gene in node-positive (r) and node-negative (n) cases, recurrence-positive (r) and recurrence-negative (n) cases, respectively. A discrimination score (DS) for each gene was defined as follows:

DS = (μ_r- μ_n) / (σ_r + σ_n)

Permutation tests were carried out to estimate the ability of individual genes to distinguish between two groups; samples were randomly permutated between the two classes 10 000 times. Since the DS data set of each gene showed a normal distribution, the present inventors calculated a P-value for the user-defined grouping (Golub et ah, Science. 1999;286(5439):531-7).

Herein, the expression data of 19 cases consisting of 13 lymph-node-positive and 6 lymph-node-negative cases, and those of 19 cases consisting of six recurrent-positive cases and 13 recurrent-negative cases was utilized. Analysis resulted in the identification of 136 genes that were associated with lymph-node status by a random permutation (P-value <0.05). Of these, 59 genes were down-regulated (Table 4), and 77 genes were relatively up-regulated (Table 5) in node-positive tumors (Figure 6). In addition, the expression profiles of six cases with recurrence were compared with those of 13 cases without recurrence after surgery during observation periods of 32 months. The sites of recurrence included local, lung, and regional lymph-nodes. 37 genes were identified that showed altered expression patterns uniquely in cases that had recurrence: 28 of them (Table 7) were relatively up-regulated and 9 of them (Table 6) were relatively down-regulated in tumors (Figure 7). Supervised hierarchical clustering analysis using these identified gene sets was also able to clearly classify the groups with regard to lymph-node status or those with recurrence (Figures 6 and 7).

Example 4: ECT2 Northern blot analysis using an ECT2 cDNA fragment as a probe identified a 4.3-kb transcript that was expressed only in testis; no expression was observed in any other organs examined. ECT2 was thought to encode a cancer-testis antigen (CTA) (Figure 3A).

To assess whether ECT2 plays a role in growth or survival of cancer cells, plasmids were designed and constructed to express siRNA against ECT2 (si-ECT2-l (#1) and -2 (#2)), along with two different control plasmids (siRNAs for EGFP and SCR), and transfected them into TE9 cells that endogenously express high levels of ECT2 to suppress expression of endogenous ECT2. The amount of ECT2 mRNA in the cells transfected with si-ECT2-l and si-ECT2-2 was significantly decreased in comparison with cells transfected with any of the two control siRNAs (Figure 4A). In accord with its suppressive effect on levels of ECT2, transfected si-ECT2-l and si-ECT2-2 caused significant decreases in colony numbers and cell viability measured by colony-formation and MTT assays (Figure 4B and 4C). Similar effects were observed in the FaDu cell line (data not shown).

Example 5: CDC45L

Northern blot analysis using a CDC45L cDNA fragment as a probe identified a 2.2-kb transcript that was expressed only in testis; no expression was observed in any other organs examined. CDC45L was thought to encode a cancer-testis antigen (CTA) (Figure 3B).

To assess whether CDC45L plays a role in growth or survival of cancer cells, plasmids were designed and constructed to express siRNA against CDC45L (si-CDC45L-l (#1) and -2 (#2)), along with two different control plasmids (siRNAs for EGFP and SCR), and transfected them into FaDu cells that endogenously express high levels of CDC45L to suppress expression of endogenous CDC45L. The amount of CDC45L mRNA in the cells transfected with si- CDC45L-1 and si- CDC45L-2 was significantly decreased in comparison with cells transfected with any of the two control siRNAs (Figure 5A). In accord with its suppressive effect on levels of CDC45L, transfected si-CDC45L-l and si-CDC45L-2 caused significant decreases in colony numbers and cell viability measured by colony- formation and MTT assays (Figure 5B and 5C). Similar effects were observed in the TE9 cell line (data not shown). Example 6: DKKl DKKl Expression in Lung and Esophageal Cancers and Normal Tissues:

To identify novel molecules that can detect cancer cells at an early stage and be applied for the individualized treatments based on the biological characteristics of cancer cells, the present inventors performed a genome-wide analysis of gene expression profiles of lung carcinoma and ESCC cells purified by laser microdissection using a cDNA microarray (Kikuchi T et al, Oncogene. 2003 Apr 10;22(14):2192-205, Int J Oncol. 2006 Apr;28(4):799-805, Kakiuchi S et al, MoI Cancer Res. 2003 May;l(7):485-99, Hum MoI Genet. 2004 Dec ^• 15;13(24):3029-43. Epub 2004 Oct 20, Yamabuki et al, Int J Oncol. 2006 Jun;28(6): 1375-84). Among 27,648 genes screened, the present inventors identified DKKl transcript, indicating 3- fold or higher mean fold expression in cancer cells than in normal epithelial cells (control) in the great majority of the lung and esophageal cancer samples examined. The present inventors confirmed its over-expression by means of semi-quantitative RT-PCR experiments in 10 of 15 lung cancer tissues, in 21 of 25 lung-cancer cell lines, in 10 of 10 ESCC tissues, and in 10 of 10 ESCC cell lines (Figs. 2A-C).

The present inventors subsequently confirmed by western-blot analysis using anti-DKKl antibody an expression of 35-kDa DKKl protein in tumor tissues in representative pairs of NSCLC samples analyzed (Fig. 2D).

Northern blot analysis using a DKKl cDNA fragment as a probe identified a transcript of about 1.8 kb that was highly expressed in placenta and at a very low level in prostate; no expression was observed in any other normal tissues (Fig. 3C). The present inventors performed immunofluorescence analysis to examine the subcellular localization of endogenous DKKl in ESCC cell line TE8 and NSCLC cell line LC319. DKKl was detected at cytoplasm of tumor cells with granular appearance (representative data of TE8 cells was shown in Fig. 3D).

Association of DKKl Expression with Poor Prognosis.

To verify the biological and clinicopathological significance of DKKl, the present inventors carried out immunohistochemical staining on tissue microarray containing tissue sections from 279 NSCLC and 220 ESCC cases that underwent curative surgical resection. DKKl staining with polyclonal antibody specific for DKKl was mainly observed at cytoplasm of tumor cells, but not detected in normal cells (Figs. 8A, C). The present inventors classified a pattern of DKKl expression on the tissue array ranging from absent (scored as 0) to weak/strong positive (scored as 1+ ~ 2+). Of the 279 NSCLCs, DKKl was strongly stained in 125 (44.8%; score 2+), weakly stained in 102 (36.6%; score 1+), and not stained in 52 cases (18.6%: score 0) (details are shown in Table 10A). The median survival time of NSCLC patients was significantly shorter in accordance with the higher expression levels of DKKl (P = 0.0039 by log-rank test; Fig. 8D). The present inventors also applied univariate analysis to evaluate associations between patient prognosis and several factors including age, gender, histology (ADC versus non-ADC), pT stage (tumor size; Tl+ T2 versus T3+T4), pN stage (NO versus N1+N2), and DKKl status (score 2+ vs 0, 1+). All those parameters were significantly associated with poor prognosis. Multivariate analysis using a Cox proportional-hazard model determined that DKKl (P = 0.0163)- was an independent prognostic factor for surgically treated NSCLC patients (Table 10B). On the other hand, of the 220 ESCC cases examined, DKKl was strongly stained in 60 (27.3%; score 2+), weakly stained in 75 (34.1%; score 1+) and not stained in 85 cases (38.6%; score 0) (details are shown in Table 9A). The median survival time of ESCC patients was significantly shorter in accordance with the higher expression levels of DKKl (P = 0.042 by log-rank test; Fig. 8B). The present inventors also applied univariate analysis to evaluate associations between ESCC patient prognosis and several factors including age, gender, pT stage (tumor depth; Tl+ T2 versus T3+T4), pN stage (NO versus Nl), and DKKl status (score.2+ vs 0, 1+). All those parameters were significantly associated with poor prognosis. Multivariate analysis using a Cox proportional-hazard model determined that DKKl was not an independent prognostic factor for surgically treated ESCC patients (Table 9B).

N-glycosylation of DKKl in Cancer Cells.

DKKl protein was reported to be expressed as approximately 35-kDa protein in cells transfected with DKKl expressing vector, and secreted in the culture medium as forms of 35 - 40 kDa protein (Fedi et al, J Biol Chem. 1999 JuI 2;274(27): 19465-72, Niida et al, Oncogene. 2004 Nov 4;23(52):8520-6). As shown in Figure 1OA, exogenous DKKl protein was recognized by western-blot analysis as band around 35 - 40-kDa in the conditioned medium of transfected COS-7 cells. Secreted DKKl protein was detected as double bands by western-blotting. Therefore, the present inventors first incubated cell extracts and proteins collected from the conditioned medium from the transfected COS-7 cells in the presence or absence of N- glycosydase F and analyzed the molecular weight of DKKl protein by western-blot analysis. Expectedly, the measured weight of the majority of DKKl protein in the cell extracts and conditioned medium treated with N-glycosydase F was smaller than that in the untreated cells (Fig. 10A). Because DKKl possesses one potential N-glycosylation site located close to the C- terminus of the protein (asparagine-256), the present inventors replaced the potential N- glycosylation site (asparagine-256) in DKKl to alanine. Mutated DKKl was detected by western-blot analysis as immunoreactive bands of similar molecular weight to the deglycosylated form of wild type DKKl in the conditioned medium and in cell pellet (Fig. 10A). Treatment with N-glycosidase F did not cause any shift of a mutant band of DKKl in the cell pellet and conditioned medium (Fig. 10A). These results suggested that asparagine-256 was a cognate N- glycosylation site of DKKl, but did not affect the secretion of DKKl.

Serum Levels of DKKl in Patients with Lung cancer or ESCC.

Since the in vitro findings had suggested a possibility to develop a novel tumor maker using the secreted forms of DKKl, the present inventors investigated whether the DKKl protein is secreted into sera of patients with lung or esophageal cancer. ELISA experiments detected DKKl protein in serological samples from these patients. The mean (± ISD) of serum DKKl in lung cancer patients was 27.2 ± 21.0 U/ml and those in ESCC patients were 33.5 ± 25.3 U/ml. In contrast, the mean (± ISD) serum levels of DKKl in healthy individuals were 6.3 ± 5.0 U/ml. The difference was significant with P-value of < 0.001 (Mann- Whitney U test). When classified according to histologic type in lung cancer, the serum levels of DKKl were 25.5 ± 18.4 U/ml in ADC patients, 24.7 ± 17.7 U/ml in SCC patients, and 31.8 ± 25.8 U/ml in SCLC patients (Fig. 9A); the differences among the three histologic types were not significant.

The levels of DKKl were additionally analyzed in serum samples from both lung cancer and ESCC patients as well as healthy individuals by drawing receiver-operating characteristic (ROC) curves to determine their cutoff levels (Fig. 9B). Cutoff level in this assay was set to result in optimal diagnostic accuracy and likelihood ratios for DKKl, i.e., 14.7 U/ml (with a sensitivity of 63.7% (191/300) and a specificity of 95.9% (211/220). The mean (± 2SD) of serum DKKl levels in healthy individuals were 16.3 U/ml, suggesting that this cutoff point is appropriate.

To evaluate the feasibility of using serum DKKl level as a tumor detection biomarker, the present inventors also measured by ELISA serum levels of CEA for NSCLC and proGRP for SCLC patients, two conventional tumor markers for these histological types of lung cancer, in the same patients and controls. The cut off value of CEA was determined to be 2.5 ng/ml (with a sensitivity of 40.3% (64/159) and a specificity of 97.1% (204/210)) in patients with NSCLC. The correlation coefficient between serum DKKl and CEA values was not significant (Spearman rank correlation coefficient: p = -0.034, P = 0.668), indicating that measuring both markers in serum can improve overall sensitivity for detection of NSCLC to 78.6% (125 of 159) (for diagnosing NSCLC, the sensitivity of CEA alone is 40.3% (64 of 159) and that of DKKl is 61.6% (98 of 159).). False-positive rates for either of the two tumor markers among normal volunteers (control group) amounted to 8.2% (17 of 208), whereas the false-positive rates for CEA and DKKl in the same control group were 2.9% (6 of 208) and 5.3% (11 of 208) individually. On the other hand, ROC analyses for proGRP in the patients with SCLC determined the cutoff value of ProGRP as 46.0 pg/ml (with a sensitivity of 60.6% (40 of 66) and a specificity of 99.3% (145 of 146). The correlation coefficient between serum DKKl and ProGRP values was not significant (Spearman rank correlation coefficient: p = 0.113 , P = 0.362), indicating that measuring both markers in serum can improve overall sensitivity for detection of SCLC to 84.8% (56 of 66) (for diagnosing SCLC, the sensitivity of ProGRP alone is 60.6% (40 of 66) and that of DKKl is 63.6% (42 of 66)). False-positive results for either of the two tumor markers among 146 normal volunteers (control group) amounted to 6.2% (9 of 146), whereas the false-positive rates for proGRP and DKKl in the same control group were 0.7% (lof 146) and 5.5% (8 of 146) individually.

Activation of Cellular Invasive Activity by DKKl.

As the immunohistochemical analysis on tissue microarray had indicated that lung and esophageal cancer patients with DKKl positive tumors showed shorter cancer-specific survival period than patients whose tumors were negative for DKKl, the present inventors examined a possible role of DKKl in cellular motility and invasion in Matrigel assays, using NIH3T3 and COS-7 cells. As shown in Figure 10B₅ C, transfection of DKKl cDNA into either cell line significantly enhanced its invasive activity through Matrigel, compared to cells transfected with mock vector.

Discussion

In spite of improvement of modern surgical techniques and adjuvant chemoradiotherapy, lung cancer and ESCC are known to reveal the worst prognosis among malignant tumors. Therefore it is now urgently required to develop novel diagnostic biomarkers for early detection of cancer and for the better choice of adjuvant treatment modalities to appropriate patients. The present inventors performed a genome-wide analysis of gene expression profiles of 101 lung cancers and 19 ESCC cells purified by laser microbeam microdissection (LMM) using a cDNA microarray containing 27,648 genes (Yamabuki et al Int J Oncol. 2006 Jun;28(6): 1375-84; Kikuchi et al, Oncogene. 2003 Apr 10;22(14):2192-205, Int J Oncol. 2006 Apr;28(4):799-805; Kakiuchi et al, MoI Cancer Res. 2003 May;l(7):485-99, Hum MoI Genet. 2004 Dec 15;13(24):3029-43. Epub 2004 Oct 20). In the process, the present inventors identified a number of genes that were potentially good candidates for development of novel diagnostic markers, therapeutic drugs, and/or immunotherapy (Suzuki et al, Cancer Res. 2003 Nov l;63(21):7038-41, Cancer Res. 2005 Dec 15;65(24):11314-25; Ishikawa et al.. Clin Cancer Res. 2004 Dec 15;10(24):8363-70, Cancer Res. 2005 Oct 15;65(20):9176-84; Kato et al, Cancer Res. 2005 JuI l;65(13):5638-46; Furukawa et al, Cancer Res. 2005 Aug 15;65(16):7102- 10). Among them, the genes encoding putative tumor-specific transmembrane or secretory proteins are considered to have significant advantages, because they are present on the cell surface or within the extracellular space, and/or in serum, making them easily accessible as molecular markers and therapeutic targets. In this study, the present inventors selected an up- regulated gene (DKKl) encoding secretory protein, and examined the protein expression status by means of tissue microarray analysis and ELISA to identify novel diagnostic and prognostic biomarker(s) for lung cancer and/or ESCC.

DKKl is a 266-amino acid protein that contains a signal peptide sequence and two cysteine-rich domains (Fedi et al, J Biol Chem. 1999 JuI 2;274(27): 19465-72), and is known to be a secreted protein that functions as a negative regulator of Wnt signaling and plays a crucial role in head formation in vertebrate development (Glinka et al, Nature. 1998 Jan

22;391(6665):357-62; Fedi et al, J Biol Chem. 1999 JuI 2;274(27): 19465-72; Mao efal, Nature.

2002 Jun 6;417(6889):664-7. Epub 2002 May 26, Nature. 2001 May 17;411(6835):321-5;

Mukhopadhyay et al, Dev Cell. 2001 Seρ;l(3):423-34). In addition, DKKl is reported to be a downstream target of β-catenin/TCF and participate in a negative feedback loop in Wnt signaling

(Gonzalez et al, Oncogene. 2005 Feb 3;24(6):1098-103; Niida et al, Oncogene. 2004 Nov

4;23(52):8520-6).

A family of human DKK (hDKK)-related genes were composed of DKKl, DKK2, DKK3, and DKK4, together with a unique DKK3 related protein termed Soggy (Sgy). hDKKs 1-4 contain two distinct cysteine-rich domains in which the positions of 10 cystein residues are highly conserved between family members. hDKKl and hDKK4, but not hDKK2, hDKK3 or Sgy, suppress Wnt-induced secondary axis induction in Xenopus embryos (Krupnik et άl, Gene. 1999 Oct l;238(2):301-13). DKK4 was found to show high specificity for gastric cancer by serial analysis of gene expression (SAGE) and quantitative reverse transcription (RT)-PCR (Aung et al, Oncogene. 2006 Apr 20;25(17):2546-57). Other studies have demonstrated over- expression of DKKl in Wilms' tumor, hepatoblastoma, and hepatocelluar carcinoma (HCC) (Wirths et al, Lab Invest. 2003 Mar;83(3):429-34; Patil et al, Oncogene. 2005 May

26;24(23):3737-47), but clinical utility of DKKl protein as a serological/histochemical marker in human cancer was not indicated previously. Like a DKKl protein, Wnt inhibitory factor- 1 (WIF-I) and Frizzeled related protein (FRP) were known to be secreted molecules, which have been indicated to bind to Wnt proteins and inhibit their activity (Hsieh et al., Nature. 1999 Apr l;398(6726):431-6; Wodarz et al, Annu Rev Cell Dev Biol. 1998;14:59-88; Moon et al, Dev Suppl. 1993;:85-94). These two proteins were reported to be associated with human cancer including colorectal carcinoma (Cebrat et al, Cancer Lett. 2004 Mar 31;206(l):107-13). FRP-4 protein showed markedly increased expression levels in colorectal cancers compared to normal mucosa, but no significant associations with pathological features or with patient outcome (Horvath et al, Clin Cancer Res. 2004 Jan 15;10(2):615-25). Since various DKK-family proteins had been described as being over-expressed in human cancers (Aung et al, Oncogene. 2006 Apr 20;25(17):2546-57; Horvath et al, Clin Cancer Res. 2004 Jan 15;10(2):615-25), DKKl seemed likely to have a potential role in tumor development or progression.

In the present invention, the present inventors demonstrated that induction of exogenous expression of DKKl enhanced the cellular migration/invasive activity of normal mammalian cells. Concordantly, the strong DKKl -staining in primary NSCLC tissues detected by tissue-microarray analyses correlated with poorer prognosis. Although the precise function of DKKl in lung and esophageal carcinogenesis is unknown, and the processes of cancer-cell invasion to adjacent tissues and distant metastasis consist of a complex series of sequential step, these results indicate that DKKl expression could promote dissemination of tumors by stimulating cell migration. DKKl has been described as a secreted protein which plays a crucial role in head formation in vertebrate development, and is known as a negative regulator of Wnt signaling (Niida et al, Oncogene. 2004 Nov 4;23(52):8520-6). DKKl binds to LRP5/6 and Kremen proteins, thus inducing LRP endocytosis, which prevents the formation of Wnt-Frizzled- LRP5/6 receptor complexes (Gonzalez et al, Oncogene. 2005 Feb 3;24(6): 1098-103). However, when the present inventors analyzed mRNA expression of DKKl and LRP5/6 in lung and esophageal cancer cell lines and cancer tissues by semi-quantitative RT-PCR, the expression pattern of LRP5/6 was not concordant with that of DKKl (data not shown). Additional studies to identify unknown binding-partners and receptors of DKKl in human cancers may contribute not only to identification of novel tumor markers and therapeutic targets, but also should yield new understanding of the signaling pathway mediated by DKKl expression.

The present inventors confirmed the C-terminus potential site, asparagines-256 was an N-glycosylation site in DKKl by using enzymatic treatment and alanine-replacement mutant, but it did not affect the secretion of DKKl . Recently, various cancer-specific antigen including carbohydrate antigens were reported as a serum tumor marker. Specific glycosylation has been used for diagnostic purposes; i.e. alpha-fetoprotein (AFP) for hepatocarcinoma (Poon et ah, Clin Chem. 2002 Jul;48(7):1021-7), human pancreatic ribonuclease, which has different oligosaccharide chains when produced by pancreatic tumor cells (Peracaula et ah, Glycobiology. 2003 Apr;13(4):227-44. Epub 2002 Nov 26), or prostate-specific antigen (PSA), the tumor marker currently used for prostate cancer screening (Tabares et ah, Glycobiology. 2006 Feb; 16(2): 132-45. Epub 2005 Sep 21). Changes inN-linked glycosylation were reported to occur during the development of cancer. Increased branching of oligosaccharides has been associated with metastasis and correlated with tumor progression in human cancers of the breast, colon and melanomas (Comunale et ah, J Proteome Res. 2006 Feb;5(2):308-15). Although further evaluation will be necessary, glycosylation of DKKl could be a novel diagnostic and therapeutic target for lung and esophageal cancer treatment.

To examine the feasibility of applying DKKl as the diagnostic tool, the present inventors compared serum levels of DKKl with those of CEA or ProGRP, a conventional diagnostic markers for NSCLCs and SCLCs, in terms of sensitivity and specificity for diagnosis. The proportions of positive cases among the same serum samples were more than 60% for DKKl, while the false-positive rate for DKKl was around 5.0%, indicating equivalent or better diagnostic power of DKKl to that of CEA. Furthermore, an assay combining both markers (DKK1+CEA or DKKl+ProGRP) increased the sensitivity such that about 80% of the patients with lung cancer were diagnosed as positive while 6.2 - 8.2% of healthy volunteers were falsely diagnosed as positive. Although further validation using a larger set of serum samples covering various clinical stages will be necessary, the data presented here sufficiently demonstrate a potential clinical application of DKKl itself as a serological/histochemical marker for lung and esophageal cancers.

In conclusion, the present inventors have identified DKKl as a potential biomarker for diagnosis of lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKKl was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKKl, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.

Industrial Applicability

The gene expression analysis of esophageal cancer described herein, obtained through a combination of laser-capture dissection and genome-wide cDNA microarray, has identified specific genes as targets for cancer prevention and therapy. Based on the expression of a subset of these differentially expressed genes, the present invention provides molecular diagnostic markers for identifying and detecting esophageal cancer.

The methods described herein are also useful in the identification of additional molecular targets for prevention, diagnosis and treatment of esophageal cancer. The data reported herein add to a comprehensive understanding of esophageal cancer, facilitate development of novel diagnostic strategies, and provide clues for identification of molecular targets for therapeutic drugs and preventative agents. Such information contributes to a more profound understanding of esophageal tumorigenesis, and provides indicators for developing novel strategies for diagnosis, treatment, and ultimately prevention of esophageal cancer.

Futhermore, the methods described herein are also useful in diagnosis of cancer including lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. Moreover, the data reported here is also provide a likely candidate for development of therapeutic approaches for cancer including lung and esophageal cancers.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, including definitions, will control.

All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.

While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope of the invention. Table.1 down-regulated genes

^Llt LMMID ACCESSION SYMBOL GENENAME

IO

Ribonuclease/angiogenin

1 A0906 NM_002939 RNH inhibitor

2 A1350 NMJH3314 BLNK B -cell linker

Gap junction protein, beta 2,

3 A1475 BCO 17048 GJB2

26kDa (connexin 26)

4 A2014 L23959 TFDPl Transcription factor Dp-I

Claudin 5 (transmembrane

A2460 AF000959 CLDN5 protein deleted in velocardiofacial syndrome)

Pancreatic lipase-related

6 A3340 M93284 PNLIPRP2 protein 2

7 A3821 NM_004925 AQP3 Aquaporin 3

SH3 domain binding glutamic

8 A4472 AF042081 SH3BGRL acid-rich protein like

9 A4587 AF070609 SLCl A3 DKFZP547J0410 protein

Discs, large homolog 3

10 A0283 NM 021120 DLG3 (neuroendocrine-dlg,

Drosophila)

Transmembrane 4 superfamily

11 A1365 D10653 TM4SF2 member 2

AHNAK nucleoprotein

12 A3322 M80899 AHNAK

(desmoyokin)

G-protein signalling modulator

13 A5658 AJ243937 GPSM3

3 (AGS3-like, C. elegans)

Aldehyde dehydrogenase 3

14 A0765 BC004102 ALDH3A1 family, member Al

15 A1215 NM 002275 KRTl 5 Keratin 15

16 A1879 U45955 GPM6B Glycoprotein M6B

Carboxylesterase 2 (intestine,

17 A1758 U60553 CES2 liver)

18 A2363 NM_000060 BTD Biotinidase

Ras homolog gene family,

19 A6156 BU616881 ARHE member E

G protein-coupled receptor

20 A2487 D 10923 GPRl 09B

109B

Caspase 5, apoptosis-related

21 A2747 NM_004347 CASP5 cysteine protease

Hydroxy steroid (11 -beta)

22 A3095 U26726 HSDl 1B2 dehydrogenase 2

Phospholipase A2 receptor 1,

23 A3605 NM_007366 ^■ PLA2R1

18OkDa

Elongation factor, RNA

24 A3701 BC028412 ELL2 polymerase II, 2

Bladder cancer associated

25 A4481 AF053470 BLCAP protein A4832 D78011 DPYS Dihydropyrimidinase

Unc-13 homolog B (C.

A4744 AF020202 UNC13B elegans) l-acylglycerol-3 -phosphate O- acyltransferase 1

A5888 U56417 AGPATl

(lysophosphatidic acid acyltransferase, alpha)

Small pro line-rich protein IB

Al 063 BU600928 SPRRlB

(cornifm)

DNA segment on chromosome

A2029 BC034227 D4S234E 4 (unique) 234 expressed sequence

Amino-terminal enhancer of

A2126 U04241 AES split

Transglutaminase 3 (E

A3237 L10386 TGM3 polypeptide, protein-glutamine- gamma-glutamyltransferase)

Sodium channel, nonvoltage-

A4875 NM 000336 SCNNlB gated 1, beta (Liddle syndrome)

Inositol(myo)-l(or 4)-

A5816 AF014398 IMPA2 monophosphatase 2

A6077 XM 499570 PLXNA2 Plexin A2

A0365 Ul 7077 BENE BENE protein

A0946 U62961 OXCTl 3-oxoacid CoA transferase 1

Oculocutaneous albinism II

A1479 NM 000275 OCA2 (pink-eye dilution homolog, mouse)

SlOO calcium binding protein

A2565 BG676358 S100A8

A8 (calgranulin A)

Protein phosphatase 1,

A2372 AF458589 PPPl Rl 2A regulatory (inhibitor) subunit

12A

Cellular retinoic acid binding

A2840 BM480033 CRABP2 protein 2

A4474 AF047433 ITGB4BP Integrin beta 4 binding protein

Aldehyde dehydrogenase 4

A5088 U24266 ALDH4A1 family, member Al

Mitogen-activated protein

A5127 AF004709 MAPKl 3 kinase 13

AO 102 BC053866 EDN3 Endothelin 3

Al 064 NM_024164 TPSB2 Tryptase, alpha

Epoxide hydrolase 2,

A0685 L05779 EPHX2 cytoplasmic

2',5'-oligoadenylate synthetase

A1591 NM_002534 OASl l, 40/46kDa

A1199 NM 005018 PDCDl Programmed cell death 1

Solute carrier family 4, anion

A2031 NM 003040 SLC4A2 exchanger, member 2

(erythrocyte membrane protein band 3-like 1)

Prostaglandin-endoperoxide A3454 M59979 PTGSl synthase 1 (prostaglandin G/H synthase and cyclooxygenase)

Lectin, galactoside-binding, A4242 BM909803 LGALS7 soluble, 7 (galectin 7)

N-deacetylase/N- A4723 NM 001543 NDSTl sulfotransferase (heparan glucosaminyl) 1

CD 58 antigen, (lymphocyte

Al 073 C A312671 CD58 function-associated antigen 3)

A2142 AF055008 GRN Granulin

SlOO calcium binding protein

A2566 BQ927179 S100A9

A9 (calgranulin B)

A2366 NM_000700 ANXAl Annexin Al

Neurofilament, light

A4109 AK075003 NEFL polypeptide 68kDa

A5695 NM 001839 CNN3 Calponin 3, acidic

Glycine amidinotransferase (L-

A0961 NM 001482 GATM arginine: glycine amidinotransferase)

Gelsolin (amyloidosis, Finnish

A1592 NMJ)OO 177 GSN type)

Al 873 M58297

A2129 M29877 FUCAl Fucosidase, alpha-L- 1, tissue

UDP glycosyltransferase 1

A3246 BCOl 1409 UGT1A6 family, polypeptide A9

Chromosome 1 open reading

A3853 AF007170 Clorf34 frame 34

A5399 R44471 NEBL Nebulette

Acetyl-Coenzyme A

Al 074 D90228 ACATl acety transferase 1 (aceto acetyl

Coenzyme A thiolase)

Glutathione peroxidase 3

A1610 NM 002084 GPX3

(plasma)

Carboxylesterase 1

A1754 AB119995 CESl (monocyte/macrophage serine esterase 1)

A2336 BC032528 LTA4H Leukotriene A4 hydrolase

A3061 U07643 LTF Lactotransferrin

A2742 NM 002272 KRT4 Keratin 4

A4614 NM_007283 MGLL Monoglyceride lipase

Mitogen-activated protein

A0830 NM_002746 MAPK3 kinase 3

A1501 NM_006225 PLCDl Phospholipase C, delta 1

Myosin, light polypeptide 1,

A2886 M20643 MYLl alkali; skeletal, fast

A5400 AK122818 BTBDI l BTB (POZ) domain containing 11

CDNA FLJl 1723 fis, clone

78 A6073 AI290541 HEMBAl 005314 Transforming growth factor,

79 A0090 BC040499 TGFBR2 beta receptor II (70/8OkDa) Lectin, galactoside-binding,

80 Al 046 AF266280 LGALS3 soluble, 3 (galectin 3) Transglutaminase 1 (K polypeptide epidermal type I,

81 A0662 BC034699 TGMl protein-glutamine-gamrna- glutamyltransferase)

82 A2608 NM_002230 JUP Junction plakoglobin • . Serine (or cysteine) proteinase

83 A3338 M93056 SERPINBl inhibitor, clade B (ovalbumin), member 1

General transcription factor

84 A3345 BC004452 GTF2H1 HH, polypeptide 1, 62kDa Aldo-keto reductase family 1,

85 A4076 BC008837 AKRlBlO member BlO (aldose reductase) Low density lipoprotein-related

86 A3738 NM 002332 LRPl protein 1 (alpha-2- macroglobulin receptor) DEAH (Asp-Glu-Ala-His) box

87 A4586 D86977 DHX38 polypeptide 38 Ras homolog gene family,

88 A6282 BC001338 RHOD member D

89 A5002 NM_006137 CD7 CD7 antigen (p41) Mitogen-activated protein

90 A0249 U09578 MAPKAPK3 kinase-activated protein kinase 3

91 A0922 NM_004394 DAP Death-associated protein MaI, T-cell differentiation

92 A0654 BC000458 MAL protein

93 A2733 NM 005013 NUCB2 Nucleobindin 2

94 A3114 M95585 HLF Hepatic leukemia factor TBCl domain family, member

95 A5230 BC021927 TBClDlO 10

96 A2188 J02770 IF I factor (complement)

97 A3037 BC030975 ILlRLl Interleukin 1 receptor-like 1 Fatty acid binding protein 5

98 A3283 BQ446473 FABP5 (psoriasis-associated) Adaptor-related protein

99 A4162 BM471531 AP2S1 complex 2, sigma 1 subunit

100 A4677 S80562 CNN3 Calponin 3, acidic Mannose-P-dolichol utilization

101 A5951 CR610474 . MPDUl defect 1

102 A4015 D29767 TEC Tec protein tyrosine kinase

103 A4054 NM 144505 KLK8 Kallikrein 8 (neuropsin/ovasin) Protease inhibitor 3, skin-

104 A4146 BQ941085 PI3 derived (SKALP) Mevalonate (diphospho)

105 A4699 NM_002461 MVD decarboxylase

V-erb-b2 erythroblastic leukemia viral oncogene

106 A5159 BC080193 ERBB2 homolog 2, neuro/glioblastoma derived oncogene homolog

(avian)

107 AlOlO D28475 CLCN6 Chloride channel 6

108 A1414 NMJ)Ol 855 COL15A1 Collagen, type XV₅ alpha 1

MADS box transcription enhancer factor 2, polypeptide

109 A1951 AL833268 MEF2C C (myocyte enhancer factor

2C)

110 A2158 NM_005410 SEPPl Selenoprotein P, plasma, 1

Solute carrier family 26 (sulfate

111 A2189 NMJ)OOl 12 SLC26A2 transporter), member 2

112 A4163 NM 006001 TUBA2 Tubulin, alpha 2

113 A4388 NM_001988 EVPL Envoplakin

Aldehyde dehydrogenase 1

114 A2291 AF003341 ALDHlAl family, member Al

Loss of heterozygosity, 11,

115 A2444 AY366508 LOH11CR2A chromosomal region 2, gene A

116 A2796 NM_006681 NMU Neuromedin U

Caspase 1, apoptosis-related

117 A2802 CR592117 CASPl cysteine protease (interleukin 1, beta, convertase)

118 A3412 NM 000552 VWF Von Willebrand factor

119 A0593 NM_002290 LAMA4 Laminin, alpha 4

3 -hydroxy-3 -methylglutaryl-

120 A1415 L25798 HMGCSl Coenzyme A synthase 1

(soluble)

Eukaryotic translation

121 A2159 L10340 EEF1A2 elongation factor 1 alpha 2

N-acylsphingosine

122 A2306 U70063 ASAHl amidohydrolase (acid ceramidase) 1

123 A4810 AF077599 RNF41 Ring finger protein 41

124 A5155 NM_000418 IL4R Interleukin 4 receptor

Single-minded homolog 2

125 A0304 U80456 SIM2 (Drosophila)

126 A0856 M32402 PI l 26 serine protease

127 A0574 NM_033018 PCTKl PCTAIRE protein kinase 1

Paired-like homeodomain

128 A1564 U70370 PITXl transcription factor 1

129 A1832 M74297 HOXA4 Homeo box A4

130 A2664 BC033820 FGL2 Fibrinogen-like 2

131 A3291 BM805032 PRSS2 Protease, serine, 2 (trypsin 2)

132 A4179 NM_002769 PRSSl Protease, serine, 1 (trypsin 1)

3 -hydroxy anthranilate 3,4-

133 A4297 NM_012205 HAAO dioxygenase 134 A4695 NM_001003395 TPD52L1 Tumor protein D52-like 1 Ankyrin repeat and SOCS box- 135 A5849 NM 024095 ASB8 containing 8

Down syndrome critical region

136 A097.1 AY034086 DSCRlLl gene 1 -like 1 Phosphoenolpyruvate 137 A2307 NM 004563 PCK2 carboxykinase 2 (mitochondrial) Inositol polyphosphate- 1-

138 A4517 L08488 INPPl phosphatase 139 A5442 AF105036 KLF4 Kruppel-like factor 4 (gut) Topoisomerase (DNA) H beta 140 A0461 NMJ)Ol 068 TOP2B 18OkDa

ATPase, aminophospholipid

141 A6143 BX648675 ATP8A1 transporter (APLT), Class I, type 8A, member 1 Calcium channel, voltage- 142 A4298 Z34821 CACNAlC dependent, L type, alpha 1C subunit

Inhibitor of DNA binding 4,

143 A5048 BC014941 ID4 dominant negative helix-loop- helix protein

144 A1553 BC023505 ECMl Extracellular matrix protein 1 Electron-transferring-

145 A2192 BCOl 1890 ETFDH flavoprotein dehydrogenase Amphiregulin (schwannoma-

146 A300.9 BC009799 AREG derived growth factor)

147 A4144 BC004376 ANXA8 Annexin A8

148 A5966 BX647538 FRMD4A FERM domain containing 4A

149 A0578 NM_004417 DUSPl Dual specificity phosphatase 1 Rab geranylgeranyltransferase,

150 A1938 Y08200 RABGGT alpha subunit Programmed cell. death 4

151 A2440 U96628 PDCD4 (neoplastic transformation inhibitor)

152 A3027 M28827 CDlC CDlC antigen, c polypeptide

153 A2836 BQ926240 TNNI2 Troponin I, skeletal, fast Pleiotrophin (heparin binding

154 A3269 NM_002825 PTN growth factor 8, neurite growth-promoting factor 1)

155 A3299 BM696587 CRYAB Crystallin, alpha B Myeloid/lymphoid or mixed- lineage leukemia (trithorax

156 A3816 NM 005938 MLLT7 homolog, Drosophila); translocated to, 7 l-acylglycerol-3 -phosphate O-

157 A5752 AL832919 AGPAT3 acyltransferase 3

158 A0451 V00497 HBB Hemoglobin, beta

159 A0597 X72760 LAMB2 Laminin, beta 2 (laminin S)

160 A1240 ABOO 1895 ARIDlA AT rich interactive domain IA (SWI- like)

Protocadherin 1 (cadherin-like

161 A1411 BC035812 PCDHl

1)

162 A1932 J03037 CA2 Carbonic anhydrase II

163 A2822 BQ015859 CSTA Cystatin A (stefϊn A)

Microsomal glutathione S-

164 A2935 BM552331 MGST2 transferase 2

Signal transducing adaptor

165 A3502 U43899 STAM molecule (SH3 domain and

ITAM motif) 1

166 A3534 NM_005554 KRT6A Keratin 6A

Rho GTPase activating protein

167 A3127 D29642 ARHGAP25

25

168 A3923 AF038440 PLD2 Phospholipase D2

SlOO calcium binding protein

169 A4145 AA586894 S100A7

A7 (psoriasin 1)

Peptidylprolyl isomerase C

170 A4265 BM907670 PPIC

(cyclophilin C)

Chromosome 14 open reading

171 A5739 AAl 02482 C14orfl l4 frame 114

Capping protein (actin

172 Al 163 M94345 CAPG filament), gelsolin-like

173 A2450 NMJ)01740 CALB2 Calbindin 2, 29kDa (calretinin)

ATPase, Ca++ transporting,

174 A3380 L20977 ATP2B2 plasma membrane 2

175 A3187 NM_000240 MAOA Monoamine oxidase A

Kallikrein 7 (chymotryptic,

176 A3300 NM_005046 KLK7 stratum corneum)

177 A4794 AF064493 LDB2 LIM domain binding 2

178 A4830 NM_004557 NOTCH4 Notch homolog 4 (Drosophila)

Elongation factor, RNA

179 A5436 BQ009281 ELL2 polymerase II, 2

180 A5200 U10248 RPL29 Ribosomal protein L29

Erythrocyte membrane protein

181 A8063 AL832598 EPB41L3 band 4.1 -like 3

Cytochrome P450, family 3,

182 A7978 BC025176 CYP3A5 subfamily A, polypeptide 5

183 A9285 AI027810 KIAAl 102 KIAAl 102 protein

B-box and SPRY domain

184 A8996 AK092607 BSPRY containing

185 B4069 M77830 DSP Desmoplakin

186 B6764 . M14338 PROSl Protein S (alpha)

187 C3614 D31883 ABLIMl Actin binding LIM protein 1

188 A8863 BM678420 Transcribed locus

189 C4904 AY359010 KLK5 Kallikrein 5

190 A7103 NM 004949 ^' DSC2 Desmocollin 2

191 A7156 X78706 CRAT Carnitine acetyltransferase

Nicotinamide nucleotide

192 B0149 AF052090 NNT transhydrogenase

193 B0259 AA234962 PKP3 Plakophilin 3 194 B4864 NM 002145 HOXB2 Homeo box B2

195 A6512 AAl 67624 HSPC159 HSPC 159 protein Neural proliferation,

196 A8688 CR597998 NPDCl differentiation and control, 1

197 A9175 NM_015270 ADCY6 Adenylate cyclase 6 GRINLlA complex upstream

198 C4884 AA036952 Gupl protein

F-box and leucine-rich repeat

199 B2793 AA603460 FBXLl 7 protein 17

200 A7307 AB032981 KIAAl 155 KIAAl 155 protein Transcribed locus, moderately similar to XP_126365.1

201 A9545 AA563634 RIKEN cDNA 9830002117 gene [Mus musculus]

202 B0878 NM 005797 EVAl Epithelial V-like antigen 1

203 B4406 AF279865 KIF13B Kinesin family member 13B

204 A8203 AK026966 AK3 Adenylate kinase 3

205 A7795 BC044582 UBL3 Ubiquitin-like 3

206 A8115 CA310913 GLTP Glycolipid transfer protein

207 A9458 AA028101 KIAA0303 KIAA0303 protein Hypothetical protein from

208 A9467 BC045658 LOC57228 clone 643

209 A7145 X52005

Signal transducing adaptor

210 A8433 NM_005843 STAM2 molecule (SH3 domain and

ITAM motif) 2

Platelet-derived growth factor

211 B4086 NM_006206 PDGFRA receptor, alpha polypeptide

212 B4409 XM 371116 MYO5B Myosin VB

213 B6820 XM 497078 NUP188 Nucleoporin 188kDa

214 A7798 BC015033 PLD2 Phospholipase D2

Chromosome 2 open reading

215 A8832 BX648017 C2orfl8 frame 18

Homo sapiens, clone

216 A9468 BXl 10596

IMAGE:4799216, mRNA

217 B2482 AI125528 KIAA0476 KIAA0476

218 A6944 AI310102 Transcribed locus

219 B0278 AB037832 KIAA1411 KIAA1411

220 B2135 X03212 KRT7 Keratin 7

GDP-mannose

221 B3676 NM_013334 GMPPB pyrophosphorylase B

Endothelial cell growth factor 1

222 B4060 NMJ)01953 ECGFl

(platelet-derived)

223 B2801 AK130734 FLJ13710 Hypothetical protein FLJl 3710

Likely ortholog of mouse

224 A6388 AK056894 FLJ32332 protein phosphatase 2C eta

Hypothetical protein

225 A6673 AL137430 LOC283070

LOC283070

226 A8525 W67837 EMP2 Epithelial membrane protein 2

227 A9178 XM 168530 PCLO Piccolo (presynaptic cytomatrix protein)

Full-length cDNA clone

228 B1734 AA633746 CSODFOl 8 YA02 of Fetal brain of Homo sapiens (human)

229 A6522 BC045177 FL J30046 Hypothetical protein FLJ30046 230 A9011 BQ772268 PCBP2 Poly(rC) binding protein 2 231 A9307 BC053677 FLJ37562 Hypothetical protein FLJ37562 Potassium channel

232 B5826 AK027572 KCTD6 tetramerisation domain containing 6

233 B4068 AB011140 PPL Periplakin 234 C2083 NM 002277 KRTHAl Keratin, hair, acidic, 1 •

235 A6317 AI205684 HSP A2 Heat shock 7OkDa protein 2 TBCl domain family, member

236 A6581 AK093231 TBClDlO 10

Phosphatidylinositol glycan,

237 A9099 N70592 PIGN class N

238 A8964 AI091459 FLJ20489 Hypothetical protein FLJ20489 239 B0629 AK126877 FLJ10521 Hypothetical protein FLJl 0521 Similar to solute carrier family

240 B1354 XM_496241 16, member 6; monocarboxylate transporter 6

241 B1614 AY555274 PF6 Projection protein PF6 242 B4141 D79994 ANKRD 15 Ankyrin repeat domain 15 243 A7204 CA430351 TXN Thioredoxin 244 A7244 BQ706286 MXD4 MAX dimerization protein 4 Snf7 homologue associated

245 B1495 AK000049 Shax3 with Alix 3

246 A6712 NM_182643 DLCl Deleted in liver cancer 1 RAB6A, member RAS

247 A7393 AK123452 RAB6A oncogene family Thyroid hormone receptor, alpha (erythroblastic leukemia

248 A7425 NM 003250 THRA viral (v-erb-a) oncogene homolog, avian) Tumor necrosis factor, alpha-

249 A8162 AL832955 TNFAIP9 induced protein 9 Receptor tyrosine kinase-like

250 A7679 M97675 RORl orphan receptor 1

251 B2073 NM 001002857 ANXA2 Annexin A2

252 B2084 S45018 CHAT Choline acetyltransferase

253 A6486 W67936 RAI RelA-associated inhibitor

254 A7454 AF007162 CRYAB Crystallin, alpha B CAMP -binding guanine nucleotide exchange factor IV

255 B2657 BM696564 (cAMP-GEFIV) mRNA, clone Wl 5, partial sequence Hypothetical protein

256 B0364 BC002714 MGC4171 MGC4171 257 B0968 BM271861 SPATAI l Spermatogenesis associated 11 N-acylsphingosine

258 A7235 M92449 ASAHL amidohydrolase (acid ceramidase)-like

Major histocompatibility

259 A7689 X00457 HLA-DPAl complex, class II, DP alpha 1

260 A9203 CR608541 PHFl 7 PHD finger protein 17

Chromosome 9 open reading

261 A9368 NM_022833 C9orf88 frame 88

262 ^• B4602 NM_005556 KRT7 Keratin 7

Sulfide quinone reductase-like

263 A6719 AI302184 SQRDL

(yeast)

CTD (carboxy-terminal- domain, RNA polymerase II,

264 A7464 AF081287 CTDPl polypeptide A) phosphatase, subunit 1

Nuclear transcription factor, X-

265 A7773 NM 002504 NFXl box binding 1

Chromosome 13 open reading

266 A8378 NM 032859 C13orf6 frame 6

Full-length cDNA clone

267 B0550 AA843150 CSODFOl 4 YA22 of Fetal brain of Homo sapiens (human)

ATP synthase, H+ transporting, mitochondrial Fl complex,

268 B4213 NM 001001937 ATP5A1 alpha subunit, isoform 1, cardiac muscle

Zinc finger protein 137 (clone

269 B4816 NM_003438 ZNF137 pHZ-30)

270 B7573 BC040481 ZHXl Zinc fingers and homeoboxes 1

SAM and SH3 domain

271 A8790 H70803 SASHl containing 1

272 B2399 AY358351 UNC5B Unc-5 homolog B (C. elegans)

273 C4330 BC006000 CAPNS2 Calpain, small subunit 2

274 A6336 AK097223 NAGK N-acetylglucosamine kinase

Hypothetical protein

275 A9115 BC001080 MGC2749

MGC2749

276 B2659 AI025259 Transcribed locus

Dishevelled associated

277 B5443 NM_014992 DAAMl activator of morphogenesis 1

Major histocompatibility

278 C4095 ^' NM_002122 HLA-DQAl complex, class II, DQ alpha 1

Benzodiazapine receptor

279 A6322 BU623850 BZRP

(peripheral)

280 A6358 AK056079 JAM2 Junctional adhesion molecule 2

Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5

281 A7432 M32313 SRD5A1 alpha-steroid delta 4- dehydrogenase alpha 1)

282 A9103 AK091635 FLJl 1200 Hypothetical protein FLJl 1200

283 B0646 AA644351 EMPl Epithelial membrane protein 1 284 B0773 AA761873 SNXl 6 Sorting nexin 16 285 B4674 AA149429 ATPlOD ATPase, Class V, type 1OD 286 B6559 AB002296 KIAA0298 KIAA0298 gene product 287 A6599 BC035309 TM4-B Tetraspanin TM4-B

Purinergic receptor P2Y, G-

288 A7467 BC034989 P2RY14 protein coupled, 14

Transmembrane 4 superfamily

289 B2658 N62647 TM4SF9 member 9

290 B0243 AKOOO 140 PLAC8 Placenta-specific 8

Immunoglobulin heavy

291 B 1676 BC025985 IGHG4 constant gamma 4 (G4m marker)

292 B2253 BX494965 Transcribed locus

Clone TUA8 Cri-du-chat

293 C4665 AK022877 region mRNA

Fer-1-like 3, myoferlin (C.

294 A6617 AF182316 FER1L3 elegans)

Adaptor protein containing pH

295 A7917 AF169797 APPL domain, PTB domain and leucine zipper motif 1

N-ethylmaleimide-sensitive

296 A9104 AF135168 NSF factor

Hypothetical protein

297 A9110 BC006282 MGC 10540

MGCl 0540

Polymerase (RNA) I

298 B0340 AK097973 MGC9850 polypeptide D, 16kDa

Hypothetical protein

299 B0774 AL832398 MGC26717

MGC26717

Mannosidase, alpha, class 1C,

300 B5066 AF318353 MANlCl member 1

301 B6561 ABO 14544 KIAA0644 KIAA0644 gene product

Killer cell lectin-like receptor

302 A6751 NM_002258 KLRBl subfamily B₅ member 1

303 A7091 N31935 ANGPTLl Angiopoietin-like 1

Secretory carrier membrane

304 A8186 BM551020 SCAMP2 protein 2

Protein phosphatase 1,

305 A8823 N26005 PPP1R3C regulatory (inhibitor) subunit

3C

306 A9125 BG745799 CRYLl Crystallin, lambda 1

307 B 1647 BC047536 SCEL Sciellin

308 B4810 BM701072 KIAAO 103 KIAAO 103

Amiloride-sensitive cation

309 B5424 NM_020039 ACCN2 channel 2, neuronal

310 B2978 AA442090 FLJl 0292 Hypothetical protein FLJ 10292

311 B7110 AKl 24752 PCDH21 Protocadherin 21

312 B8940 BX641066 KLF8 Kruppel-like factor 8

Methionine sulfoxide reductase

313 B9198 AK123132 MSRA

A RAS guanyl releasing protein 1

314 A9475N AF081195 RASGRPl (calcium and DAG-regulated) 315 B4930 ALl 10157 DUSP7 Dual specificity phosphatase 7 Syndecan binding protein 316 B6765N AI346913 SDCBP2 (syntenin) 2 Phospholysine

317 B6373 BX423161 LHPP phosphohistidine inorganic pyrophosphate phosphatase Lymphocyte antigen 6

318 B8264 NM_025261 LY6G6C complex, locus G6C 319 B8308 NM_001001936 KIAA1914 KIAA1914

RAB25, member RAS ^• 320 B8276 BC009831 RAB25 oncogene family 321 A3308N NM_000889 ITGB7 Integrin, beta 7

Protein kinase, lysine deficient

322 A8588 BM683764 PRKWNK4 4 323 B4591 BM747025 PERP PERP, TP53 apoptosis effector Solute carrier family 6

324 B6688 NM 003042 SLC6A1 (neurotransmitter transporter, GABA), member 1 Clone IMAGE: 110436 mRNA

325 B6103 T89283 sequence

G protein-coupled receptor

326 B7741^" NMJ77551 GPRl 09A 109A

Actin binding LIM protein

327 B8954 NM_032432 ABLIM2 family, member 2 Carboxypeptidase A3 (mast

328 A0774N BC012613 CP A3 cell)

329 B1821N AA886340 CDHl 6 Cadherin 16, KSP-cadherin Inhibitor of DNA binding 4,

330 B0830N BM473615 ID4 dominant negative helix-loop- helix protein Hypothetical protein

331 B4592 BC051895 AMMECRl LOC286505 PDZ and LIM domain 2

332 B7105 AK055782 PDLIM2 (mystique)

Family with sequence

333 B7281 NM_058186 FAM3B similarity 3, member B

334 B8081 BM981462 FLJ13710 Hypothetical protein FLJl 3710

335 B9611 AB051541 KIAAl 754 KIAAl 754

336 A0720N L21998 MUC2 Mucin 2, intestinal/tracheal

337 A9346N AY358379 PP2135 PP2135 protein

338 B3339 AA728828 TNNI2 Troponin I, skeletal, fast

339 B4613 H57105 FLJ20273 RNA-binding protein Phosphatidylinositol glycan,

340 B7353N NM_176787 ■ PIGN class N

T-complex-associated-testis-

341 A0955N NM_006520 TCTElL expressed 1 -like

342 B3349N AK056590 FLJ32028 Hypothetical protein FLJ32028

343 B3762 BC035311 ZD52F10 Dermokine Hypothetical protein

344 B6524 BM992839 MGC39820

MGC39820

Adenomatosis polyposis coli

345 B7323N ABl 04887 APCDDl down-regulated 1

346 B9836 R79561 ARRDC3 Arrestin domain containing 3

Leukocyte immunoglobulin- like receptor, subfamily B

347 A1779N AF025534 LILRB5

(with TM and ITIM domains), member 5

Lectin, galacto side-binding,

348 A6777 BQ276959 LGALS2 soluble, 2 (galectin 2)

349 B3330 AA709236 Transcribed locus

Similar to 2010300C02Rik

350 B3655 BC068277 MGC42367 protein

Suppressor of cytokine

351 B3929 AK024356 SOCS6 signaling 6

Interferon consensus sequence

352 B6319 BX414085 ICSBPl binding protein 1

Cytochrome P450, family 2,

353 B7526 R40594 CYP2U1 subfamily U, polypeptide 1

Leukotriene B4 12-

354 B7360 BU619898 LTB4DH hydroxydehydrogenase

355 A0708N NM_000092 COL4A4 Collagen, type IV, alpha 4

SH3 domain binding glutamic

356 B5126 BXl 09845 SH3BGRL2 acid-rich protein like 2

357 B5917N BX648213 PALMD Palmdelphin

Glycerol-3 -phosphate

358 B5381N D42047 GPDlL dehydrogenase 1 -like

359 B6553 AF506799 KIBRA KIBRA protein

Hy droxypro staglandin

360 A1807N NM_000860 HPGD dehydrogenase 15-(NAD)

361 A9493N BX094381

Chromosome 14 open reading

362 B3930 XM_290629 C14orf78 frame 78

Elongation factor, RNA

363 B3965 BX538289 ELL2 polymerase II, 2 RAB40A, member RAS

364 B9454 AA033857 RAB40A oncogene family GRB2-associated binding

365 B9462 BC030115 GABl protein 1

Cytoplasmic polyadenylation

366 B9652 N47682 CPEB4 element binding protein 4 RABl 1 family interacting

367 A6574N AJ314646 RAB11FIP4 protein 4 (class II) Low density lipoprotein

368 B4922N AY358399 LRPlO receptor-related protein 10 Hypothetical protein

369 B7465 AL161983 MGC39820 MGC39820

370 B8295 NM 003884 PCAF P300/CBP-associated factor WD40 repeat protein

371 B8485 CA308403 WIPI49 Interacting with phospholnositides of 49kDa

Transcribed locus, weakly similar to XP_375099.1

372 B9620 AL050204 hypothetical protein

LOC283585 [Homo sapiens]

373 A3079 J04599 BGN Biglycan

374 A1981 U58514 CHI3L2 Chitinase 3 -like 2

Complement component 1, q

375 A6696 NM_012072 ClQRl subcomponent, receptor 1

EGF, latrophilin and seven

376 B3933 AY358360 ELTDl transmembrane domain containing 1

377 B4392N BC006428 CXXC5 CXXC finger 5

378 B7167N BC059408 OVOLl Ovo-like l(Drosophila)

Similar to B230208J24Rik

379 B9455 BQ447358 protein

Hypothetical protein

380 B7425 BC033858 MGC45474 MGC45474

381 B9112 AI096890 RRAGD Ras-related GTP binding D

SlOO calcium binding protein

AlO (annexin II ligand,

382 A2547N BMO 17946 SlOOAlO calpactin I, light polypeptide

CpH))

383 A4385N BC039031 IL1R2 Interleukin 1 receptor, type II

Protein phosphatase 2,

384 B3586 AA748009 PPP2R5E regulatory subunit B (B56), epsilon isoform

385 B4083 NM_003156 STIMl Stromal interaction molecule 1

Benzodiazapine receptor

386 A7666N CA426441 BZRP (peripheral)

387 B4291 AK025198 XIST X (inactive)-specific transcript

388 B5776N AF492675 HOP Homeodomain-only protein

389 B8377 AAl 94913 FLJ38725 Hypothetical protein FLJ38725

CDNA clone

390 B7082 AK055323 IMAGE: 5263177, partial cds

391 B8932 AK127123 TOLLIP Toll interacting protein

Chromosome 1 open reading

392 B9135 BC066977 Clorf40 frame 40

393 A0240N NM 198974 PTK9 PTK9 protein tyrosine kinase 9

394 B3108 NMJ)15669 PCDHB5 Protocadherin beta 5

Retinol dehydrogenase 12 (all-

395 B6482 BC025724 RDH12 trans and 9-cis)

396 B9470 N29574 RRAGD Ras-related GTP binding D

397 A8259N AA496108 BNC2 Basonuclin 2

398 A8292N AB037811 FLJl 1280 Hypothetical protein FLJl 1280

Cyclin-dependent kinase

399 B3851 BC018984 CDKN2B inhibitor 2B (pi 5, inhibits

CDK4) 400 B6267 AB020715 PCYOXl Prenylcysteine oxidase 1

NAD(P)H dehydrogenase,

401 B6807N AA921756 NQOl quinone 1

402 A2019N AA442410 EMPl Epithelial membrane protein 1

3 -hydroxy-3 -methylglutaryl-

403 A8869N BU737722 HMGCR

Coenzyme A reductase

Heat shock protein (hspl 10

404 B4042 AW966019 APG-I family)

Chromosome 14 open reading

405 B8379 XM_113763 C14orfl25 frame 125

Serine (or cysteine) proteinase

406 A2081N BC012609 SERPINB2 inhibitor, clade B (ovalbumin), member 2

407 B5059N T88953 Transcribed locus

408 B6498 CR613330 PYM PYM protein

Solute carrier family 7 (cationic

409 B5992 NM_003045 SLC7A1 amino acid transporter, y+ system), member 1

410 B8234 AF070632 Clone 24405 mRNA sequence

Regulator of G-protein

411 A4375N NM_003617 RGS5 signalling 5

Kruppel-like factor 5

412 B5419 AF287272 KLF5

(intestinal)

413 B6656 BU624522 Transcribed locus

Alpha-methylacyl-CoA

414 B7367 CR616479 AMACR racemase

415 B7435 AK093246 RPLl 3 Ribosomal protein Ll 3

RAB27B, member RAS

416 B8627 R39044 RAB27B oncogene family

CDNA: FLJ21274 fis, clone

417 B8909 BM786734

COL01781

Malic enzyme 1, NADP(+)-

418 B6405 AA045332 MEl dependent, cytosolic

419 B7221N AW952452 KNS2 Kinesin 2 60/7OkDa

Early endosome antigen 1 ,

420 B8404 AF173389 EEAl

162kD

Endometrial bleeding associated factor (left-right

421 A4381N U81523 EBAF determination, factor A; transforming growth factor beta superfamily)

422 B3417 AA719160 Transcribed locus

Chromosome 10 open reading

423 B3725 AL832397 C10orf57 frame 57

424 B4062 X14640 KRTl 3 Keratin 13

425 B4848N AY052784 ^' PRSS2 Protease, serine, 2 (trypsin 2)

426 B7193N BX109986 Transcribed locus

Dimethylarginine

427 B4114 NM_012137 DDAHl dimethylaminohydrolase 1

428 B4330 AB020637 KIAA0830 KIAA0830 protein Chromosome 9 open reading

429 B6510 BX648949 C9orf45 frame 45

430 C0800 AI037967 TWIST2 Twist homolog 2 (Drosophila)

T-cell lymphoma invasion and

431 C8469 CR597039 TIAMl metastasis 1

Phosphatidylinositol transfer

432 C4440 AA807607 PITPNCl protein, cytoplasmic 1

Family with sequence

433 C6675 AY358677 FAM3D similarity 3, member D

434 C8953 AL136678 DEPDC6 DEP domain containing 6

Hypothetical protein

435 C6100 BC071614 DKFZp762A217

DKFZp762A217

436 C7625 BU684240 EHF Ets homologous factor 437 C7512 NMJ)OO 186 . CFH Complement factor H

RNA (guanine-9-)

438 C9271 AV728846 RG9MTD3 methyltransferase domain containing 3

RABlO, member RAS

439 C3769 AK023223 RABlO oncogene family

440 C6082 AB041036 KLKI l Kallikrein l l

Lectin, galactoside-binding,

441 C7013 AA058314 LGALS3 soluble, 3 (galectin 3)

442 C7133 NM 139205 HDAC5 Histone deacetylase 5 443 C7172 AF377960 CTTNBP2 Cortactin binding protein 2

Cytochrome P450, family 1,

444 C8462 NM_000104 CYPlBl subfamily B, polypeptide 1

Chromosome 20 open reading

445 C8844 BM916826 C20orfl04 frame 104

446 C4549 N64370 TMOD2 Tropomodulin 2 (neuronal)

Sterile alpha motif domain

447 C7157 NMJ) 17654 SAMD9 containing 9

448 C8471 NM_006315 RNF3 Ring finger protein 3

CDNA: FLJ22256 fis, clone

449 C1018 BU615310

HRC02860

450 C6068 AL831998 ITGB6 Integrin, beta 6

Solute carrier family 9

451 C4936 BX648303 SLC9A3R1 (sodium/hydrogen exchanger), isoform 3 regulator 1

452 C8058 BM701368 UNQ1912 HGS_RE408

453 C9354 NM_005555 KRT6B Keratin 6B

Collagen, type XIV, alpha 1

454 C1520 BC014640 COL14A1

(undulin)

Suppression of tumorigenicity

455 D1161 BX537988 ST7L

7 like

Calmodulin 1 (phosphorylase

456 C3647 NMJ306888 . CALMl kinase, delta)

Propionyl Coenzyme A

457 C3690 BC000140 PCCA carboxylase, alpha polypeptide

Glutamine-fructose-6-

458 C6110 W67193 GFPTl phosphate transaminase 1 459 C6130 W68668 Transcribed locus

Zinc finger, DHHC domain

460 C6808 AA040053 ZDHHC21 containing 21

GRB2-associated binding

461 C1466 H03229 GABl protein 1

Hypothetical protein

462 C6664 AI142832 MGC34923

MGC34923

463 C7461 CR609766 SNX24 Sorting nexing 24

464 C7847 BM696919 CRYAB Crystallin, alpha B

Similar to RIKEN cDNA

465 C8786 AA215586 LOC389119

6530418L21

466 C8060 AW293412 HDACI l Histone deacetylase 11 •

Peroxisome proliferative

467 C7882 NM_013261 PPARGClA activated receptor, gamma, coactivator 1, alpha

468 C8848 AF214736 EHD3 EH-domain containing 3

469 C9764 AY358433 UNQ473 DMC

Deiodinase, iodothyronine,

470 C2154 AF007144 DIO2 type II

471 C1030 R87741 Transcribed locus

472 C4886 AI336346 Transcribed locus

CDNA: FLJ22648 fis, clone

473 C6915 AW016811

HSI07329

474 C7731 AF245505 DKFZp564I1922 Adlican

Serine (or cysteine) proteinase

475 C2086 W61361 SERPINB8 inhibitor, clade B (ovalbumin), member 8

Dual adaptor of

476 C6882 AFl 86022 DAPPl phosphotyrosine and 3- phosphoinositides

CCAAT/enhancer binding

477 C8161 AI359788 CEBPA protein (C/EBP), alpha

478 C9877 BQ001493 EHD3 EH-domain containing 3

Sema domain, immunoglobulin domain (Ig), short basic

479 C0909 U38276 SEMA3 domain, secreted, (semaphorin)

3F

CDNA FLJl 3904 fis, clone

480 C4328 AK023966

THYRO 1001895

481 C6559 AW272352 Transcribed locus

482 C6871 BC028377 ZNF502 Zinc finger protein 502

Likely ortholog of mouse

483 C7403 XM_166203 CHASM calponin homology-associated smooth muscle protein

484 C8321 CA435349 ABLIMl Actin binding LIM protein 1

AT rich interactive domain 4B

485 C8174 NM_016374 ARID4B

(RBPl- like)

CDNA: FLJ23006 fis, clone

486 C8380 AK026659 LNG00414

487 C9008 D82786 TA-PP2C T-cell activation protein phosphatase 2C

488 C0716 AI097310 Transcribed locus

489 C7721 NM 000361 THBD Thrombomodulin

490 C9243 AF218020 DBNL Drebrin-like

491 C0922 AF378757 PLXDC2 Plexin domain containing 2

492 C6572 NM 005197 CHESl Checkpoint suppressor 1

493 C8146 BF697545 MGP Matrix GIa protein

494 C4182 BU681491 Transcribed locus Gap junction protein, beta 5

495 C7601 AK129509 GJB5 (connexin 31.1)

MRNA full length insert cDNA

496 B9861 AL137346 clone EUROIMAGE 1509279

497 C4331 CR749576 FLJ37099 FL J37099 protein

498 C7353 AK122903 EPS8L2 EPS8-like 2 MRNA; cDNA

499 D 1274 BF435815 DKFZp564O0862 (from clone DKFZp564O0862) Zinc finger CCCH type domain

500 C7231 XM_036115 ZC3HDC5 containing 5

501 D1135 BX100753 COBL Cordon-bleu homolog (mouse) GRB2-associated binding

502 D1258 BC064848 GABl protein 1

Solute carrier family 9

503 C0357 BC035779 SLC9A9 (sodium/hydrogen exchanger), isoform 9

504 C 1422 AA095034 GKOOl GKOOl protein Aldehyde dehydrogenase 1

505 C4970 K03000 ALDHlAl family, member Al MOBl, Mps One Binder kinase

506 C8182 NM_024761 MOBKL2B activator-like 2B (yeast)

507 C8897 AA422013 KRT24 Keratin 24

Roundabout, axon guidance

508 C0568 BX648828 ROBO2 receptor, homolog 2 (Drosophila)

509 C0903 X80197 KRTHBl Keratin, hair, basic, 1

510 C4194 XM_291315 KIAAl 815 KIAAl 815

Gap junction protein, beta 6

511 C4545 N64339 GJB6 (connexin 30)

512 C6719 BC013892 PVRL4 Poliovirus receptor-related 4 Chromosome 19 open reading

513 C8167 BC008201 C19orf32 frame 32

Calcium binding protein 39-

514 C8880 AA224978 CAB39L like

515 D0410 BX116168 Transcribed locus Opioid growth factor receptor-

516 C0358 AA037425 . OGFRLl like 1

Similar to RIKEN cDNA

517 C0578 AA844234 F730108M23 gene OGT(O-GIc-NAc transferase)-

518 C0706 BX647199 OIP106 interacting protein 106 KDa 519 C2245 AI346181 MAX MAX protein

520 C4281 XM 087672 KIAAl 935 KIAAl 935 protein

521 C4981 AK074480 ANXAl Annexin Al

522 C8388 N92299 AZI2 5-azacytidine induced 2

523 C7956 AKOO 1763 FLJ10901 Hypothetical protein FLJ10901 Phytanoyl-CoA hydroxylase

524 C8152 D87463 PHYHIP interacting protein

525 C9054 AW629018

526 C8580 CR611223 CLDN7 Claudin 7

527 D0385 AK125106 SYTL5 Synaptotagmin-like 5

528 D1418 BC014006 PGLS 6-phosphogluconolactonase

Major histocompatibility

529 C8023 M81141 HLA-DQBl complex, class II, DQ beta 1

Mitochondrial ribosomal

530 D2960 NM_033281 MRPS36 protein S36

531 D3738 AA854756 ZYX Zyxin

Hypothetical protein

532 D3747 AA843607 LOC120376

LOC120376

Solute carrier family 7 (cationic

533 E0702 BE045592 SLC7A1 amino acid transporter, y+ system), member 1

534 D6549 BC004888 FLJ10052 Hypothetical protein FLJ 10052

RAB7B, member RAS

535 D7675 AK127140 RAB7B oncogene family

V-maf musculoaponeurotic

536 E0203 BC081542 MAF fibrosarcoma oncogene homolog (avian)

Aldehyde dehydrogenase 3

537 E1379 AK123877 ALDH3A2 family, member A2

538 D3758 H28090 CYYRl Cysteine and tyrosine-rich 1

539 D9508 AA928325 FLJ25124 Hypothetical protein FLJ25124

Specifically androgen-

540 D3013 AK096741 SARG regulated protein

541 E0942 NMJ73060 CAST Calpastatin

Tankyrase, TRFl -interacting

542 E0921 AF309033 TNKS2 ankyrin-related ADP-ribose polymerase 2

543 D3229 BC054488 RICS Rho GTPase-activating protein

Wingless-type MMTV

544 D5318 NM_004185 WNT2B integration site family, member

2B

545 D5082 . XMJ74137 Hypothetical LOC389328

AHNAK nucleoprotein

546 E0523 BC017483 AHNAK

(desmoyokin)

Nedd4 family interacting

547 E1815 XM_041162 ■ NDFIP2 protein 2

CDC42 effector protein (Rho

548 E0542 NMJ 52243 CDC42EP:

GTPase binding) 1

549 E0387 AI242329 ANKRD22 Ankyrin repeat domain 22 NACHT, leucine rich repeat

550 E0785 BC039269 NALP2 and PYD containing 2 Calcium channel, voltage-

551 D3359 AJ272268 CACNA2D3 dependent, alpha 2/delta 3 subunit

552 ^■ D4215 AB096175 SP5 Sp5 transcription factor Peptidyl arginine deiminase,

553 D4784 AK026652 PADIl type I

554- D5720 AA970157 FLJl 0052 Hypothetical protein FLJl 0052 Hypothetical protein

555 D9210 CA844321 MGC3196 MGC3196

Zinc finger, BED domain

556 D8412 BC071956 ZBED2 containing 2

557 E0009 AA947873

558 D5189 BXl 01094 FLJ21128 Hypothetical protein FLJ21128

559 D7736 AI022908 Transcribed locus

560 D3893 AK074037 CAPN3 Calpain 3, (p94)

561 D3442 NM 145800 6-Sep Septin 6

562 D5553 AA031882 Transcribed locus

563 D3309 AA768426 EVAl Epithelial V-like antigen 1

564 . D4861 AA913741 Transcribed locus

565 D5799 CA450336 Transcribed locus Hypothetical protein

566 D9407 CR749484 LOC152519 LOC 152519

567 E0630 CR591347 KRTl 3 Keratin 13

568 D4231 C05897 ARL5 ADP-ribosylation factor-like 5 DEAD (Asp-Glu-Ala-Asp) box

569 E0476 AF000984 DDX3Y polypeptide 3, Y-linked ATP synthase, H+ transporting, mitochondrial Fl complex,

570 E0606 AUl 59959 ATP5A1 alpha subunit, isoform I₅ cardiac muscle

571 E0733 NM_004684 SPARCLl SPARC-like 1 (mast9, hevin)

572 E1304

UDP-N-acetyl-alpha-D- galactosamine:polypeptide N-

573 D6657 AA554045 GALNT12 acetylgalactosaminyltransferase

12 (GalNAc-T12)

Programmed cell death 4

574 D8524 BX537500 PDCD4 (neoplastic transformation inhibitor)

CDNA FLJ25106 fis, clone

575 D1811 AK128814

CBRO 1467

576 D4059 BF512606 Transcribed locus

Hypothetical protein

577 D4493 BC040438 MGC48915

MGC48915

Hypothetical protein

578 D7516 AI074524 DKFZp434H2111

DKFZp434H2111

Serine (or cysteine) proteinase

579 D4241 CD356848 SERPINBl inhibitor, clade B (ovalbumin), member 1

580 D5210 AA937197 Transcribed locus

581 D5265 NM 015976 SNX7 Sorting nexin 7

582 D8527 CR613409 CA2 Carbonic anhydrase II Cytoplasmic polyadenylation

583 D8911 NM_014912 CPEB3 element binding protein 3 Ecotropic viral integration site

584 E1348 BX640908 EVIl 1

585 D3664 BM726206 Hypothetical LOC387723 Acetyl-Coenzyme A acyltransferase 2

586 D8494 CR599578 ACAA2 (mitochondrial 3-oxoacyl- Coenzyme A thiolase)

587 El 775 NM 002773 PRSS8 Protease, serine, 8 (prostasin)

588 D 1767 BC014357 CCND2 Cyclin D2

Transcriptional regulating

589 D3483 AI261804 TRERFl factor 1

590 E0274 AI094825 Transcribed locus

591 D4235 BC068512 FLJ20323 Hypothetical protein FLJ20323

592 D4858 AA913711 T2BP TRAF2 binding protein

593 D9098 BM971909 HOXA3 Homeo box A3

Syntrophin, beta 1 (dystrophin-

594 D9339 AI033474 SNTBl associated protein Al, 59kDa, basic component 1)

595 D9939 CA313473 Transcribed locus

596 A3096 CR601701 ANXA3 Annexin A3

Sialyltransferase 7 ((alpha-N- acetylneuraminyl-2,3 -beta-

597 F0352 NM 018414 SIAT7A galactosyl- 1 ,3)-N-acetyl galactosaminide alpha-2,6- sialyltransferase) A Hypothetical protein

598 B2819N XM 209073 LOC284207 LOC284207 SAM and SH3 domain

599 F2306 NM 015278 SASHl containing 1

V-maf musculoaponeurotic

600 F3391 NM 005461 MAFB fibrosarcoma oncogene homolog B (avian) Chromosome 14 open reading

601 F7019 AKOOl 590 C14orfl32 frame 132

Retinitis pigmentosa 2 (X-

602 F8408 AJ007590 RP2 linked recessive)

603 A3113 M60445 HDC Histidine decarboxylase

604 B7331 H45412 EHD2 EH-domain containing 2

605 F1393 CR623808 CPBl Carboxypeptidase Bl (tissue) Flavin containing

606 F1134 AL833218 FMO2 monooxygenase 2 Creatine kinase, mitochondrial

607 F2073 NM 020990 CKMTl 1 (ubiquitous) MRNA full length insert cDNA

608 F6601 AL360204 clone EUROIMAGE 980547

Transcribed locus, weakly similar to NP_035609.1 serine

609 B6922 AK075271 palmitoyltransferase, long chain base subunit 2 [Mus musculus]

610 F3501 AK021708 PDZ domain containing RING

PDZRN3 finger 3

Chloride channel, calcium

611 F8409 BC041096 CLCA2 activated, family member 2

612 A3116 M38258 RARG Retinoic acid receptor, gamma

613 F3313 AK025164 FLJ21511 Hypothetical protein FLJ21511

SH3 domain binding glutamic

614 F3839 AF131754 SH3BGRL2 acid-rich protein like 2

Gap junction protein, beta 6

615 F5488 AK075247 GJB6

(connexin 30)

616 A4387N AB006190 AQP7 Aquaporin 7

Betaine-homocysteine

617 F0482 AK000008 BHMT2 methyltransferase 2

Chromosome 9 open reading

618 F1478 BC030816 C9orfl3 frame 13

619 F5638 NM_004669 CLIC3 Chloride intracellular channel 3

Major histocompatibility

620 F5279 L76566 HLA-DRB6 complex, class II, DR beta 6

(pseudogene)

Chromosome 10 open reading

621 F6365 AL080114 C10orf72 frame 72

622 F7620 AI090141 KSR Kinase suppressor of ras

Hypothetical gene supported by

623 F8132 AW975713

AK125149

624 F8153 BF435861 Similar to EVI-5 homolog

Protein phosphatase 1,

625 F3457 AB020630 PPP1R16B regulatory (inhibitor) subunit

16B

626 F6060 AK023814 FLJ41603 FLJ41603 protein

Similar to Envoplakin (210 kDa paraneoplastic pemphigus

627 F6860 BE464137 antigen) (p210) (210 kDa cornified envelope precursor)

628 F7748 AW139719 Transcribed locus

Cyclin-dependent kinase 5,

629 B8706 R52614 CDK5R1 regulatory subunit 1 (p35)

Clone IMAGE: 116415, mRNA

630 G0364 AF339767 sequence

CDNA FLJ43676 fis, clone

631 C8700 AK125664

SYNOV4009129

632 F0411 AW898615

633 C6003 M20030 SPRR2B Small proline-rich protein 2B

634 D8310 AA772401 ELOVL family member 6, elongation of long chain fatty

635 F3398 AK027031 ELOVL6 acids (FEN1/Elo2₅ SUR4/Elo3- like, yeast)

Fibroblast growth factor

636 F4079 M60047 FGFBPl binding protein 1

637 F5885 AK023050

Tumor necrosis factor receptor

638 A0203N NM_000043 TNFRSF6 superfamily, member 6

Eukaryotic translation initiation

639 E2113 BC005248 EIFlAY factor IA, Y-linked

640 F3641 AY099469 SLAC2-B SLAC2-B

BCL2-like 10 (apoptosis

641 B8192 R53538 BCL2L10 facilitator)

MRNA; cDNA ^'

642 D8475 AI242023 DKFZp564F212 (from clone

DKFZp564F212)

Hypothetical protein

643 F0236 AK021710 KIAAl 164

KIAAl 164

Cytochrome P450, family 2,

644 F3279 M61854 CYP2C19 subfamily C, polypeptide 19

Transcribed locus, weakly similar to XP_375099.1

645 F5888 AK001044 hypothetical protein

LOC283585 [Homo sapiens]

Hypothetical gene supported by

646 F7716 BE178490 AK093334; AL833330;

BC020871; BC032492

Ras-related associated with

647 A0375N BC057815 RRAD diabetes

648 F1451 NM_000070 CAPN3 Calpain 3, (p94)

Glycoprotein, alpha-

649 F7080 AW973637 GGTAl galactosyltransferase 1

650 F7457 BQ276976 PIP Prolactin-induced protein 651 F7477 AW868740 SYNPO2 Synaptopodin 2

Coagulation factor VIII-

652 F8116 BF593260 F8A associated (intronic transcript)

Hypothetical protein

653 F0672 AB007861 MGC22014

MGC22014

654 A3263N CR591371 CSTB Cystatin B (stefin B)

Similar to Calpain 9 (Digestive

655 B3543 AK092257 tract-specific calpain) (nCL-4)

(CG36 protein)

656 B4617 BG259776 COBLLl COBL-like 1

Hypothetical protein

657 C6813 BC025756 ■ MGC35558

MGC35558

Full length insert cDNA clone

658 F0243 AL359055

ZD75H06

659 F0647 AKOOl 160 MANSCl MANSC domain containing 1 CDK5 regulatory subunit

660 F2106 AK000349 CDKALl associated protein 1 -like 1

661 F3287 X56807 DSC2 Desmocollin 2 Male sterility domain

662 A5977N BX648892 MLSTD2 containing 2

Cytochrome P450, family 4,

663 F0035 NM_000779 CYP4B1 subfamily B, polypeptide 1 Hypothetical protein

664. F0461 BC033897 LOC51244 LOC51244

Cyclin-dependent kinase

665 F0501 NM_000389 CDKNlA inhibitor IA (ρ21₅ Cipl) Cytochrome P450, family 2,

666 F3565 M61853 CYP2C18 subfamily C, polypeptide 18 Immune associated nucleotide

667 B9118 AK002158 IAN4L1 4 like 1 (mouse)

668 C4829 AK095022 BOK BCL2-related ovarian killer Hypothetical protein

669 D8392 BC040326 LOC338758 LOC338758 Thrombospondin repeat

670 F0726 AF217974 TSRCl containing 1

671 F0555 BC004557 FLJ22457 Hypothetical protein FLJ22457 Hypothetical protein

672 F2445 AK022644 MGC3101 MGC3101

MaI₅ T-cell differentiation

673 F3821 ALl 17612 MAL2 protein 2

674 F5702 AK024358 MPEGl Macrophage expressed gene 1

675 F0471 AK025015 FLJ13955 Hypothetical protein FLJ13955

676 F1552 AF 163573 CARKL Carbohydrate kinase-like Caspase recruitment domain

677 E0382 AF178930 CARD 15 family, member 15 Sialyltransferase 4A (beta-

678 F3433 L13972 SIAT4A galactoside alpha-2,3- sialyltransferase)

679 F0915 M55284 - PRKCH Protein kinase C₅ eta

680 F1655 AL137343 NSEl NSEl

Sterol-C5-desaturase (ERG3

681 F3545 ABO 16247 SC5DL delta-5-desaturase homolog, fungal)-like

682 F7934 AI632692 Transcribed locus

683 A8350 BG210119 Transcribed locus

684 C6412 BX090035 Transcribed locus

685 D1066 . AI271468 LOC146439 Hypothetical LOC 146439

686 F4941 U83115 AIMl Absent in melanoma 1

687 F5083 CR596715 FLJl 1036 Hypothetical protein FLJl 1036 X-ray repair complementing defective repair in Chinese

688 F5815 AK022162 XRCC5 hamster cells 5 (double-strand- break rejoining; Ku autoantigen, 8OkDa)

689 F5904 XM 171054 KIAA0527 KIAA0527 protein Programmed cell death 1 ligand

690 F0238 AKOOl 872 PDCD 1LG2

2

691 B1756 NM_017520 HSMPP8 M-phase phosphoprotein, mpp8

Hypothetical gene supported by

692 B3485 AA725671

BC039682

693 G2700 AK126982 LHX6 LIM homeobox 6

Homo sapiens, clone

694 G3894 BC034423 IMAGE:4821006₅ mRNA, partial cds

695 F1384 AK024438 FLJ38705 Hypothetical protein FLJ38705

Mitochondrial ribosomal

696 G4040 NM 176792 MRPL43 protein L43

Transcribed locus, moderately similar to XP_371769.1

697 F0428 AL442080 hypothetical LOC389321

[Homo sapiens]

698 F6366 BE646407 PP12104

699 F3811 AK025142

700 F9134 NM 052931 SLAMF6 SLAM family member 6

701 G2865 BM973051 NEBL Nebulette

Potassium voltage-gated

702 G0171 BCO 14429 KCNE4 channel, Isk-related family, member 4

RAS and EF hand domain

703 G2920 AK056882 RASEF containing

Hypothetical gene supported by

704 F1391 AF131741

AF131741

MRNA; cDNA

705 G3995 AL833666 DKFZp667H1521 (from clone

DKFZp667H1521)

MRNA; cDNA

706 G4008 AL832268 DKFZp667N1617 (from clone

DKFZp667N1617)

Fucosyltransferase 3

(galactoside 3(4)-L-

707 F0475 NM 000149 FUT3 fucosyltransferase, Lewis blood group included)

Discs, large (Drosophila)

708 B2314N R41489 DLGAP3 homolog-associated protein 3

Hypothetical gene supported by

709 G3565 AK055411

AK055411

CDNA FLJ36210 fis, clone

710 G6825 AK093529

THYMU2000155

Serine (or cysteine) proteinase

711 G7829 BM978663 SERPINB3 inhibitor, clade B (ovalbumin), member 3

Fucosyltransferase 5 (alpha

712 F0996 NM 002034 FUT5

(1,3) fucosyltransferase)

Proline rich GIa (G-

713 F9178 AF326350 PRRG3 carboxyglutamic acid) 3 (transmembrane)

Hypothetical gene supported by

714 G3989 AK091263

AK091263

Sodium channel, nonvoltage-

715 F0078 AKl 72792 SCNNlA gated 1 alpha

Mitogen-activated protein

716 F0216 NM_003954 MAP3K14 kinase kinase kinase 14

717 F0595 AK024035 KIAAl 160 KIAAl 160 protein

Hypothetical protein

718 F9938 XMJ73433 LOC90379

BC002926

719 F9254 AK027740 FLJ14834 Hypothetical protein FLJ14834

Zinc finger protein 185 (LIM

720 G2576 BX537525 ZNFl 85 domain)

Hypothetical gene supported by

721 G4004 AL832797

AL832797

722 G5799 AA946808 DEFBl Defensin, beta 1

723 G3001 NM_003956 CH25H Cholesterol 25-hydroxylase

Rhesus blood group, C

724 G3299 AF193809 RHCG glycoprotein

CDNA FLJ38681 fis, clone

725 G3825 AK096000

KIDNE2000678

726 F1071 AL357535 MESPl Mesoderm posterior 1

727 F4167 AK092850 SVIL Supervillin

Table2. up-regulated genes

Assignme LMMI ACCESSIO _CVΛ/ror>τ GENE NAME nt NO D N

728 A0816 NM_004506 HSF2 Heat shock transcription factor 2

Ubiquitin specific protease 13 (isopeptidase

729 A1571 NM_003940 USP 13

T-3)

730 Al 604 X52186 ITGB4 Integrin, beta 4

Procollagen-proline, 2-oxoglutarate 4-

731 A1757 M24486 P4HA1 dioxygenase (proline 4-hydroxylase), alpha polypeptide I

732 A2480 NM 004484 GPC3 Glypican 3

733 A3565 L10678 PFN2 Profilin 2

734 A4866 NM 001631 ALPI Alkaline phosphatase, intestinal

735 A0378 CR599617 ADM Adrenomedullin

Interferon, alpha-inducible protein (clone IFI-

736 A1054 M13755 G1P2

15K)

Fc fragment of IgG, low affinity IHb, receptor

737 A0797 J04162 FCGR3A for (CD 16)

738 A1589 U97188 IMP-3 IGF-II mRNA-binding protein 3

739 Al 764 NM_002526 NT5E 5'-nucleotidase, ecto (CD73)

CDC45 cell division cycle 45-like (S.

740 A2466 AJ223728 CDC45L cerevisiae)

Transforming growth factor beta 1 induced

741 A2237 AB082525 TGFB 114 transcript 4 742 A2355 BC047350 HSPDl Heat shock 6OkDa protein 1 (chaperonin)

743 A4630 U89281 RODH 3-hydroxysteroid epimerase

744 A4873 NM 002362 MAGEA4 Melanoma antigen, family A, 4

745 A4963 AB000449 VRKl Vaccinia related kinase 1

746 A5215 H59101 USP52 Ubiquitin specific protease 52

747 A6100 BC014274 STARD7 START domain containing 7

748 Al 605 NM 203401 STMNl Stathmin 1 /oncoprotein 18

749 A1581 NM 002318 LOXL2 Lysyl oxidase-like 2

750 A3058 NM 202002 FOXMl Forkhead box Ml

751 A2735 BC036811 PTHR2 Parathyroid hormone receptor 2

Ubiquitin carboxyl-terminal esterase Ll

752 A2978 X04741 UCHLl

(ubiquitin thiolesterase)

753 A3981 AJ000522 DNAHl 7 Dynein, axonemal, heavy polypeptide 17

754 A4611 S79851 TXNRDl Thioredoxin reductase 1

755 A4860 NM 000057 BLM Bloom syndrome

756 A4750 AL833398 CTBP2 C-terminal binding protein 2

757 A5634 XM_031561 C15orf23 Chromosome 15 open reading frame 23

Nuclear factor of kappa light polypeptide gene

758 A1463 BC002601 NFKBIA enhancer in B -cells inhibitor, alpha

759 A3243 CR624652 TTK TTK protein kinase

760 A5623 AF044588 PRCl Protein regulator of cytokinesis 1

761 A0084 BC075838 LAMB3 Laminin, beta 3

762 A0812 M16937 HOXB7 Homeo box B7

763 A0782 M26481 TACSTDl Tumor-associated calcium signal transducer 1

764 A1209 NM 001071 TYMS Thymidylate synthetase

765 A2254 NM 006845 KIF2C Kinesin family member 2C

766 A3097 M65199 EDN2 Endothelin 2

767 A4862 NM_175743 MAGEA2 Melanoma antigen, family A, 2

Leucine-rich repeats and immunoglobulin-like

768 A5211 R55332 LRIGl domains 1

769 A0094 NM_002293 LAMCl Laminin, gamma 1 (formerly LAMB2)

Stress-induced-phosphoprotein 1

770 A0372 BC039299 STIPl

(Hsp70/Hsp90-organizing protein)

771 A0277 NM_001406 EFNB3 Ephrin-B3

ATPase, Na+/K+ transporting, beta 3

772 Al 774 NM_001679 ATP 1B3 polypeptide

773 A2241 BCO 15122 LDHB Lactate dehydrogenase B

Fascin homolog 1, actin-bundling protein

774 A3587 NM_003088 FSCNl

(Strongylocentrotus purpuratus)

Sialyltransferase 4C (beta-galactoside alpha-

775 A0947 NM_006278 SIAT4C

2,3 -sialyltransferase)

776 A1618 X70683 SOX4 SRY (sex determining region Y)-box 4

777 A4193 BU737730 RBPl Retinol binding protein 1, cellular

778 A4619 U73727 PTPRU Protein tyrosine phosphatase, receptor type, U

779 A4959 AF042282 EXOl Exonuclease 1

780 A0246 U07620 MAPKlO Mitogen-activated protein kinase 10 Secreted phosphoprotein 1 (osteopontin, bone

781 A0384 NM 000582 SPPl sialoprotein I₅ early T-lymphocyte activation

1)

Integrin, alpha 3 (antigen CD49C, alpha 3

782 A0828 M59911 ITGA3 subunit of VLA- 3 receptor)

783 A1231 X83957 NEB Nebulin

784 A2352 NM_006907 PYCRl Pyrroline-5-carboxylate reductase 1

Potassium voltage-gated channel, delayed-

785 A4960 AF043472 KCNS3 rectifier, subfamily S, member 3

786 A2143 NM_001219 CALU Calumenin

Procollagen-lysine, 2-oxoglutarate 5-

787 A2490 BCOl 1674 PLOD3 dioxygenase 3

788 A3984 AJ001381 MYOlB Myosin IB

789 A4585 CR591649 SMS Spermine synthase

790 A4962 S76474 NTRK2 Neurotrophic tyrosine kinase, receptor, type 2

791 A5207 CA422300 MAC30 Hypothetical protein MAC30

792 A1907 X53586 ITGA6 Integrin, alpha 6

Palmitoyl-protein thioesterase 1 (ceroid-

793 A2149 U44772 PPTl lipofuscinosis, neuronal 1, infantile) N-acetylglucosamine- 1 -phosphotransferase,

794 A5229 AA128437 GNPTAG gamma subunit

Clusterin (complement lysis inhibitor, SP- 40,40, sulfated glycoprotein 2, testosterone-

795 A0905 Xl 4723 CLU repressed prostate message 2, apolipoprotein

J)

796 A2027 D83018 NELL2 NEL-like 2 (chicken)

LOC8156

797 A2576 U20582 Actin like protein 9

798 A3730 X02761 FNl Fibronectin 1

Transforming growth factor, beta-induced,

799 A0415 M77349 TGFBI

68kDa

800 A0964 L36818 INPPLl Inositol polyphosphate phosphatase-like 1

801 A3351 NM_005544 IRSl Insulin receptor substrate 1

Transmembrane, prostate androgen induced

802 A5262 NM_020182 TMEPAI

RNA

HSPC 150 protein similar to ubiquitin-

803 A5657 BQ219156 HSPC15C conjugating enzyme

Aryl-hydrocarbon receptor nuclear

804 A5407 AB002305 ARNT2 translocator 2

V-yes-1 Yamaguchi sarcoma viral related

805 AO 148 M16038 LYN oncogene homolog

MCM6 minichromosome maintenance

806 A0289 U46838 MCM6 deficient 6 (MIS 5 homolog, S. pombe) (S. cerevisiae)

807 A0692 X57548 CDH2 Cadherin 2, type 1 , N-cadherin (neuronal)

808 A1788 D10704 CHKA Choline kinase alpha

809 A1687 U29171 CSNKlD Casein kinase 1, delta

RCDl required for cell differentiation 1

810 A3526 BQ423966 RQCDl homolog (S. pombe) Amyloid beta (A4) precursor protein-binding,

811 A4376 NM_173075 APBB2 family B, member 2 (Fe65-like)

812 A4513 Z21488 CNTNl Contactin 1

E74-like factor 4 (ets domain transcription

813 A4685 NM_001421 ELF4 factor)

814 A2523 D21238 GLRX Glutaredoxin (thioltransferase)

815 A2555 AK056446 HSPCA Heat shock 9OkDa protein 1, alpha

816 A0161 BC000013 IGFBP3 Insulin-like growth factor binding protein 3

817 A1682 D87119 TRIB2 Tribbles homolog 2 (Drosophila)

818 A2543 NM 213674 TPM2 Tropomyosin 2 (beta)

819 A4141 D84239 FCGBP Fc fragment of IgG binding protein

Transcribed locus, moderately similar to

820 A5679 BC037430 XP_375099.1 hypothetical protein

LOC283585 [Homo sapiens]

Solute carrier family 12

821 A6307 AA639599 SLC12A2 (sodium/potassium/chloride transporters) , member 2

822 Al 153 M61199 SSF A2 Sperm specific antigen 2

TIAl cytotoxic granule-associated RNA

823 A4672 NM_022173 TIAl binding protein

824 A4700 U51336 ITPKl Inositol 1,3,4-triphosphate 5/6 kinase

V-myb myeloblastosis viral oncogene

825 A0333 NM_002466 MYBL2 homolog (avian)-like 2

MCM7 minichromosome maintenance

826 A1783 AK055379 MCM7 deficient 7 (S. cerevisiae)

827 Al 824 NM 002224 ITPR3 Inositol 1,4,5-triphosphate receptor, type 3

828 A3889 NM 002226 JAG2 Jagged 2

829 A5576 BC008141 TREX2 Three prime repair exonuclease 2

830 AOOl 8 NM 198433 STK6 Serine/threonine kinase 6

831 A4559 AK055599 CTSL Cathepsin L

DKFZP56

832 A5290 AK126848 Hypothetical protein DKFZρ564K0822 4K0822

833 A1510 NM_004385 CSPG2 Chondroitin sulfate proteoglycan 2 (versican)

Chromobox homolog 3 (HPl gamma

834 A2898 AB030905 CBX3 homolog, Drosophila) Collagen, type VII, alpha 1 (epidermolysis

835 A3156 L02870 COL7A1 bullosa, dystrophic, dominant and recessive)

ALOX12P

836 A3890 AF020774 Arachidonate 12-lipoxygenase pseudogene 2

2

GALNAC

837 A5422 W91908 B cell RAG associated protein 4S-6ST

838 A0215 NM 021874 CDC25B Cell division cycle 25B

839 A1797 D00244 PLAU Plasminogen activator, urokinase

840 A3298 M91670 UBE2S Ubiquitin-conjugating enzyme E2S

841 A3555 K02581 TKl Thymidine kinase 1, soluble

842 A4954 AB024402 INGl Inhibitor of growth family, member 1

843 A5556 BC071586 TIMP2 Tissue inhibitor of metalloproteinase 2

844 A0429 BM554470 UBE2C Ubiquitin-conjugating enzyme E2C 845 A3015 NM 201442 CIS Complement component I₅ s subcomponent

Ets variant gene 4 (ElA enhancer binding

846 A1835 U18018 ETV4 protein, ElAF)

847 A2647 NM_004350 RUNX3 Runt-related transcription factor 3

Pleckstrin homology-like domain, family B,

848 A6089 CR749654 PHLDB2 member 2

Dystrophin (muscular dystrophy, Duchenne

849 A1956 NM_004010 DMD and Becker types)

850 A4895 BC007290 TSPAN-I Tetraspan 1

851 A0611 BC037236 DUSP6 Dual specificity phosphatase 6

852 A2324 M16650 ODCl Ornithine decarboxylase 1

853 A3181 NM 002193 INHBB Inhibin, beta B (activin AB beta polypeptide)

854 A6389 AB005754 POLS Polymerase (DNA directed) sigma

KIAA093

855 A8210 BM682097 KIAA0934 4

LAGl longevity assurance homolog 2 (S.

856 A9464 NMJ81746 LASS2 cerevisiae)

857 B0593 Z98457 TNIK TRAF2 and NCK interacting kinase

Stress 70 protein chaperone, microsome-

858 B2439 U04735 STCH associated, 6OkDa

Cytochrome P450, family 26, subfamily A,

859 B8086 AK027560 CYP26A1 polypeptide 1

860 CIl Yl AI022193 AlBG Alpha- 1 -B glycoprotein

861 C0649 AK095608 CA5BL Carbonic anhydrase VB-like

862 A7341 N68321 Transcribed locus

863 B3449 AF269150 SMBP SM-11044 binding protein

Pyrroline-5-carboxylate reductase family,

864 B4367 BC020553 PYCR2 member 2

865 B4849 NM 005964 MYHlO Myosin, heavy polypeptide 10, non-muscle

866 B6782 NM_025076 UXSl UDP-glucuronate decarboxylase 1

LOC2557

867 A6532 AY358336 Hypothetical protein LOC255743

43

868 A6923 AA677283 KIRREL Kin of IRRE like (Drosophila) Neural precursor cell expressed,

869 A7793 AI376713 NEDD4L developmentally down-regulated 4-like

870 A9286 AA453356 TNRC6 Trinucleotide repeat containing 6

871 A9174 ABOl 1089 TRIM2 Tripartite motif-containing 2

872 B2466 BX537724 ITPKB Inositol 1,4,5-trisphosphate 3-kinase B

873 B4033 CR624122 TUSC3 Tumor suppressor candidate 3 SMC4 structural maintenance of

874 C4869 AA621719 SMC4L1 chromosomes 4-like 1 (yeast)

875 A9531 BM680495 TOPlMT Topoisomerase (DNA) I, mitochondrial

876 A9014 AK023320 FTS Fused toes homolog (mouse)

ANKRDl

877 A9357 R98981 Ankyrin repeat domain 10 0 ^'

878 B0727 AA631782 Transcribed locus

Amyloid beta (A4) precursor protein (protease

879 B4084 NM 000484 APP nexin-II, Alzheimer disease) Low density lipoprotein receptor-related

880 B8220 AF074264 LRP6 protein 6

881 C3692 AI816254 USPI l Ubiquitin specific protease 11 882 A6670 ABO 18279 SV2A Synaptic vesicle glycoprotein 2A 883 A8106 AA868635

KIAAl 12

884 A8521 AI253195 KIAAl 126 protein 6

MRNA; cDNA DKFZp686C24246 (from

885 B0604 AK128046 clone DKFZp686C24246) 886 B4227 CR625671 FLJl 0439 Hypothetical protein FLJ 10439

Solute carrier family 20 (phosphate 887 C4982 BX647555 SLC20A1 transporter), member 1

A disintegrin and metalloproteinase domain

888 A6518 AJ005580 ADAM23

23

889 A6656 AK096350 C9or£25 Chromosome 9 open reading frame 25 890 A7144 X51441 SAA2 Serum amyloid A2 891 A7856 AA237013 HNRPL Heterogeneous nuclear ribonucleoprotein L 892 A6681 AK023594 SMYD3 SET and MYND domain containing 3 893 A7277 N34387 GRK7 G protein-coupled receptor kinase 7

Neural precursor cell expressed,

894 A8204 BX648041 NEDD9 developmental^ down-regulated 9

Serine (or cysteine) proteinase inhibitor, clade

SERPINA

895 B4078 AK093049 A (alpha- 1 antiproteinase, antitrypsin), member 3.

896 A6657 BX451670 FLJ30525 Hypothetical protein FLJ30525 897 A6786 CR594469 RHOQ Ras homolog gene family, member Q 898 A7296 N47009 FLJ00012 Hypothetical protein FLJOOO 12 899 A8544 NM_014519 ZNF232 Zinc fmger protein 232

Solute carrier family 20 (phosphate

900 B0930 AI671885 SLC20A1 transporter), member 1

ATPase, Na+/K+ transporting, beta 3

901 B1423 AA151771 ATP1B3 polypeptide

902 A6387 NM_016548 GOLPH2 Golgi phosphoprotein 2 903 A6508 R15881 CHRM3 Cholinergic receptor, muscarinic 3

Dehydrogenase/reductase (SDR family)

904 A8883 AY358553 DHRS 8 member 8

905 A9459 CR607674 MESDCl Mesoderm development candidate 1 906 B0741 BM991954 Transcribed locus

ATPase family homolog up-regulated in

907 B5994 T81301 AFURSl senescence cells

908 B6773 BC077077 DPYSL3 Dihydropyrimidinase-like 3 909 A6410 XM_496907 PEGlO Paternally expressed 10 910 B 1742 BX648888 SSFA2 Sperm specific antigen 2

Fibroblast growth factor receptor 1 (fms-

911 B2451 BM994359 FGFRl related tyrosine kinase 2, Pfeiffer syndrome)

912 B4097 CR596974 MLP MARCKS-lilc e protein 9.13 A7280 NM_152740 HIBADH 3 -hydroxyisobutyrate dehydrogenase 914 A9825 AF052120 FLJ43806 Hypothetical protein FLJ43806 915 A6979 AI357616 LOC9013 Hypothetical protein LOC90133 3

916 A7190 BX537966 TFRC Transferrin receptor (p90, CD71)

Latent transforming growth factor beta

917 B4847 AA490011 LTBPl binding protein 1

Chromobox homolog 2 (Pc class homolog,

918 A7608 BG354579 CBX2

Drosophila)

919 A7863 NM_003388 CYLN2 Cytoplasmic linker 2

KIAA087

920 A8172 XM_371891 KIAA0877 protein 7

DKFZp76

921 A8287 R87657 Hypothetical protein DKFZp762E1312

2E1312

922 B6662 AK128043 OSBPL9 Oxysterol binding protein-like 9

923 A6625 BX538010 NRCAM Neuronal cell adhesion molecule

924 A6724 BC033453 DHX35 DEAH (Asp-Glu-Ala-His) box polypeptide 35

925 B4210 NM 004444 EPHB4 EphB4

926 B9283 NM 015213 RAB6IP1 RAB 6 interacting protein 1

927 A8787 AF281255 BCL2L14 BCL2-like 14 (apoptosis facilitator)

928 B0811 AWl 83154 KIF 14 Kinesin family member 14

Homo sapiens, clone IMAGE:5301514,

929 A6363 CR621577 mRNA

930 A6725 AK096250 LHX4 LIM homeobox 4

931 A7710 AK125609 CKIP-I CK2 interacting protein 1 ; HQ0024c protein

MGC3363

932 A8335 BC028421 Hypothetical protein MGC33630 0

933 A7426 BG617617 SAA2 Serum amyloid A2

934 A7908 AA490691 HOXDI l Homeo box DI l

935 A8487 AA523105 TRIAD3 TRIAD3 protein

936 B0232 BC060858 SOCS3 Suppressor of cytokine signaling 3

937 A9723 BC067131 RDHlO Retinol dehydrogenase 10 (all-trans)

938 B2375 BQ025233 BCAS3 Breast carcinoma amplified sequence 3

939 A6585 R46164

940 A8648 X54101 GNLY Granulysin

941 A9371 AB098597 FAD 104 FAD 104

942 B9250 AB027289 HERC5 Hect domain and RLD 5

943 A6598 BM677885 RASLI lB RAS-like, family 11, member B

944 A7024 BU734286 RBPl Retinol binding protein I₅ cellular

Transcription factor 3 (E2A immunoglobulin

945 A6869 BCOl 1665 TCF3 enhancer binding factors E12/E47)

946 A8156 BQ010373 HEG HEG homolog

947 B3019 CR627386 HEXA Hexosaminidase A (alpha polypeptide)

948 B4536 AK091608 FADS3 Fatty acid desaturase 3

949 B4008 XM 167709 C10orf38 Chromosome 10 open reading frame 38

950 C4166 BQ230791 TNNI3 Troponin I₃ cardiac

951 A7230 NM 001845 COL4A1 Collagen, type IV, alpha 1

952 A9381 ALl 17605 CDNA: FLJ21418 fis, clone COL04072

LAPTM4 Lysosomal associated protein transmembrane

953 B0338 ALl 36942 B 4 beta

954 B1799 NM 013437 LRP12 Low density lipoprotein-related protein 12 Similar to uroplakin 3B isoform b; uroplakin

955 B1677 CN415212

IHb

SWI/SNF related, matrix associated, actin

SMARCA

956 B4220 AA459632 dependent regulator of chromatin, subfamily a, member 3

957 B3753 AK000437 WDR8 WD repeat domain 8 DKFZP58 958 B4692 AA525966 DKFZP586L0724 protein 6L0724 959 B4556 NM 020531 C20orf3 Chromosome 20 open reading frame 3

UDP-N-acetyl-alpha-D- galactosamine:polypeptide N-

960 B7330

BM726315 GALNT6

N acetylgalactosaminyltransferase 6 (GaINAc-

T6)

961 B8953 R50344 Transcribed locus . 962 B9826 AA055976 SLIT2 Slit homolog 2 (Drosophila) 963 A7605 R15801 NRNl Neuritin 1 964 B4394 N46424 RAI14 Retinoic acid induced 14 965 B3827 N20989 ANTXRl Anthrax toxin receptor 1 966 B5904 BC008947 C10orf3 Chromosome 10 open reading frame 3 967 B7534 AI298501 SDKl Sidekick homolog 1 (chicken) 968 B9633 XM_085049 A9236

969 BXl 17945 Transcribed locus N

Adaptor-related protein complex 1, sigma 2 970 B5489 NM 003916 AP1S2 subunit

KIAA121

971 B6359 AA608839 KIAA1212

2 972 B6905 BU675191 CGI-72 CGI-72 protein

B4721 973 BE795997 NCOR2 Nuclear receptor co-repressor 2

N

974 B6779 D86961 LHFPL2 Lipoma HMGIC fusion partner-like 2 975 B7749 BC023152 GYG2 Glycogenin 2

Leucine-rich repeats and calponin homology

976 B7968 R46597 LRCH3 (CH) domain containing 3

KIAA064 977 B9223 AK023319 KIAA0643 protein 3

A4739 ATPase family homolog up-regulated in

978 AJ306929 AFURSl

N senescence cells

A8317

979 BQ013695 FLJl 0420 Hypothetical protein FLJl 0420

N

980 B4161 BX538214 C6orfl67 Chromosome 6 open reading frame 167

B4558 MGC4573

981 AK027019 Hypothetical protein MGC45731

N 1

B5373

982 D86962 GRB 10 Growth factor receptor-bound protein 10

N

983 B7887 BU580616 FLJl 0159 Hypothetical protein FLJl 0159

984 B9579 AK055994 FLJ25084 Hypothetical protein FLJ25084

A6448

985 AK127801 FLJ46603 FLJ46603 protein

N

986 A8508 BX647338 TM4SF13 Transmembrane 4 superfamily member 13 N A9518 Hypothetical gene supported by AK096951;

987 AA570186

N BC066547

Suppressor of variegation 3-9 homolog 2 988 B8814 BC007754 SUV39H2

(Drosophila)

A3200 989 AKl 22763 COL5A1 Collagen, type V, alpha 1

N

ATPase, H+ transporting, lysosomal 7OkDa, 990 A5073 L09235 ATP6V1A Vl subunit A

B5175 991 CAMTAl Calmodulin binding transcription activator 1

N BC038183 992 B8480 KIAAl 57

N62352 KIAAl 573 protein 3

B96 MRNA; cDNA DKFZp434L201 (from clone 993 15 CA314364

DKFZp434L201)

A8542 AHAl, activator of heat shock 9OkDa protein 994 AF542548 AHSA2

N ATPase homolog 2 (yeast)

A9534

995 AK000993 C7orf28B Chromosome 7 open reading frame 28B

N

996 A5065 BC036661 CMKORl Chemokine orphan receptor 1

Cleavage and polyadenylation specific factor

997 B3358 AA731746 CPSF6

6, 68kDa

998 B3958 AF145713 SCHIPl Schwannomin interacting protein 1 MGC5782

999 B4587 AB096683 Similar to RIKEN cDNA 2700049P18 gene 7

1000 B4217 BU608626 WFDC2 WAP four-disulfide core domain 2 B6125

1001 T57349 DREl DREl protein

N

MGC2267

1002 B6968 BC016950 Hypothetical protein MGC22679

9

PPP IRl 4 Protein phosphatase 1, regulatory (inhibitor)

1003 B7480 AF407165

C subunit 14C 1004 B7554 CA503163 ADNP Activity-dependent neuroprotector

Synuclein, alpha interacting protein 1005 B8521 AK001617 SNCAIP

(synphilin) 1006 B9234 AK090777 PGM2L1 Phosphoglucomutase 2-like 1

B3160 LOC3746 Similar to kinesin family member 21 A; N-5 1007 AA778238

N 54 kinesin

B4915 Core-binding factor, runt domain, alpha

1008 NMJ75864 CBFA2T2

N subunit 2; translocated to, 2

B5382

1009 AKl 25194 MAPlB Microtubule-associated protein IB

N 1010 B7109 AA872071 Cl lorf23 Chromosome 11 open reading frame 23

MGC3338 1011 B9838 AA018510 2 Hypothetical protein MGC33382

ANKRDl

1012 B7484 CR617865 Ankyrin repeat domain 10 0

Epithelial cell transforming sequence 2

1013 B8716 AY376439 ECT2 oncogene 1014 A5678 BC037346 TMPO Thymopoietin N

B4818

1015 NM_033641 COL4A6 Collagen, type IV₃ alpha 6

N

1016 B5451 CR627457 11-Sep Septin 11

MCM8 minichromosome maintenance

1017 B5461 R56840 MCM8 deficient 8 (S. cerevisiae)

1018 B7370 AAOO 1074 CNNM4 Cyclin M4

NY-REN-

1019 B8211 AF382034 Hypothetical protein AF301222 41

1020 A9044 BC003186 Pfs2 DNA replication complex GINS protein PSF2

1021 B6813 BX092653 Transcribed locus

A5346 PRKWNK

1022 AA747005 Protein kinase, lysine deficient 2

N 2

1023 A3822 BC067289 CTSL2 Cathepsin L2

A0327 Matrix metalloproteinase 1 (interstitial

1024 NM_002421 MMPl

N collagenase)

A0584

1025 NM_003236 TGFA Transforming growth factor, alpha

N

1026 B8016 AA528243 RTN4RL1 Reticulon 4 receptor-like 1

1027 A3538 J03464 COL1A2 Collagen, type I₅ alpha 2

BUBl budding uninhibited by benzimidazoles

1028 A0061 AF053306 BUBlB

1 homolog beta (yeast)

A9617 Family with sequence similarity 24, member

1029 BXl 09949 FAM24A

N A

1030 B4456 BX537652 FLJ12892 Hypothetical protein FLJ12892

1031 B9482 NM_020919 ALS2 Amyotrophic lateral sclerosis 2 (juvenile)

A2065

1032 AKl 24656 ENO2 Enolase 2 (gamma, neuronal)

N

Citron (rho-interacting, serine/threonine

1033 B6283 AY257469 CIT kinase 21)

RE V3 -like, catalytic subunit of DNA

1034 B2587 BC038986 REV3L polymerase zeta (yeast)

1035 B5279 BC004107 FST Follistatin

1036 B6262 NM_001259 CDK6 Cyclin-dependent kinase 6

B7198 Ubiquitin specific protease 13 (isopeptidase

1037 AAl 93472 USP 13

N T-3)

Pregnancy upregulated non-ubiquitously

1038 B8547 BC033746 PNCK expressed CaM kinase

A8900

1039 AL512760 FADSl Fatty acid desaturase 1

N

1040 B3732 XM 499250 LFNG Lunatic fringe homolog (Drosophila)

1041 B8059 BCOI lOOO CDCA5 Cell division cycle associated 5 Methylene tetrahydrofolate dehydrogenase

1042 A2515 X16396 MTHFD2 (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase

B2404

1043 AF200348 D2S448 Melanoma associated gene

N

LOC3399

1044 B4250 CA420794 Hypothetical protein LOC339924

24 1045 B8048 BQ448718 CDKI l Cyclin-dependent kinase (CDC2-like) 11

1046 B9094 AF084481 WFSl Wolfram syndrome 1 (wolframin)

B5081

1047 AL832416 C9orfl3 Chromosome 9 open reading frame 13

N

B4812 APOBEC Apolipoprotein B mRNA editing enzyme,

1048 NM_004900

N 3B catalytic polypeptide-like 3B

1049 B8930 AA513445 RBM21 RNA binding motif protein 21

1050 C1730 BU682808 GNAS GNAS complex locus

1051 C3653 BC066956 VIM Vimentin

1052 C4599 AF189011 RNASE3L Nuclear RNase III Drosha

1053 C6048 AK075509 NRM Nurim (nuclear envelope membrane protein)

1054 C6771 NM_002610 PDKl Pyruvate dehydrogenase kinase, isoenzyme 1

1055 C6425 W94690 Full length insert cDNA clone ZE04G11

1056 C7835 NM 000356 TCOFl ^■ Treacher Collins-Franceschetti syndrome 1

1057 C8621 AWl 95492 TYRPl Tyrosinase-related protein 1

1058 C9718 W94051 DTNA Dystrobrevin, alpha

1059 B9997 All 84562 SR140 U2-associated SRl 40 protein

1060 C2050 BF060678 C14orfl l8 Chromosome 14 open reading frame 118

1061 C3797 BC025729 CD99L2 CD99 antigen-like 2

KIAAl 19

1062 C4763 AB103330 9 KIAAl 199

1063 C8947 AL833303 Full length insert cDNA clone YZ04E02

1064 C8802 AA436403 FZD3 ^' Frizzled homolog 3 (Drosophila)

1065 D1199 NM 001426 ENl Engrailed homolog 1

1066 D1348 BC064663 NLK Nemo like kinase

1067 B9974 AK126766 LEPREL2 Leprecan-like 2

1068 C8075 X07290 ZNF3 Zinc finger protein 3 (A8-51)

1069 C8479 BI768625 UNC84B Unc-84 homolog B (C. elegans)

1070 B9998 H99016 USPI l Ubiquitin specific protease 11

1071 C0236 BC021252 SCMHl Sex comb on midleg homolog 1 (Drosophila)

1072 C3636 XM 056455 D2S448 Melanoma associated gene

1073 C2208 AL049246 FLJ10618 Hypothetical protein FLJ 10618

Transient receptor potential cation channel,

1074 C4385 AB032427 TRPV4 . subfamily V, member 4

ATP -binding cassette, sub-family C

1075 C4622 N66741 ABCCl

(CFTR/MRP), member 1

1076 C6454 BC060820 ZNF281 Zinc finger protein 281

1077 C8632 BM682754 IREB2 Iron-responsive element binding protein 2

1078 C0658 W60844 FLJ31340 Hypothetical protein FLJ31340

Transcribed locus, moderately similar to

1079 C0777 BC047362 XP_375099.1 hypothetical protein

LOC283585 [Homo sapiens]

1080 C2020 CA420307 SF3B1 Splicing factor 3b, subunit 1, 155kDa

1081 C1538 BM683254 DLGl DKFZP586B0319 protein

1082 C7256 NM 021963 NAP1L2 Nucleosome assembly protein 1 -like 2

1083 C8051 BM685415 C10orfl l6 Chromosome 10 open reading frame 116

Sparc/osteonectin, cwcv and kazal-like

1084 C8088 D87465 SPOCK2 domains proteoglycan (testican) 2

1085 C8624 NM 005858 AKAP8 A kinase (PRKA) anchor protein 8 1086 C9490 N26092 SNAI2 Snail homolog 2 (Drosophila)

1087 C0488 AA781195 PRAME Preferentially expressed antigen in melanoma

SLC39A1 Solute carrier family 39 (zinc transporter),

1088 CO 186 CR749813 O member 10

1089 C4883 N79601

KIAA074

1090 C5287 N91945 KIAA0746 protein 6

1091 C7529 AF311339 C6orfl62 Chromosome 6 open reading frame 162

1092 C9527 R27734

1093 C0772 AF326917 AUTS2 Autism susceptibility candidate 2 UDP glycosyltransferase 8 (UDP-galactose

1094 C2021 ALl 18812 UGT8 ceramide galactosyltransferase)

HSPA5BP Heat shock 7OkDa protein 5 (glucose-

1095 C8611 NM_017870 1 regulated protein, 78kDa) binding protein 1

PLEKHH Pleckstrin homology domain containing,

1096 C0787 AL832207

2 family H (with MyTH4 domain) member 2

1097 D0587 AA872040 INHBB Inhibin, beta B (activin AB beta polypeptide)

1098 C1849 BC049171 FJXl Four jointed box 1 (Drosophila)

1099 C0458 H05777 Transcribed locus

1100 C3803 NM 004265 FADS2 Fatty acid desaturase 2

1101 C3648 AK023450 ANTXR2 Anthrax toxin receptor 2 Transcriptional co-activator with PDZ-

1102 C7674 AA148213 TAZ binding motif (TAZ) Polymerase (RNA) II (DNA directed)

1103 C9517 H73947 P0LR2J polypeptide J, 13.3kDa Similar to bK246H3.1 (immunoglobulin

LOC9131

1104 C6826 X52203 lambda-like polypeptide 1, pre-B-cell 6 specific)

1105 C8487 T56982 PDE7A Phosphodiesterase 7A

1106 D0748 H03747 CDNA: FLJ21652 fis, clone COL08582

1107 C4973 BC013575 PLAU Plasminogen activator, urokinase

1108 C8121 BC040492 SCRNl Secernin 1

1109 C9016 AA255900 STK38L Serine/threonine kinase 38 like

1110 C9976 CA431254 SH3MD1 SH3 multiple domains 1

1111 C9189 BC065544 C14orfl06 Chromosome 14 open reading frame 106

1112 C9608 AI762244 GSTA2 Glutathione S-transferase A2 Similar to sodium- and chloride-dependent

1113 D0491 AA815427 FLJ43855 creatine transporter

Activating transcription factor 7 interacting

1114 D0058 BC041882 ATF7IP2 protein 2

Solute carrier family 12 (potassium/chloride

1115 B9930 AK024493 SLC12A7 transporters), member 7 Transmembrane, prostate androgen induced

1116 C8557 AA536113 TMEPAI RNA

1117 C9858 NM_006892 DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta

1118 C6209 AF130988 EDAR Ectodysplasin A receptor

Acidic (leucine-rich) nuclear phosphoprotein

1119 C7607 AL832674 ANP32E

32 family, member E 1120 D0006 NM_145697 CDCAl Cell division cycle associated 1 1121 D0062 CR593221 OSR2 Odd-skipped-related 2A protein 1122 C0400 BC021290 IMP-2 IGF-II mRNA-binding protein 2 1123 C0764 AA045020 RDHlO Retinol dehydrogenase 10 (all-trans)

ProSAPiP

1124 C9231 ABOl 1124 ProSAPiP 1 protein

1 1125 C0318 M16451 CKB Creatine kinase, brain

NK3 transcription factor related, locus 1 1126 C5950 CF146489 NKX3-1

(Drosophila)

Fusion (involved in t( 12; 16) in malignant

1127 C5013 CR602284 FUS liposarcoma) 1128 C6875 AA043381 HOXDlO Homeo box DIO LOCI 524 1129 C3905 AK091130 Hypothetical protein LOC 152485 85 yg63fO2.sl Soares infant brain INIB Homo

1130 C7105 R50993 sapiens cDNA clone IMAGE:37373 3', mRNA sequence.

1131 C9041 AJ580093 ATPI lC ATPase, Class VI₅ type 11C 1132 C1093 AW976357 CDCAl Cell division cycle associated 1

CR594190

1133 C1948 DKKl Dickkopf homolog 1 (Xenopus laevis)

NM_012242

1134 C5005 BX648571 FLJ38736 Hypothetical protein FLJ38736 1135 C8384 X98834 SALL2 Sal-like 2 (Drosophila) 1136 C 1442 AA807192 FLJ20522 Hypothetical protein FLJ20522

Family with sequence similarity 13, member

1137 C7756 H03641 FAM13A1

Al 1138 C8926 BU569535 CHODL Chondrolectin

DKFZp43 1139 C6880 AK027224 Hypothetical protein DKFZp434B227

4B227

MGC4210

1140 D0648 AA416843 Hypothetical protein MGC42105

5

1141 C6217 NMJ)01448 GPC4 Glypican 4 1142 C6906 AKl 22672 RAI3 Retinoic acid induced 3

MGC3321

1143 C9046 BC034999 Similar to RIKEN cDNA 4933439B08 gene

1

Membrane-associated guanylate kinase- 1144 D3549 BU620736 MAGI-3 related (MAGI-3)

GTF2IRD

1145 D6450 BQ001345 GTF2I repeat domain containing 2 2B

1146 E0002 BF195994 PIAS2 Protein inhibitor of activated STAT, 2 1147 E0537 BX647115 DPYSL2 Dihydropyrimidinase-like 2 1148 D4376 AA883952 Transcribed locus 1149 D7468 BC010943 OSMR Oncostatin M receptor Syndecan 2 (heparan sulfate proteoglycan 1,

1150 E0838 BC030133 SDC2 cell surface-associated, fibroglycan) 1151 E1278 BF353850 ATPI lB ATPase, Class VI₅ type I₁IB TGFB-induced factor 2 (TALE family 1152 D9484 NM 021809 TGIF2 homeobox) Procollagen-proline, 2-oxoglutarate 4-

1153 El 173 CB250397 P4HA1 dioxygenase (proline 4-hydroxylase), alpha polypeptide I

Solute carrier family 16 (monocarboxylic acid

1154 E1497 BU625507 SLCl 6A3 transporters), member 3

1155 D6136 AF448439 CLIC6 Chloride intracellular channel 6 1156 D6767 BM312795 Transcribed locus

Ubiquitin specific protease 13 (isopeptidase

1157 D8920 AI038231 USP 13

T-3)

1158 D8587 AI223250 Transcribed locus 1159 E1387 D87448 TOPBPl Topoisomerase (DNA) II binding protein 1 1160 D3218 ALl 22043 C20orfl l2 Chromosome 20 open reading frame- 112 1161 D9500 AI361654

Protein kinase, interferon-inducible double

1162 D8150 BF965334 PRKRA stranded RNA dependent activator

1163 D9437 W67209 SESN3 Sestrin 3 1164 EO 167 AI090289 DREl DREl protein

1165 E0694 BX641036 CSPG2 Chondroitin sulfate proteoglycan 2 (versican) 1166 D5491 AA947258 Transcribed locus

Family with sequence similarity 13, member 1167 D6311 BI771102 PHYHIPL

Cl

1168 E0663 CR600961 TM4SF13 Transmembrane 4 superfamily member 13 1169 E0556 BM997546 ECEl Endothelin converting enzyme 1 1170 E0686 BC036067 FLJ14146 Hypothetical protein FLJl 4146 1171 E0787 BM697477 ShrmL Shroom-related protein

Methyl CpG binding protein 2 (Rett

1172 D4351 BXl 02008 MECP2 syndrome)

1173 D9504 BC010918 NTS Neurotensin 1174 E0664 AY299090 SPRED2 Sprouty-related, EVHl domain containing 2 1175 E0552 AL832438 FLJ20152 Hypothetical protein FLJ20152 1176 D6314 NM 018243 11-Sep Septin 11

Calcium-binding tyrosine-(Y)-

1177 D8837 NM 012189 CABYR phosphorylation regulated (fibrousheathin 2)

Solute carrier family 7, (cationic amino acid

1178 E0837 AB040875 SLC7A11 transporter, y+ system) member 11

1179 D8001 AW976634 Transcribed locus 1180 D9027 CN480522 WTIP WTl -interacting protein 1181 E0451 BC005963 MAGEA3 Melanoma antigen, family A, 3

Family with sequence similarity 20, member

1182 E0139 AL390147 FAM20C

C

1183 E1423 NM_152624 DCP2 Decapping enzyme hDcp2 1184 D8457 AA830551 FLJl 3848 Hypothetical protein FLJl 3848

LIM domain containing preferred

1185 D9933 BX648297 LPP translocation partner in lipoma

Malignant fibrous histiocytoma amplified

1186 D6668 AA744607 MFHASl sequence 1

1187 D4093 CK299098 Hypothetical gene supported by BC044741 1188 D8458 AA830668 1189 D9544 H05758 Transcribed locus 1190 E0598 NM_005504 BCATl Branched chain aminotransferase 1 , cytosolic

1191 ElOOl NM 018212 ENAH Enabled homolog (Drosophila)

1192 D6398 AI792205 Transcribed locus

1193 E0455 CR614398 ODCl Ornithine decarboxylase 1

1194 D8515 CR591759 LUM Lumican

1195 D5583 AK125904 DDHD2 DDHD domain containing 2

1196 D5596 BM991753 CDNA clone IMAGE:4862812, partial cds

1197 E0133 AW451133 FLJ10719 Hypothetical protein FLJl 0719

1198 D8466 AI619500 Transcribed locus

Mitogen-activated protein kinase kinase

1199 D8905 AI021894 MAP4K3 kinase kinase 3

B0869 Ubiquitin-like, containing PHD and RING

1200 AF274048 UHRFl

N finger domains, 1

Serine (or cysteine) proteinase inhibitor, clade

SERPINE

1201 F1457 M16006 E (nexin, plasminogen activator inhibitor type 1

1), member 1

1202 F5449 AK026753

1203 F8140 AW976457 MBNLl Muscleblind-like (Drosophila)

1204 F9101 BC010527 CDNA FLJ31059 fis, clone HSYRA2000832

ELK4, ETS-domain protein (SRF accessory

1205 F8575 BF433322 ELK4 protein 1)

1206 A7714 AB002351 DMN Desmuslin

B4412 Discoidin, CUB and LCCL domain containing

1207 BC016815 DCBLD2

N 2

1208 E1732 NM 014916 LMTK2 Lemur tyrosine kinase 2

AU147322.

1209 E1395 1 EDD E3 identified by differential display

1210 F2724 AK024275 FLJ14213 Hypothetical protein FLJ14213

Protein tyrosine phosphatase, receptor type, f

1211 F3387 AK126185 PPFIA4 polypeptide (PTPRF)₅ interacting protein

(liprin), alpha 4

1212 F5148 AL831813 RUNDCl RUN domain containing 1

Protein tyrosine phosphatase, receptor type, f

1213 F3888 U22816 PPFIAl polypeptide (PTPRF), interacting protein

(liprin), alpha 1

1214 F0969 AK026201 RAB3IP RAB3A interacting protein (rabin3)

1215 F0931 AF026941 cig5 Viperin

Likely ortholog of mouse limb-bud and heart

1216 F2986 AK027232 LBH gene

KIAA093

1217 F3496 AB023148 1 KIAA0931 protein

1218 F6350 AL389956 FBXO32 F-box protein 32

1219 F3184 NM_033380 COL4A5 Collagen, type IV, alpha 5 (Alport syndrome)

B4350

1220 AF037364 PNMAl Paraneoplastic antigen MAl

N

1221 F 1277 AFl 51020 TMEM9 Transmembrane protein 9

A0576

1222 NMJ38555 KIF23 Kinesin family member 23

N LAPTM4 Lysosomal associated protein transmembrane

1223 B0068 R15836 B 4 beta

LOC2213

1224 FOl 19 AL049354 Hypothetical protein LOC221362 62

1225 F0938 AK160383 CENTD2 Centaurin, delta 2

1226 F2217 AF288571 LEFl Lymphoid enhancer-binding factor 1

1227 F4281 AFl 99023 PLSCR4 Phospholipid scramblase 4

ATP6V1E ATPase, H+ transporting, lysosomal 3IkDa,

1228 F7951 N66690 2 Vl subunit E isoform 2

Homo sapiens, clone IMAGE:3887266,

1229 F9119 BC015512 mRNA

1230 F0896 AF131790 SHANK2 SH3 and multiple ankyrin repeat domains 2

Runt-related transcription factor 1 (acute

1231 A1375 D43968 RUNXl myeloid leukemia 1; amll oncogene)

1232 A7732 BC017984 ARG99 ARG99 protein

FAT tumor suppressor homolog 1

1233 A3802 NM_005245 FAT

(Drosophila)

1234 F0299 NM_145693 LPINl Lipin 1

RA-regulated nuclear matrix-associated

1235 F3374 AF195765 RAMP protein

1236 F4635 AK021519 FLJl 1457 Hypothetical protein FLJl 1457

1237 A6660 CA418643 GPRl 53 G protein-coupled receptor 153

ITGBlBP

1238 F5376 AK025105 1 Integrin beta 1 binding protein 1

1239 F7497 AW973864 SYNJ2BP Synaptojanin 2 binding protein

1240 F0924 NMJ)12309 SHANK2 SH3 and multiple ankyrin repeat domains 2

1241 A2921 NM_002391 MDK Midkine (neurite growth-promoting factor 2)

B4390 KIAA028

1242 AB006624 KIAA0286 protein

N 6

1243 B4479 AF258572 GSDML Gasdermin-like

Protein kinase, interferon-inducible double

1244 F1415 NM_002759 PRKR stranded RNA dependent

Solute carrier organic anion transporter

1245 F2746 AJ251506 SLCO 1B3 family, member 1B3

Hairy/enhancer-of-split related with YRPW

1246 F2092 BCOOl 873 HEYl motif 1

1247 F7332 AI936859 RTKN Rhotekin

1248 D8010 AI734110 FMNL2 Formin-like 2

1249 F0920 AF098269 PCOLCE2 Procollagen C-endopeptidase enhancer 2

Adaptor-related protein complex 2, beta 1

1250 F2294 AK024900 AP2B1 subunit

CDC6 cell division cycle 6 homolog (S.

1251 F2929 AF022109 CDC6 cerevisiae)

CDC42EP CDC42 effector protein (Rho GTPase

1252 F2095 NM_006449 3 ^' binding) 3

1253 F3395 AB032953 ODZ2 Odz, odd Oz/ten-m homolog 2 (Drosophila)

NIMA (never in mitosis gene a)-related kinase

1254 A0636 Z29066 NEK2

2 1255 F0410 AW369770 PACSl Phosphofurin acidic cluster sorting protein 1

1256 F1732 AK023642 CDNA FLJ13580 fis, clone PLACE1008851

1257 F3598 AK001332 LRRC5 Leucine rich repeat containing 5

Proteasome (prosome, macropain) subunit,

1258 F6994 BM920112 PSMB9 beta type, 9 (large multifunctional protease 2)

1259 F7579 AW629129 SVH SVH protein

Transcribed locus, weakly similar to

1260 F8888 AK027091 XP_375099.1 hypothetical protein

LOC283585 [Homo sapiens]

B5040 Carbohydrate (N-acetylglucosamineτ6-O)

1261 AA126782 CHST2

N sulfotransferase 2

1262 F5946 AL137529 FLJ23751 Hypothetical protein FLJ23751

APOBEC Apolipoprotein B mRNA editing enzyme,

1263 F4158 BC047767 2 catalytic polypeptide-like 2

1264 A3896 BC015050 OIP5 Opa-interacting protein 5

1265 E2104 CN280172 CDNA clone IMAGE:4734740, partial cds

AMP-activated protein kinase family member

1266 Fl 646 ABOl 1109 ARK5

5

1267 F 1446 AJ277587 SPIREl Spire homolog 1 (Drosophila)

1268 B9057 AF361494 SOSTDCl Sclerostin domain containing 1

Phospholipase C, beta 1 (phosphoinositide-

1269 F2462 NMJ 82734 PLCBl specific)

A0359

1270 BC015753 CXCL2 Chemokine (C-X-C motif) ligand 2

N

1271 F8483 BG003072 TFCP2L3 Transcription factor CP2-like 3

BUBl budding uninhibited by benzimidazoles

1272 A2439 AF053305 BUBl

1 homolog (yeast)

1273 A9111 NM_016607 ARMCX3 Armadillo repeat containing, X-linked 3

Sialyltransferase 9 (CMP-

1274 F1916 AFl 19418 SIAT9 NeuAc:lactosylceramide alpha-2,3- sialyltransferase; GM3 synthase)

HDGFRP Hepatoma-derived growth factor, related

1275 . F4063 ALl 09779

3 protein 3

FERM₅ RhoGEF (ARHGEF) and pleckstrin

1276 E2082 BX537667 FARPl domain protein 1 (chondrocyte-derived)

1277 F9079 AF339769 Clone IMAGE: 123704, mRNA sequence

Tumor necrosis factor, alpha-induced protein

1278 A3453 BC064689 TNFAIP3

3

1279 E0341 AK093143 SSFA2 Sperm specific antigen 2

1280 F0283 AK123311 GAP43 Growth associated protein 43

1281 F3997 AL049987 FLJ40092 FLJ40092 protein

MRNA; cDNA DKFZp564Gl 162 (from clone

1282 F4952 AL080082

DKFZp564G1162)

SLC39A1 Solute carrier family 39 (zinc transporter),

1283 F3618 AKl 72810

4 member 14

LOC8029

1284 F2037 AK024124 Transcription termination factor-like protein 8

1285 F4451 AK022204 EDD E3 identified by differential display KIAA137

1286 F3878 NM_020800 KIAAl 374 protein 4

1287 F8184 AK022856 CDNA FLJl 2794 fis, clone NT2RP2002041

MGC1560

1288 F9909 BC009431 Hypothetical protein MGC15606 6

1289 G2245 AW450464 ZNFl 81 Zinc finger protein 181 (HHZl 81)

1290 G2660 AK094334 MRPS25 Mitochondrial ribosomal protein S25 Kelch repeat and BTB (POZ) domain

1291 G2984 AA778186 KBTBD9 containing 9

KIAAO 14

1292 G3257 BQ020994 KIAAO 146 protein 6

1293 G4110 AA128462 Transcribed locus

1294 G4171 BXl 06478 Transcribed locus

Transcribed locus, weakly similar to

1295 G4302 AI733332 XP_375099.1 hypothetical protein

LOC283585 [Homo sapiens]

1296 G4661 AK057918 Hypothetical gene supported by AK057918

1297 G4356 BX094336 Similar to AE2 protein

Chromodomain helicase DNA binding protein

1298 G4650 AK057706 CHD7

7

Transcribed locus, weakly similar to

1299 G4705 AK090872 XP_375099.1 hypothetical protein

LOC283585 [Homo sapiens]

1300 G5030 BX091458 MTSSl Metastasis suppressor 1

1301 G5296 AW975990 HepG2 partial cDNA, clone hmdlaO8m5.

1302 G6837 AA703048 TOPl Topoisomerase (DNA) I

Eukaryotic translation elongation factor 1

1303 G6924 CA503069 EEFlG gamma

1304 G7153 BM991930 Transcribed locus

1305 G7142 BQl 84075 Transcribed locus

1306 G7476 BF591074

1307 G7204 BX537577 HepG2 3' region cDNA, clone hmdlcO7.

1308 G7867 BQ004940

1309 G7894 BX648286 RAB22A RAB22A, member RAS oncogene family

1310 G7821 BM974197 STXBP6 Syntaxin binding protein 6 (amisyn)

1311 G7860 BM996527 OPHNl Oligophrenin 1

1312 G7888 BQ025514 ADK Adenosine kinase

CR988892 RZPD no.9017 Homo sapiens

NM 003519

1313 F5967 cDNA clone RZPDp9017D0310 5'₅mRNA CR988892 sequence.

1314 G1119 AK025202 LARGE Like-glycosyltransferase

Defective in sister chromatid cohesion

1315 F9145 BC001316 MGC5528 homolog 1 (S. cerevisiae)

1316 G1899 BI490961 ETV6 Ets variant gene 6 (TEL oncogene)

1317 G2801 U55853 GOLPH4 Golgi phosphoprotein 4

1318 G3085 BM992422 FHOD3 Formin homology 2 domain containing 3

1319 G2825 BQ773653 JAG2 Jagged 2

Pleckstrin homology domain interacting

1320 G3673 BM677658 PHIP protein SWI/SNF related, matrix associated, actin

SMARCA

1321 G3374 AI740551 dependent regulator of chromatin, subfamily 2 a, member 2

HSPC 150 protein similar to ubiquitin-

1322 G4230 AA460431 HSPCl 50 conjugating enzyme

1323 G5380 BC012776 KUB3 Ku70-binding protein 3

1324 G5190 NM_006544 SEClOLl SEClO-like 1 (S. cerevisiae)

PHACTR

1325 G7017 AL832577 Phosphatase and actin regulator 3

3

1326 G7052 AW376957 FP6778

Transcription factor 12 (HTF4, helix-loop-

1327 G7074 AW057520 TCF12 helix transcription factors 4) Immunoglobulin heavy chain, V-region

1328 G7311 AW273713 (SPHl.17)

Protein kinase, DNA-activated, catalytic

1329 G7334 AW444577 PRKDC polypeptide

KIAA128

1330 G7392 AI700994 KIAA1287 protein 7

1331 G7756 BM673560 CULl Cullin 1

1332 G7409 AV661871 ALDOB Aldolase B, fructose-bisphosphate

1333 G7433 AK022426

B-cell CLL/lymphoma 1 IA (zinc finger

1334 G7944 AL833181 BCLI lA protein)

1335 G8118 BC041347 FLNB Filamin B, beta (actin binding protein 278)

1336 F3260 AK022675 FLJ20542 Hypothetical protein FLJ20542

1337 G1502 BG219755 JMY Junction-mediating and regulatory protein

Basic helix-loop-helix domain containing,

1338 G2206 AB044088 BHLHB3 class B, 3

1339 G2234 BI496248 VEZATIN Transmembrane protein vezatin

1340 G2919 BFl 14768 FLJ10808 Hypothetical protein FLJl 0808

1341 G2629 AK091973 IGFlR Insulin-like growth factor 1 receptor

Mitogen-activated protein kinase kinase

1342 G2620 N39603 MAP3K5 kinase 5

1343 G3228 AW450394 PLAGl Pleomorphic adenoma gene 1

1344 G4095 AA022935 FMNL2 Formin-like 2

1345 G4140 BI918168 CDNA clone IMAGE:4811759, partial cds

Polycystic kidney disease 2 (autosomal

1346 G4068 BU078631 PKD2 dominant)

Transcribed locus, highly similar to

1347 G4120 AAl 51666 XP_343158.1 similar to RIKEN cDNA

0910001B06 [Rattus norvegicus]

1348 G4165 BM470637 KLF3 Kruppel-like factor 3 (basic)

Transcribed locus, weakly similar to

XP_214982.2 similar to junction-mediating

1349 G4451 AUl 22725 and regulatory protein; p300 transcriptional cofactor JMY [Rattus norvegicus]

Potassium voltage-gated channel, subfamily H

1350 G4999 BC043409 KCNH5

(eag-related), member 5

Homo sapiens, clone IMAGE:4821290₃

1351 G5013 H16790 mRNA DnaJ (Hsp40) homolog, subfamily C, member

1352 G6627 BC043583 DNAJC 13

13

1353 G6831 BQ447463 SAMD4 Sterile alpha motif domain containing 4 1354 G7491 AI088195 CDNA FLJ41461 fis, clone BRSTN2016335 1355 G7220 AI373767 Transcribed locus 1356 G7267 AW081263 Transcribed locus 1357 G8169 AL832210 WWOX WW domain containing oxidoreductase

Guanine nucleotide binding protein (G

1358 G7895 BQ027862 GNB5 protein), beta 5

Solute carrier family 7 (cationic amino acid

1359 G7889 BQ025551 SLC7A8 transporter, y+ system), member 8

DKFZp781G05150_rl 781 (synonym: hlcc4)

AK021742

1360 F1800 Homo sapiens cDNA clone BX951495

DKFZp781G05150 5', mRNA sequence.

1361 G4204 BXl 00147 Hypothetical LOC402485 1362 G5381 XM 373575 Similar to hypothetical protein 1363 G5148 N59381 FLJ12476 Hypothetical protein FLJ 12476 1364 G6967 AK093278 CDNA FLJ35959 fis, clone TESTI2012444

Solute carrier family 30 (zinc transporter),

1365 G5819 AL832755 SLC30A6 member 6

1366 G5976 H57111 ZNF518 Zinc finger protein 518 1367 G7727 BM666927 PROXl Prospero-related homeobox 1 LOC2835

1368 G7320 AK096522 Similar to seven in absentia 2 14

Pleckstrin homology domain interacting

1369 G7410 BQ025216 PHIP protein

1370 G7434 AK023377 HEXA Hexosaminidase A (alpha polypeptide) 1371 G7945 AK097655 CDNA FLJ40336 fis, clone TESTI2031986

DKFZP56

1372 G8773 AV699579 Hypothetical protein DKFZp564K0822

4K0822

Transcribed locus, moderately similar to

1373 G7236 AK130576 NP_083546.1 Rho GTPase activating protein 24 [Mus musculμs]

601659547R1 NIH_MGC_70 Homo sapiens

1374 F6729 BE965780 cDNA clone IMAGE:3896243 3', mRNA sequence.

1375 G0226 BC006512 MGC4308 Hypothetical protein MGC4308 A disintegrin-like and metalloprotease

ADAMTS

1376 G2260 NM_182920 (reprolysin type) with thrombospondin type 1 9 motif, 9

1377 G2686 AK056824 PWWPl PWWP domain containing 1

1378 G4082 AA004878 STARD 13 START domain containing 13

1379 G4173 AK091238 FLJ10211 Hypothetical protein FLJ10211 Disabled homolog 2, mitogen-responsive

1380 G5034 CB959761 DAB2 phosphoprotein (Drosophila) CD58 antigen, (lymphocyte function-

1381 G5053 H66650 CD58 associated antigen 3)

1382 G5300 AW007021 TFDPl Transcription factor Dp-I Solute carrier family 2 (facilitated glucose

1383 G5085 AL833602 SLC2A12 transporter), member 12 Phosphodiesterase 4D interacting protein

1384 G6746 BQ027724 PDE4DIP

(myomegalin)

Solute carrier family 33 (acetyl-CoA

1385 G7446 BC029450 SLC33A1 transporter), member 1

LOC9113

1386 G7163 AI968300 Hypothetical protein BC017169

7

1387 G7188 BX093022 A2M Alpha-2 -macro globulin 1388 G8170 AL832099 ATXN7L4 Ataxin 7-like 1

UDP-Gal:betaGlcNAc beta 1,4-

1389 G7824 BM975524 B4GALT5 galactosyltransferase, polypeptide 5

1390 G8216 BI494395 ADD3 Adducin 3 (gamma)

High density lipoprotein binding protein

1391 F8600 AW977584 HDLBP

(vigilin)

1392 G2452 AA525021 MACFl Microtubule-actin crosslinking factor 1 1393 G2580 AW975290 Transcribed locus 1394 G2876 BX099865 NRXNl Neurexin 1 1395 G2853 BQ026279 THOC2 THO complex 2 1396 G2869 BM674818 CENTG2 Trinucleotide repeat containing 17 1397 G3659 BM718282 FP6778 1398 G3755 BQ025315 FLJ32810 Hypothetical protein FLJ32810

Protein tyrosine phosphatase, non-receptor

1399 G4205 AA448989 PTPN3 type 3

Phosphoinositide-3 -kinase, catalytic, gamma

1400 G4233 AK127860 PIK3CG polypeptide

1401 G4245 AA703239 FAD 104 FAD 104 1402 G4271 AL599933 PRKGl Protein kinase, cGMP-dependent, type I

DKFZp686B17119_rl 686 (synonym: hlcc3)

AK056722

1403 G4594 Homo sapiens cDNA clone AL700484

DKFZp686B17119 5', mRNA sequence.

1404 G6993 BM968300 Transcribed locus 1405 G7010 AW149839 NPAS3 Neuronal PAS domain protein 3 1406 G7115 BF508564 RJ3BP7 Retinoblastoma binding protein 7 1407 G7021 BGl 90202 FBXO 15 F-box protein 15 1408 G6144 R41724 FMNL2 Formin-like 2 1409 G7315 AW277126 Transcribed locus

1410 G7728 BM669438 BFSP2 Beaded filament structural protein 2, phakinin

1411 G7695 AKl 22626 GPR82 G protein-coupled receptor 82 1412 G7948 AW593931 CENTB2 Centaurin, beta 2

Homo sapiens, clone IMAGE:4827253,

1413 G8010 BQ447982 mRNA

1414 G8055 AK096377 FLJ39058 Hypothetical protein FLJ39058

Amyloid beta (A4) precursor protein (protease

1415 G7929 AI827546 APP nexin-II, Alzheimer disease)

B-cell neoplasia associated transcript, (BCMS

1416 G2316 AJ412030 gene), splice variant E, non coding transcript

1417 G2990 AW973337 SPRED2 Sprouty-related, EVHl domain containing 2 UI-E-EOl-aiy-h-05-O-UI.sl UI-E-EOl Homo

1418 G3606 BM680332 sapiens cDNA clone UI-E-EO l-aiy-h-05-O-UI 3¹, mRNA sequence.

1419 G4372 CK816153 DLGl DKFZP586B0319 protein

1420 G5585 BE729311 XYLTl Xylosyltransferase I

MCM2 minichromosome maintenance

1421 G6788 X67334 MCM2 deficient 2, mitotin (S. cerevisiae)

Homo sapiens, clone IMAGE:4821804,

1422 G6876 AK055712 mRNA, partial cds

1423 G5694 AAl 02634 TRAF5 TNF receptor-associated factor 5

1424 G5547 BF997835 DOCK5 Dedicator of cytokinesis 5

1425 G6851 AK056005 ZNF232 Zinc finger protein 232

1426 G6893 AI056903 Transcribed locus

Solute carrier family 13 (sodium-dependent

1427 G7199 BF431313 SLC13A3 dicarboxylate transporter), member 3

1428 G7216 AI953227 Transcribed locus

1429 G7145 AFl 50329 VAV3 Vav 3 oncogene

AFTIPHI

1430 G7189 AW977068 Aftiphilin protein LIN

Transcribed locus, weakly similar to

1431 G7518 AK097137 NP_078841.2 hypothetical protein FLJ14166 [Homo sapiens]

1432 G7222 BXl 10631 NT5C2 5'-nucleotidase, cytosolic II Coagulation factor II (thrombin) receptor-like

1433 G7870 BQ007450 F2RL2 2

UI-H-EIl-azf-m-15-0-UI.sl NCI_CGAP_EIl

1434 G7877 BQ015552 Homo sapiens cDNA clone IMAGE:5848118 3', mRNA sequence.

1435 F8619 AI632567 TFCP2L1 Transcription factor CP2-like 1

1436 G0874 BC023611 EFHD2 EF hand domain containing 2

1437 G2535 AI700987 Cllorf23 Chromosome 11 open reading frame 23

1438 G3171 AWl 88318 Transcribed locus

1439 G2892 AI024536 Transcribed locus

Full-length cDNA clone CS0DI067YL24 of

1440 G3123 AL552527 Placenta Cot 25 -normalized of Homo sapiens (human)

UI-E-DXl-agw-g-08-0-UI.sl UI-E-DXl Homo sapiens cDNA clone

1441 G3676 BM669634 UI-E-DXl-agw-g-08-O-UI 3', mRNA sequence.

1442 G3386 BC069024 CENTGl Centaurin, gamma 1 1443 G3756 BQ025740 DSTN Destrin (actin depolymerizing factor) 1444 G3996 AL833566 ALCAM Activated leukocyte cell adhesion molecule 1445 G4272 AA669226 Similar to RIKEN cDNA 3110050N22 RAD51 homolog (RecA homolog, E. coli) (S.

1446 G4286 AA873056 RAD51 cerevisiae)

CACNAl Calcium channel, voltage-dependent, P/Q

1447 G4495 AK054746

A type, alpha IA subunit , Potassium large conductance calcium-

1448 G5129 N51068 KCNMAl activated channel, subfamily M, alpha member 1

1449 G5187 BU626581 NQO2 NAD(P)H dehydrogenase, quinone 2 1450 G5193 AFl13687 RGS6 Regulator of G-protein signalling 6 1451 G6969 AI798727 Transcribed locus ym36aO8.sl Soares infant brain INIB Homo

1452 G5950 H17455 sapiens cDNA clone

IMAGE:50060 3', mRNA sequence.

Thyroid hormone receptor associated protein 1453 G6034 N51961 THRAPl

1 tx53fO4.xl NCI_CGAP_Lu24 Homo sapiens

1454 G7101 AI630821 cDNA clone IMAGE:2273311 3'₅mRNA sequence.

1455 G7316 AK097857 Hypothetical LOCI 57813 1456 G7353 AF085854 Full length insert cDNA clone YI54D04

Protein phosphatase IH (PP2C domain

1457 G7713 BM678413 PPMlH containing)

1458 G7772 BM677476 TOX Thymus high mobility group box protein TOX 1459 G7699 BC020838 CLDN20 Claudin 20 PHGDHL 1460 G7364 AW978315 Phosphoglycerate dehydrogenase like 1

1

Thyroid hormone receptor associated protein

1461 G8584 BQ310416 THRAP2

2 1462 G8030 AK098270 FP6778

UI-H-EUO-azv-1- 14-0-UI. s 1

1463 G7967 BQ181903 NCI_CGAP_Carl Homo sapiens cDNA clone

IMAGE:5854237 3', mRNA sequence. 1464 G8082 AK094332 Hypothetical gene supported by AK094332

Ubiquitin protein ligase E3 A (human 1465 F8283 AI133478 UBE3A papilloma virus E6-associated protein,

Angelman syndrome)

PRKWNK

1466 G2616 BX470806 Protein kinase, lysine deficient 1

1 1467 G2943 BQ448624 C7orf6 Chromosome 7 open reading frame 6

Chromodomain helicase DNA binding protein 1468 G2981 AA573217 CHDlL

1-like

1469 G3016 XM_499110 LOC441345 1470 G2992 AI807658 SNX27 Sorting nexin family member 27

SUV420H Suppressor of variegation 4-20 homolog 1

1471 G3600 AK074226

1 (Drosophila) 1472 G4136 AI800735 CDNA FLJl 1397 fis, clone HEMBA1000622

UI-H-EUl-bac-c-08-0-UI.sl NCI_CGAP_Ctl

Homo sapiens cDNA clone

1473 G3870 • BQ446672

UI-H-EUl-bac-c-08-O-UI 3', mRNA sequence.

Ubiquitin-conjugating enzyme E2B (RAD6

1474 G4645 AK057639 UBE2B homolog) yj83dO8.x5 Soares breast 2NbHBst Homo

1475 G4332 AI668557 sapiens cDNA clone

IMAGE: 155343 3', mRNA sequence.

1476 G5235 R40058 NRCAM Neuronal cell adhesion molecule

1477 G5028 R11869 ATF6 Activating transcription factor 6 yb49cl2.sl Stratagene fetal spleen (#937205)

1478 G5270 T59016 Homo sapiens cDNA . clone IMAGE:74518 3', niRNA sequence.

1479 G5043 AW973785 NIPBL Nipped-B homolog (Drosophila)

1480 G5587 BG281555 Hypothetical gene supported by BCOl 9009

1481 G6767 AB036693 RAB9B RAB9B, member RAS oncogene family MR2-NT0135-161100-006-a08 NT0135

1482 G7916 BF921173 Homo sapiens cDNA, mRNA sequence.

B5869

1483 NM_015259 ICOSL Inducible T-cell co-stimulator ligand

N

1484 G2037 BG462138 Transcribed locus

1485 G2819 AK095968 CDNA FLJ38649 fis, clone HHDPC2007302

QV0-HT0368-310100-091-h06 HT0368

1486 G3342 BE156543 Homo sapiens cDNA, mRNA sequence. Phosphodiesterase 4B, cAMP-specific

1487 G4254 BU739793 PDE4B (phosphodiesterase E4 dunce homolog, Drosophila)

KIAA093

1488 G4287 BX537672 KIAA0934 4

LOC1467

1489 G4511 AK054893 Hypothetical protein LOC146713 13

1490 G4531 AK055134 STAGl Stromal antigen 1

1491 G4894 AK096262 CDNA FLJ38943 fis, clone NT2NE2017480

1492 G4925 AK097171 CDNA FLJ39852 fis, clone SPLEN2014865

1493 G5095 H98216 C14orf24 Chromosome 14 open reading frame 24

1494 G5160 N63395 MLSTD2 Male sterility domain containing 2

1495 G5123 N48593 CDNA FLJ36725 fis, clone UTERU2012230

1496 G6039 BC036620 C9orf99 Chromosome 9 open reading frame 99

1497 G7046 AK074042 PARVG Parvin, gamma

PLEKHA Pleckstrin homology domain containing,

1498 G7119 BM977618

5 family A member 5

1499 G6983 CN479411 IREM2 Immune receptor expressed on myeloid cells 2

PLEKHA Pleckstrin homology domain containing,

1500 G6059 N67553

5 family A member 5

1501 G7317 AW292370 Transcribed locus

Protein phosphatase, EF hand calcium- 1502 G7733 BM676496 PPEF2 binding domain 2

Sema domain, transmembrane domain (TM),

1503 G7651 AK055059 SEMA6A and cytoplasmic domain, (semaphorin) 6A Protein tyrosine phosphatase, receptor type, f

1504 G7346 AW470328 PPFIAl polypeptide (PTPRF), interacting protein (liprin), alpha 1

1505 G7960 BI430555 Transcribed locus nf93dO2.sl NCI_CGAP_Co3 Homo sapiens

1506 G7979 AA535272 cDNA clone IMAGE:927459 3 '.mRNA sequence.

1507 G0130 AB058773 COL27A1 Collagen, type XXVII, alpha 1

1508 F8082 BF058212 FLJ40125 Hypothetical protein FLJ40125 1509 G2925 AK093779 Hypothetical gene supported by AK093779

Mouse Mammary Turmor Virus Receptor

1510 G3578 AK057616 MTVRl homolog 1

Ubiquitin-conjugating enzyme E2E 3

1511 G3255 AK002088 UBE2E:

(UBC4/5 homolog, yeast)

1512 G4118 AA149783 Transcribed locus

MGC34ι

1513 G4145 W25631 Hypothetical protein MGC34646 6

RaI guanine nucleotide dissociation

1514 G4124 AA169173 RGLl stimulator-like 1

1515 G4333 AI668582 ZNF609 Zinc finger protein 609

1516 G5221 NM 005867 DSCR4 Down syndrome critical region gene 4

1517 G5037 H56731 Transcribed locus

1518 G5542 XM 209824 Similar to matrilin 2 precursor

XM 212106 MR3-GN0186-211100-009-f09 GN0186

1519 G5642 BG004461 Homo sapiens cDNA, mRNA sequence.

1520 G7141 BQ001753 DISCI Disrupted in schizophrenia 1

1521 G7202 AI825890 Transcribed locus

1522 G7241 AW003728 Transcribed locus

1523 G7264 AW069500 Transcribed locus

1524 G7462 BF055457 Transcribed locus

1525 G7224 AI951426 DUSPK Dual specificity phosphatase 10 X-ray repair complementing defective repair

1526 G7257 AK023296 XRCC5 in Chinese hamster cells 5 (double-strand- break rejoining; Ku autoantigen, 8OkDa) UI-H-BWO-aih-c-01-O-UI.sl

1527 G8180 AW292980 NCI_CGAP_Sub6 Homo sapiens cDNA clone IMAGE:2729089 3', mRNA sequence.

1528 G8234 BU076203 MAPKlO Mitogen-activated protein kinase 10

1529 G2403 CR591879 TncRNA Trophoblast-derived noncoding RNA MRNA full length insert cDNA clone

1530 G3135 ALl 09783 EUROIMAGE 163507

1531 G3399 AF295378 MAGEFl Melanoma antigen, family F, 1

1532 G4514 AK054930

1533 G4608 AK057035 CDNA FLJ32473 fis, clone SKNMC2000374 yv31bO9.rl Soares fetal liver spleen INFLS

1534 G5177 N72313 Homo sapiens cDNA clone IMAGE:244313 5', mRNA sequence.

1535 G6269 BG755974 C14orfl25 Chromosome 14 open reading frame 125

1536 G6250 W86987 IGFlR Insulin-like growth factor 1 receptor

ZMYNDl

1537 G7318 BFl 96963 Zinc finger, MYND domain containing 11 1

Solute carrier family 27 (fatty acid

1538 G7668 BQ712480 SLC27A1 transporter), member 1

1539 G7717 BM681618 Transcribed locus

1540 G7432 AK022190 LDB2 LIM domain binding 2

1541 G7398 BE501478 Transcribed locus

1542 G8512 BC028198 FLJ25200 Hypothetical protein FLJ25200 Transcribed locus, weakly similar to NP_872601.1 ubiquitously transcribed

1543 G8117 AK091697 tetratricopeptide repeat gene, Y-linked [Homo sapiens]

Table.3 RT-PCR primer set

LMMI SEQ SEQ

F-primer R-primer

D ID NO ID NO

CACAACCATTTTG GCTTCTACATCTC

A2466 34 4

ACCTCTCAGT AAATCATGTCC

CCTCAGGTCTTCA TGCCATGTACAAT A2735 35 36

CTCTTTCTTCT GTAGTAACAGC

TAGAGAACCCCA TCAGTAAGAAAG A3802 37 38

TGCCCCTTA ACTGGCTAATGGT

AGCCATTTGATGG TGGATGAAGGGG A4513 39 40

AGAAGAATG TTCCCGAAT

CCAGTCTTGGCTG CTCTCTGAAATGC A5065 41 42

AAATGTTTT AACTGTTCGT

GAGGAAGAATTG TTTTAAAGTGCAT A6598 43 44

CTTTTCTCTTACC CTGTGGAGG

GTGGTAACGTTCA ATGGCTCCTTACC A7296 45 46

GCAAAAGC TGAGAGAAAC

GACAGCAAAGTC AAAGTGGCTGGG A7608 47 48

TTGACTCCTTC AGTAAGGTATC

AGACAAAGAGAG AGAGGATCCTATT A7856 49 50

AAAGAGACGCA GTCTTGGAGG

CAGAATCGCAGG GTGACTCATGCCT A7908 51 52

ATGAAAGATA TGATATGACA

TATCTGTGATTGT GCCCATCCTTACT A8172 53 54

TGCTCACCTG TTCCTCATAC

CTTGAAGAAGAA AATGTTCTAAAGA A8335 55 56

CTTCCAGACGA TGAGAGGGGG

GCCTTAAAACTGG TAGCAGAGCGCA A8487 57 58

AGAGAGGAAT CAAACATTTA

GTGCACCAAAAC GGCTTTGCAACTT A9371 59 60

ACTGACATTT TGTCCATT

TCTGAAGCCTGAT ATGTGCACTGGAC A9723 61 62

TACTGTGTGA TGAAACATCT

TGTGTGAGCATTT AATTTTAACAGCA B3827 63 64

GACAAGACT AGTGGTGGG

ACTGCAAATGGG GGAGAGGGTATG

B4161 65 66

AGTGCTTAGTA AGTCCTTTGAT

B6125 CAGCTGTATCCCC GGTGAGGTATCCT 67 68

N TAAACAACC GTCTTCAGAG

TCCAGAATTGCTT GGTTCTCAGAGCT

B7534 69 70 ^'

GTTACGTAGG GTTTTGCTT

GTATTACCGATGC TGAGGTGTATGGC B8814 71 72

CTCTGAAAAG AAGTTGAATC TAGAGTCTAGAA CAAAAACTATCA

C1948 73 74

CGCAAGGATCTC CAGCCTAAAGGG

ATTAGAATTCTGG CTACCCTGGGGTG C6209 75 76

GGCTGTAAGG TTTTCTAAAT

GGTGCATAAACA GTTAAAAGGAGC C8926 77 78

CTAATGCAGTC ACAGGGACATA

CACCCATAACCA GGGATGTCTGTTC C9016 79 80

AGAGAACTCAG CTTTTATTCC

GTGGCCACTGAAT AGTAACTCTGTCT C9046 81 82

GTAAAACAAC TCATCCGCAG

CAATTTTCCCATG GCGTTTTCAAGAT C9098 1 2

GTCTTATCC CTAGCATGTG

GTTTTGGCCCAAT GCACTTGGAAGG C9490 83 84

TAACCAGTA GGTATTGTATT

ATTCATTCTGGAC TCTACTGTGGACA C9517 85 86

CAAAGATCC AGAAGCCTGT

AGCAGTCAGGGA AAGGTAAACTCT C9858 87

CAGACATACAT AGGCATCCGTC

AAAGAGGAACAC AGGAGCCTAGAG D8457 89 90

ACTGGGTGTAA AAGCAATCATC

TCTTCAGCATGAT TGAGAGATTCATG D9504 91 92

GTGTTGTGT AGGAAGTCTTG

AGGTGTACTGAGT CTGGCATAACAGT E0133 93 94

GGGGAAGAAT GGCTTAAGTT

GCTCCTTCTCTCA CAAGTGGGTAAA E0341 95 96

TGGATTACCT ATGCTGTCTTC

ACAAGTGCGAAG ACAGTGGTATTTG E0556 97 98

TCTGGTAAG TGGCGTATC

CCAAAAGCTAAG CTGTGCAACAGTT E2191 99 100

CAGTGGTGAAC CCCAAAATG

TTGACAAGCTGTA AAAGTTGGAATG F5946 101 102

GAACTGGATT CCGATGACA

CAGCCTCAATGG GCTAGAAAGCAA G3996 103 104

ATACTGGC ACTCATGCTCTG

TATGGTCTCCGTG ATACAGACAGGA A3097 107 108

CCTACCAC AAAGCAGAGCA

CAAGTCAGTGTAC ACTB GAGGTGATAGCA 105 106

TTGCTTTCG AGGTAAGC

Table.4 down-regulated genes in lymph-node-positive casees

Assignme LMMI

ACCESSION SYMBOL GENENAME nt NO D 1544 C8947 AL833303 Full length insert cDNA clone YZ04E02 1545 B2112 S74221 IK IK cytokine, down-regulator of HLA II 1546 A2720 AJ002231 GNPDAl Glucosamine-6-phosphate deaminase 1 1547 B4433 AJ420556 SEC5L1 SEC5-like 1 (S. cerevisiae) 1548 B8117 AA994071 Zinc finger protein 192 1549 C1063 AK096960 RADl RADl homolog (S. pombe) 1550 A5355 NM 201222 MAGED2 Melanoma antigen family D₅ 2 Phospholysine phosphohistidine inorganic

1551 B6373 BX423161 LHPP pyrophosphate phosphatase

RAS guanyl releasing protein 1 (calcium

1552 AF081195 RASGRPl

N and DAG-regulated)

Solute carrier family 9 (sodium/hydrogen

1553 B7525 NM_015266 SLC9A8 exchanger), isoform 8

1554 B4394 N46424 RAI14 Retinoic acid induced 14

A2301 Solute carrier family 20 (phosphate

1555 BC028600 SLC2A2

N transporter), member 2

1556 A1219 NM 001905 CTPS CTP synthase

1557 A6309 BM701413 SEC61B Sec61 beta subunit

1558 D3350 R45979 EST

1559 D6495 AA993602 HSPC63 HSPC063 protein

1560 A1084 BM905965 HSPEl Heat shock 1OkDa protein 1 (chaperonin 10)

1561 F3819 AK000471 EST

1562 D4231 C05897 ARL5 ADP-ribosylation factor-like 5

SH3 domain binding glutamic acid-rich

1563 B5126 BX109845 SH3BGRL2 protein like 2

1564 B6528 AFl 59447 SUFU Suppressor of fused homolog (Drosophila)

A1859 NM 0010022

1565 GATA3 GATA binding protein 3

N 95

1566 F6308 XM 375105 KIAA329 KIAA0329

1567 B3960 AF234532 MYOl Myosin X

1568 B6051 R32860 MOBKL2B Transcribed locus

1569 C7642 AKOO 1431 FLJl 569 Hypothetical protein FLJl 0569

1570 C6830 R49122 FLJ148 Hypothetical protein FLJl 4800

1571 C4865 AK095215 C21orfl8 Chromosome 21 open reading frame 18

1572 B4932 AA909294 MUMl Melanoma associated antigen (mutated) 1

1573 B4159 BU634102 C9orfl l6 Chromosome 9 open reading frame 116

1574 B6560 BCOl 1728 ARMC7 Armadillo repeat containing 7

1575 B9577 N48793 KIAAl 546 KI AA 1546 protein

1576 B4930 AL110157 DUSP7 Dual specificity phosphatase 7

A2759

1577 Xl 6260 ITIHl Inter-alpha (globulin) inhibitor Hl

N

1578 B9454 AA033857 RAB4A RAB40A, member RAS oncogene family

1579 B7123 CA418716 STXBP5 Syntaxinbinding protein 5 (tomosyn)

1580 B8754 AL833264 FEMlB Fem-1 homolog b (C. elegans)

B0830 Inhibitor of DNA binding 4, dominant

1581 BM473615 ID4

N negative helix-loop-helix protein

N-acylsphingosine amidohydrolase (acid

1582 C3772 U70063 ASAHl ceramidase) 1

1583 B9198 AKl 23132 MSRA Methionine sulfoxide reductase A

1584 A6996 AL832899 RAPGEF6 KIAAl 961 gene

1585 A5364 BC004309 RAB4A RAB4A, member RAS oncogene family

Collaborates/cooperates with ARF (alternate

1586 B3769 N91145 CARF reading frame) protein

Clone 114 tumor rejection antigen mRNA,

1587 B8469 CR598871 GFPTl complete cds

B1465

1588 AK074306 FLJ23518 Hypothetical protein FLJ23518

N 1589 B8098 R42864 PAPOLA PoIy(A) polymerase alpha

1590 B8277 H05711 FLJ3536 Hypothetical protein FLJ35036

A6649

1591 AK026613 GOLGA7 Golgi autoantigen, golgin subfamily a, 7

N

A4647

1592 NM_004169 SHMTl Serine hydroxymethyltransferase 1 (soluble)

N

1593 B4176 AF037629 Transcribed locus

A6342 Signal-induced proliferation-associated gene

1594 AI057185 SIPAl

N 1

DKFZP434

1595 B8141 BC042478 Hypothetical protein DKFZp434F0318 F318

1596 B9157 R44292 FLJ3778 Hypothetical protein FLJ37078 ^•

A3384

1597 NM_002024 FMRl Fragile X mental retardation 1

N

1598 B5168 AL834437 FLJ31818 Hypothetical protein FLJ31818 Lectin, galactoside-binding, soluble, 2

1599 A6777 BQ276959 LGALS2 (galectin 2)

Membrane targeting (tandem) C2 domain

1600 C6087 BU676496 MTAC2D1 containing 1

A1878

1601 U88666 SRPK2 SFRS protein kinase 2

N

1602 B6103 T89283 Clone IMAGE: 110436 mRNA sequence

Table.5 up-regulated genes in lymph-node-positive casees Assⁱgnment _LMMD ACCESSION SYMBOL GENENAME

NO

Glutamine-fructose-6-phosphate

1603 A3166N BX953609 GFPTl transaminase 1

1604 A1750 D31716 BTEBl Kruppel-like factor 9

1605 B3701 AY249859 DUSP22 Dual specificity phosphatase 22

1606 C3692 AI816254 USPI l Ubiquitin specific protease 11

Galactose- 1 -phosphate

1607 Al 026 M60091 GALT uridylyltransferase

1608 B3777 AW574563 CERK Ceramide kinase

1609 A3923 AF038440 PLD2 Phospholipase D2

1610 B9111 NM 014811 KIAA649 KIAA0649

Anaphase promoting complex

1611 B8069 NM 013366 ANAPC2 subunit 2

Serine/threonine kinase 24 (STE20

1612 B6768N AA919178 STK24 homolog, yeast)

1613 B3543 AK092257 Calpain 14

1614 A1350 NM 013314 BLNK B-cell linker

1615 B8715 NM 080836 STK35 Serine/threonine kinase 35

1616 B9038 AY304473 WDR26 WD repeat domain 26

1617 B4721N BE795997 . NCOR2 Nuclear receptor co-repressor 2

Short-chain

1618 B9158 CR622145 SCDRl dehydrogenase/reductase 10

1619 B3350 AK056402 TDRKH Tudor and KH domain containing

1620 A4791 AF065482 SNX2 Sorting nexin 2

1621 F3895 AFl 00742 ZFR Zinc finger RNA binding protein 1622 A2321 NM 005831 NDP52 Nuclear domain 10 protein

1623 BO 122 BC009534 PINKl PTEN induced putative kinase 1

TAF7 RNA polymerase II, TATA

1624 A2374 X97999 TAF7 box binding protein (TBP)- associated factor, 55kDa

1625 A1619 BCO 13873 CETN2 Centrin, EF-hand protein, 2

CDC23 (cell division cycle 23,

1626 A3953 NM_004661 CDC23 yeast, homolog)

1627 A5419 BU630296 ARRDC4 Arrestin domain containing 4

1628 B3737 NM 014647 LKAP Limkain bl

1629 B4095 BC014070 MAGEDl Melanoma antigen family D, 1

ATPase, H+ transporting, lysosomal

1630 A2079 NMJ)Ol 183 ATP6AP1 accessory protein 1

1631 A6411 ALl 37764 LOC64744 Hypothetical protein AL133206

Procollagen-lysine, 2-oxoglutarate 5-

1632 A2490 BCOl 1674 PLOD3 dioxygenase 3

1633 A5269 U80743 EP4 ElA binding protein p400

1634 A3130 L36529 THOCl THO complex 1

PR domain containing 2, with ZNF

1635 A4415 U17838 PRDM2 domain

Chromosome 5 open reading frame

1636 B0132 AK056512 C5orfl4

14

1637 A8596 AA632025 Transcribed locus

1638 C4735 AL136805 ZNF537 Zinc finger protein 537

HMTl hnRNP methyltransferase-

1639 A4325 AK123352 HRMTlLl like 1 (S. cerevisiae)

1640 B3943 XM_377060 LOC23547 Hypothetical protein LOC203547

Protein inhibitor of activated STAT₅

1641 A6891 BU616541 PIAS2

2

Chromosome 18 open reading frame

1642 A5825 BX640683 C18orf25

25

Glyceronephosphate O-

1643 A2228 AK023953 GNPAT acyltransferase

Transmembrane protein induced by

1644 A9256 BC051850 TMPIT tumor necrosis factor alpha

1645 A0582 BC034409 ICAM3 Intercellular adhesion molecule 3

Additional sex combs like 2

1646 B4362 BX648218 ASXL2

(Drosophila)

1647 B7278 BC005125 FLJ1475 Hypothetical LOC79954 1648 B3770 BQ650605 Dlc2 Dynein light chain 2 1649 B8113 BC020848 RNASE6 Ribonuclease, RNase A family, k6 1650 A5767 AI096898 NKAP NF-kappaB activating protein

Phosphoinositide-3 -kinase, catalytic,

1651 A0232 NM_006219 PIK3CB beta polypeptide

GRINLlA complex upstream

1652 C4884 AA036952 ^■ Gupl protein

1653 B6529 C A314443 PLXNA3 Plexin A3

Chemokine-like factor super family

1654 C3645 AK000403 CKLFSF6

6 Amyloid beta (A4) precursor protein

1655 C0258 NM 000484 APP (protease nexin-II, Alzheimer disease)

Chromosome 21 open reading frame

1656 B5104 CR613027 C21orf4

4

Chromosome 20 open reading frame

1657 B4556 NM_020531 C2orf3

3

Phosphatidylinositol binding clathrin

1658 A4719N BC048259 PICALM assembly protein

1659 D9475 AW089912 OAZl Ornithine decarboxylase antizyme 1

1660 E0215 AI091879 Transcribed locus

Ubiquitin specific protease 7 (herpes

1661 El 229 NM_003470 USP7 virus-associated)

1662 E1378 AK025645 SLA2 Src-like-adaptor 2

1663 AOl 83N NM 004431 EPHA2 EPH receptor A2

1664 D7869 NM_007175 C8orf2 SPFH domain family, member 2

Proteasome (prosome, macropain)

1665 E0052 AI081459 PSMA6 subunit, alpha type, 6

1666 El 522 BM550980 MGC521 Hypothetical protein MGC52010

Full-length cDNA clone

1667 C0328 CR592555 CSODEOl 1YI04 of Placenta of

Homo sapiens (human)

AHNAK nucleoprotein

1668 E0523 BCO 17483 AHNAK

(desmoyokin)

Aldehyde dehydrogenase 3 family,

1669 E1379 AK123877 ALDH3A2 member A2

1670 D6549 BC004888 FLJl 52 Hypothetical protein FLJl 0052 1671 D3747 AA843607 LOC12376 Hypothetical protein LOC 120376 1672 . C7731 AF245505 DKFZp564I1922 Adlican 1673 A0954 NM 000252 MTMl Myotubularin 1 1674 B2801 AKl 30734 FLJ1371 Hypothetical protein FLJl 3710

Neural proliferation, differentiation

1675 A8688 CR597998 NPDCl and control, 1

1676 B0629 AK126877 FLJ1521 Hypothetical protein FLJl 0521 1677 A7145 X52005 EST

Killer cell lectin-like receptor

1678 A6751 NM_002258 KLRBl subfamily B, member 1

1679 A9307 BC053677 FLJ37562 Hypothetical protein FLJ37562

Table 6 Down-re ulated enes in recurrence- ositive casees

Table 7 U -re ulated enes in recurrence-positive casees

Table 8 Sequence of specific double- stranded oligonucleotide inserted into siRNA expression vector and tar et sequences of each siRNAs.

Table 9A. Association between DKKl-positivity in ESCC tissues and patients' characteristics (n=220)

P-value

DKKl DKKl

DKKl strong/weak

Total strong weak absent VS positive positive absent n = 220 n = 60 n = 75 n = 85

Gender

Male 202 53 69 80 TvT C

Female 18 7 6 5

Age (years)

< 65 138 40 52 46

IN o

≥65 82 20 23 39 pT factor

T1+T2 98 20 37 41 u.u4 /y

T3+T4 122 40 38 44 pN factor

NO 80 15 30 35 π U. C U\AH-CU\ΔH-*

N1+N2 140 45 45 50

ADC₅ adenocarcinoma; SCC, squamous-cell carcinoma *P < 0.05 (Fisher's exact test) NS, no significance

Table 9B. Cox's proportional hazards model analysis of prognostic factors in patients with ESCCs

Variables Hazards ratio 95% CI Unfavorable/Favorable P-value

Univariate analysis

DKKl 1.477 1.012-2.157 Strong(+)/Weak(+) or (-) 0.0433*

Age ( years ) 0.911 0.629-1.319 65 ≥ / <65 NS

Gender 2.120 0.932-4.819 Male / Female NS pT factor 1.889 1.411-2.528 T3+T4 / T1+T2 O.0001* pN factor 2.76 1.626-4.571 N1+N2 /N0 0.0001^*

Multivariate analysis

DKKl 1.181 0.804-1.734 Strong(+)/Weak(+) or (-) NS pT factor 2.054 1.223-3.447 T3+T4 / T1+T2 0.0065^* pN factor 2.256 1.454-3.502 N1+N2 /N0 0.0003^*

*P < 0.05 NS₅ no significance Table 1OA. Association between DKKl-positivity in NSCLC tissues and patients' characteristics (n=279)

P-value

DKKl DKKl

DKKl strong vs

Total strong weak absent weak/ positive positive absent n = 279 n = 125 n = 102 n = 52

Gender

Male 183 94 62 27

0.0024* Female 96 31 40 25

Age (years)

<65 134 51 59 24

0.0309*

≥65 145 74 43 28

Histological type

ADC 161 48 70 43

< U. UU l non-ADC 118 77 32 9 pT factor

T1+T2 241 111 84 46

JNo

T3+T4 38 14 18 6 pN factor

NO 210 88 85 37 X INfCo

N1+N2 69 37 17 15

ADC, adenocarcinoma; SCC, squamous-cell carcinoma non-ADC, SCC, large-cell carcinoma (LCC), and adenosquamous-cell carcinoma (ASC)

*P < 0.05 (Fisher's exact test)

NS, no significance

Table 1OB. Cox's proportional hazards model analysis of prognostic factors in patients with

NSCLCs

Variables Hazards ratio 95% CI Unfavorable/Favorable P-value

Univariate analysis

DKKl 1.977 1.234-3.169 Strong(+)/Weak(+) or (-) 0.0046*

Age ( years ) 2.214 1.365-3.592 65 ≥ / <65 0.0013*

Gender 1.958 1.147-3.345 Male / Female 0.0138*

Histological type 2.279 1.418-3.661 non-ADC/ADCl 0.0007* pT factor 2.431 1.374-4.303 T3+T4/T1+T2 0.0023 * pN factor 3.811 2.387-6.084 N1+N2 / N0 O.0001*

Multivariate analysis

DKKl 1.798 1.114-2.903 Strong(+)/Weak(+) or (-) 0.0163* pT factor 2.407 1.349-4.294 T3+T4 / T1+T2 0.0029 * pN factor 3.418 2.124-5.500 N1+N2 / N0 O.0001*

1 ADC, adenocarcinoma *P < 0.05

Claims

1. A method of diagnosing esophageal cancer or a predisposition for developing esophageal cancer in a subject, comprising determining a level of expression of an esophageal cancer-associated gene in a biological sample from a patient, wherein an increase or decrease in said sample expression level as compared to a normal control expression level of said gene indicates that said subject suffers from or is at risk of developing esophageal cancer.

2. The method of claim 1, wherein said esophageal cancer-associated gene is selected from the group consisting of the genes of EC Nos.728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7), further wherein an increase in said sample expression level as compared to a normal control level indicates said subject suffers from or is at risk of developing esophageal cancer.

3. The method of claim 2, wherein said sample expression level is at least 10% greater than said normal control level.

4. The method of claim 1, wherein said esophageal cancer-associated gene is selected from the group consisting of the genes of EC Nos. 1-727 (table 1), 1544-1602 (table 4), and 1680-1688 (table 6), further wherein a decrease in said sample expression level as compared to a normal control level indicates said subject suffers from or is at risk of developing esophageal cancer.

5. The method of claim 4, wherein said sample expression level is at least 10% lower than said normal control level.

6. The method of claim 1, wherein said esophageal cancer is esophageal squamous-cell carcinoma.

7. The method of claim 1, wherein said biological sample comprises an epithelial cell.

8. The method of claim I₅ wherein said biological sample comprises an esophageal cancer cell.

9. The method of claim 1, wherein said biological sample comprises an epithelial cell from an esophageal cancer.

10. The method of claim 1, wherein said method further comprises determining the level of expression of a plurality of esophageal cancer-associated genes.

11. The method of claim 1 , wherein gene expression level is determined by a method selected from the group consisting of: (a) detecting mRNA of the esophageal cancer- associated gene,

(b) detecting a protein encoded by the esophageal cancer-associated gene, and

(c) detecting a biological activity of a protein encoded by the esophageal cancer- associated gene.

12. The method of claim 10, wherein said detection is carried out on a DNA array.

13. An esophageal cancer reference expression profile comprising a pattern of gene expression for two or more esophageal cancer-associated genes selected from the group consisting of the genes of EC Nos. 1-1716.

14. A method of screening for a compound for treating or preventing esophageal cancer, said method comprising the steps of: (a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of EC Nos. 1-1716;

(b) detecting the binding activity between the polypeptide and the test compound; and

(c) selecting the test compound that binds to the polypeptide.

15 A method of screening for a compound for treating or preventing esophageal cancer, said method comprising the steps of:

(a) contacting a candidate compound with a cell expressing one or more marker genes, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1-1716; and

(b) selecting the candidate compound that reduces the expression level of one or more marker genes selected from the group consisting of the genes of EC Nos. 728-1543

(table 2), 1603-1679 (table 5), and 1689-1716 (table 7), or elevates the expression level of one or more marker genes selected from the group consisting of the genes of EC Nos. 1-727 (table 1), 1544-1602 (table 4), and 1680-1688 (table 6), as compared to an expression level detected in the absence of the candidate compound.

16. The method of claim 15, wherein said cell comprises an esophageal cancer cell.

17. A method of screening for a compound for treating or preventing esophageal cancer, said method comprising the steps of:

(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of EC Nos. 1-1716; (b) detecting the biological activity of the polypeptide of step (a); and

(c) selecting the test compound that suppresses the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7), or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of EC Nos. 1-727 (table 1), 1544-1602 (table 4), and 1680-1688 (table 6)as compared to the biological activity of said polypeptide detected in the absence of the test compound.

18. A method of screening for compound for treating or preventing esophageal cancer, said method comprising the steps of: (a) contacting a candidate compound with a cell into which a vector, comprising the transcriptional regulatory region of one or more marker genes and a reporter gene that is expressed under the control of the transcriptional regulatory region, has been introduced, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos.1-1716; (b) measuring the expression level or activity of said reporter gene; and

(c) selecting the candidate compound that reduces the expression level or activity of said reporter gene when said marker gene is an up-regulated marker gene selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7), or that enhances the expression level or activity of said reporter gene when said marker gene is a down-regulated marker gene selected from the group consisting of the genes of EC Nos. 1-727 (table 1), 1544-1602 (table 4), and 1680-1688 (table 6), as compared to an expression level or activity detected in the absence of the candidate compound.

19. A kit comprising a detection reagent which binds to (a) two or more nucleic acid sequences selected from the group consisting of the genes of EC Nos. 1-1716, or (b) polypeptides encoded thereby.

20. An array comprising two or more nucleic acids which bind to one or more nucleic acid sequences selected from the group consisting of the genes of EC Nos. 1-1716.

21. A method of treating or preventing esophageal cancer in a subject comprising administering to said subject an antisense composition, said antiseήse composition comprising a nucleotide sequence complementary to a coding sequence selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7).

22. A method of treating or preventing esophageal cancer in a subject comprising administering to said subject an siRNA composition, wherein said siRNA composition reduces the expression of a nucleic acid sequence selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7).

23. The method of claim 22, wherein the nucleotide sequence is selected from group consisting of SEQ ID NOs: 30 (ECT2) and 32 (CDC45L), and said siRNA comprises a sense strand comprising a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NO: 8, 9, 10, and 11.

24. A method for treating or preventing esophageal cancer in a subject comprising the step of administering to said subject a pharmaceutically effective amount of an antibody, or immunologically active fragment thereof, that binds to a protein encoded by any one gene selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7).

25. A method of treating or preventing esophageal cancer in a subject comprising administering to said subject a vaccine comprising (a) a polypeptide encoded by a nucleic acid selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7), (b) an immunologically active fragment of said polypeptide, or (c) a polynucleotide encoding the polypeptide.

26. A method for inducing an anti-tumor immunity, said method comprising the step of contacting with an antigen presenting cell a polypeptide, a polynucleotide encoding the polypeptide or a vector comprising the polynucleotide, wherein the polypeptide is encoded by a gene selected from the group consisting of EC No. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7), or the fragment thereof.

27. The method for inducing an anti-tumor immunity of claim 26, wherein the method further comprises the step of administering the antigen presenting cell to a subject.

28. A method of treating or preventing esophageal cancer in a subject comprising administering to said subject a compound that increases (a) the expression of a polynucleotide selected from the group consisting of the genes of EC Nos. 1-727 (table I)₅ 1544-1602 (table 4), and 1680-1688 (table 6) or (b) the activity of a polypeptide encoded thereby.

29. A method for treating or preventing esophageal cancer in a subject, said method comprising the step of administering a compound obtained by a method according to any one of claims 14-18.

30. A method of treating or preventing esophageal cancer in a subject comprising administering to said subject a pharmaceutically effective amount of an agent comprising (a) a polynucleotide selected from the group consisting of the genes of EC Nos. 1-727 (table 1), 1544-1602 (table 4), and 1680-1688 (table 6), or (b) a polypeptide encoded thereby.

31. A composition for treating or preventing esophageal cancer, said composition comprising a pharmaceutically effective amount of an antisense polynucleotide or siRNA against a polynucleotide selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7).

32. The composition of claim 31, wherein said siRNA comprises a sense strand comprising a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NO: 8, 9, 10, and 11.

33. A composition for treating or preventing esophageal cancer, said composition comprising a pharmaceutically effective amount of an antibody or fragment thereof that binds to a protein encoded by a gene selected from the group consisting of the genes of EC Nos. 728-1543 (table 2), 1603-1679 (table 5), and 1689-1716 (table 7).

34. A composition for treating or preventing esophageal cancer, said composition comprising as an active ingredient a pharmaceutically effective amount of a compound selected by a method of any one of claims 14-18, and a pharmaceutically acceptable carrier.

35. A method of screening for a compound for treating or preventing esophageal cancer metastasis, said method comprising the steps of:

(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of EC Nos. 1544-1679 (tables 4-5); (b) detecting the binding activity between the polypeptide and the test compound; and

(c) selecting the test compound that binds to the polypeptide.

36. A method of screening for a compound for treating or preventing esophageal cancer metastasis, said method comprising the steps of:

(a) contacting a candidate compound with a cell expressing one or more marker genes, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1544-1679 (tables 4-5); and

(b) selecting the candidate compound that reduces the expression level of one or more marker genes selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5), or elevates the expression level of one or more marker genes selected from the group consisting of the genes of EC Nos. 1544-1602 (table 4), as compared to an expression level detected in the absence of the candidate compound.

37. A method of screening for a compound for treating or preventing esophageal cancer metastasis, said method comprising the steps of:

(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of EC Nos. 1544-1679 (tables 4-5); (b) detecting the biological activity of the polypeptide of step (a); and

(c) selecting the test compound that suppresses the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5), or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of EC Nos. 1544- 1602 (table 4) as compared to the biological activity of said polypeptide detected in the absence of the test compound.

38. A method of screening for compound for treating or preventing esophageal cancer metastasis, said method comprising the steps of:

(a) contacting a candidate compound with a cell into which a vector, comprising the transcriptional regulatory region of one or more marker genes and a reporter gene that is expressed under the control of the transcriptional regulatory region, has been introduced, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1544-1679 (tables 4-5);

(b) measuring the expression level or activity of said reporter gene; and (c) selecting the candidate compound that reduces the expression level or activity of said reporter gene when said marker gene is an up-regulated marker gene selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5), or that enhances the expression level or activity of said reporter gene when said marker gene is a down-regulated marker gene selected from the group consisting of the genes of EC Nos. 1544-1602 (table 4), as compared to an expression level or activity detected in the absence of the candidate compound.

39. A method of treating or preventing esophageal cancer metastasis in a subject comprising administering to said subject an antisense composition, said antisense composition comprising a nucleotide sequence complementary to a coding sequence selected from the group consisting of the genes of EC Nos.1603-1679 (table 5).

40. A method of treating or preventing esophageal cancer metastasis in a subject comprising administering to said subject an siRNA composition, wherein said siRNA composition reduces the expression of a nucleic acid sequence selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5).

41. A method for treating or preventing esophageal cancer metastasis in a subject comprising the step of administering to said subject a pharmaceutically effective amount of an antibody, or fragment thereof, that binds to a protein encoded by a gene selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5).

42. A method of treating or preventing esophageal cancer metastasis in a subject comprising administering to said subject a vaccine comprising (a) a polypeptide encoded by a nucleic acid selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5), (b) an immunologically active fragment of said polypeptide, or (c) a polynucleotide encoding said polypeptide.

43. A method of treating or preventing esophageal cancer metastasis in a subject comprising administering to said subject a compound that increases (a) the expression of a polynucleotide selected from the group consisting of the genes of EC Nos. 1544-1602 (table 4) or (b) the activity of a polypeptide encoded by said polynucleotide.

44. A method of treating or preventing esophageal cancer metastasis in a subject comprising administering to said subject a pharmaceutically effective amount of an agent comprising (a) a polynucleotide selected from the group consisting of the genes of EC Nos. 1544- 1602 (table 4), or (b) polypeptide encoded by said polynucleotide.

45. A composition for treating or preventing esophageal cancer metastasis, said composition comprising a pharmaceutically effective amount of an antisense polynucleotide or a small interfering RNA against a polynucleotide selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5).

46. A composition for treating or preventing esophageal cancer metastasis, said composition comprising a pharmaceutically effective amount of an antibody, or fragment thereof, that binds to a protein encoded by a gene selected from the group consisting of the genes of EC Nos. 1603-1679 (table 5).

47. A composition for treating or preventing esophageal cancer metastasis, said composition comprising a pharmaceutically effective amount of the compound selected by the method of any one of claims 35-38 as an active ingredient, and a pharmaceutically acceptable carrier.

48. A method of screening for a compound for treating or preventing esophageal cancer recurrence, said method comprising the steps of:

(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of EC Nos. 1680-1716 (tables 6-7);

(b) detecting the binding activity between the polypeptide and the test compound; and

(c) selecting the test compound that binds to the polypeptide.

49. A method of screening for a compound for treating or preventing esophageal cancer recurrence, said method comprising the steps of:

(a) contacting a candidate compound with a cell expressing one or more marker genes, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1680-1716 (tables 6-7); and (b) selecting the candidate compound that reduces the expression level of one or more marker genes selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7), or elevates the expression level of one or more marker genes selected from the group consisting of the genes of EC Nos. 1680-1688 (table 6), as compared to an expression level detected in the absence of the candidate compound.

50. A method of screening for a compound for treating or preventing esophageal cancer recurrence, said method comprising the steps of:

(a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of EC Nos. 1680-1716 (tables 6-7);

(b) detecting the biological activity of the polypeptide of step (a); and (c) selecting the test compound that suppresses the biological activity' of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7), or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of EC Nos. 1680-1688 (table 6) as compared to the biological activity of said polypeptide detected in the absence of the test compound.

51. A method of screening for compound for treating or preventing esophageal cancer recurrence, said method comprising the steps of:

(a) contacting a candidate compound with a cell into which a vector, comprising the transcriptional regulatory region of one or more marker genes and a reporter gene that is expressed under the control of the transcriptional regulatory region, has been introduced, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1680-1716 (tables 6-7);

(b) measuring the expression level or activity of said reporter gene; and

(c) selecting the candidate compound that reduces the expression level or activity of said reporter gene when said marker gene is an up-regulated marker gene selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7), or that enhances the expression level or activity of said reporter gene when said marker gene is a down-regulated marker gene selected from the group consisting of the genes of EC Nos. 1680-1688 (table 6), as compared to an expression level or activity detected in the absence of the candidate compound.

52. A method of treating or preventing esophageal cancer recurrence in a subject comprising administering to said subject an antisense composition, said antisense composition comprising a nucleotide sequence complementary to a coding sequence selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7).

53. A method of treating or preventing esophageal cancer recurrence in a subject comprising administering to said subject an siRNA composition, wherein said siRNA composition reduces the expression of a nucleic acid sequence selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7).

54. A method for treating or preventing esophageal cancer recurrence in a subject comprising the step of administering to said subject a pharmaceutically effective amount of an antibody, or fragment thereof, that binds to a protein encoded by a gene selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7).

55. A method of treating or preventing esophageal cancer recurrence in a subject comprising administering to said subject a vaccine comprising (a) a polypeptide encoded by a nucleic acid selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7), (b) an immunologically active fragment of said polypeptide, or (c) a polynucleotide encoding said polypeptide.

56. A method of treating or preventing esophageal cancer recurrence in a subject comprising administering to said subject a compound that increases (a) the expression of a polynucleotide selected from the group consisting of the genes of EC Nos. 1680-1688 (table 6) or (b) the activity of a polypeptide encoded by said polynucleotide.

57. A method of treating or preventing esophageal cancer recurrence in a subject comprising administering to said subject a pharmaceutically effective amount of an agent comprising (a) a polynucleotide selected from the group consisting of the genes of EC Nos. 1680-

1688 (table 6), or (b) polypeptide encoded by said polynucleotide.

58. A composition for treating or preventing esophageal cancer recurrence, said composition comprising a pharmaceutically effective amount of an antisense polynucleotide or a small interfering RNA against a polynucleotide selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7).

59. A composition for treating or preventing esophageal cancer recurrence, said composition comprising a pharmaceutically effective amount of an antibody, or fragment thereof, that binds to a protein encoded by a gene selected from the group consisting of the genes of EC Nos. 1689-1716 (table 7).

60. A composition for treating or preventing esophageal cancer recurrence, said composition comprising a pharmaceutically effective amount of the compound selected by the method of any one of claims 48-51 as an active ingredient, and a pharmaceutically acceptable carrier.

61. A method for predicting metastasis of esophageal cancer in a subject, the method comprising the steps of:

(a) detecting an expression level of one or more marker genes in a specimen collected from said subject, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1544-1679 (tables 4-5);

(b) comparing the expression level of the one or more marker genes in said specimen to that of a metastasis positive case and metastasis negative case; and

(c) wherein a specimen expression level similar to that of a metastasis positive case indicates a high risk of metastasis of esophageal cancer, and wherein specimen expression level similar to that of a metastasis negative case indicates a low risk of metastasis of esophageal cancer.

62. A method for predicting recurrence of esophageal cancer in a subject, the method comprising the steps of: (a) detecting an expression level of one or more marker genes in a specimen collected from said subject, wherein the one or more marker genes are selected from the group consisting of the genes of EC Nos. 1680-1716 (tables 6-7); (b) comparing the expression level of the one or more marker genes in said specimen to that of a recurrence positive case and recurrence negative case; and (c) wherein specimen expression level similar to that of a recurrence positive case indicates a high risk of recurrence of esophageal cancer, and wherein specimen expression level similar to that of a recurrence negative case indicates a low risk of recurrence of esophageal cancer.

63. A method for diagnosing cancer in a subject, comprising the steps of: (a) collecting a blood sample from a subject to be diagnosed;

(b) determining a level of DKKl in the blood sample;

(c) comparing the DKKl level determined in step (b) with that of a normal control; and

(d) judging that a high DKKl level in the blood sample, compared to the normal control, indicates that the subject suffers from cancer.

64. The method of claim 63, wherein the cancer is esophageal and lung cancer.

65. The method of claim 63, wherein the blood sample is selected from the group consisting of whole blood, serum, and plasma.

66. The method of claim 63, wherein the DKKl level is determined by detecting the DKKl protein in the serum.

67. The method of claim 66, wherein the DKKl protein is detected by immunoassay.

68. The method of claim 67, wherein the immunoassay is an ELISA.

69. The method of claim 67, wherein the immunoassay is sandwich method which uses an anti-DKKl polyclonal antibody as a detection antibody.

70. A kit for detecting a cancer, wherein the kit comprises: (a) an immunoassay reagent for determining a level of DKKl in a blood sample; and

(b) a positive control sample for DKKl .

71. The kit of claim 70, wherein the cancer is esophageal and lung cancer.

72. The kit of claim 70, wherein the positive control sample is positive for DKKl.

73. The kit of claim 72, wherein the positive control sample is liquid form.

74. A positive control blood sample for detecting a cancer, wherein the blood sample comprises more than normal level of both of DKKl .

75. The positive control blood sample of claim 74, wherein the cancer is esophageal and lung cancer.

76. A method for assessing the prognosis of a patient with cancer, which method comprises the steps of: (a) detecting the expression level of DKKl gene in a patient-derived biological sample;

(b) comparing the detected expression level to a control level; and

(c) determining the prognosis of the patient based on the comparison of (b).

77. The method of claim 76, wherein the control level is a good prognosis control level and an increase of the expression level compared to the control level is determined as poor prognosis.

78. The method of claim 77, wherein the increase is at least 10% greater than said control level.

79. The method of claim 76, wherein said method comprises determining the expression level of other cancer-associated genes.

80. The method of claim 76, wherein said expression level is determined by any one method selected from the group consisting of:

(a) detecting mRNA of the DKKl gene;

(b) detecting the DKKl protein; and

(c) detecting the biological activity of the DKKl protein.

81. The method of claim 76, wherein said expression level is determined by detecting hybridization of a probe to a gene transcript of the DKKl gene.

82. The method of claim 81, wherein the hybridization step is carried out on a DNA array.

83. The method of claim 76, wherein said expression level is determined by detecting the binding of an antibody against the DKKl protein as the expression level of the DKKl gene.

84. The method of claim 76, wherein said biological sample comprises sputum or blood.

85. The method of claim 76, wherein the cancer is esophageal and lung cancer.

86. A kit for assessing the prognosis of a patient with cancer, which comprises a reagent selected from the group consisting of:

(a) a reagent for detecting mRNA of the DKKl gene;

(b) a reagent for detecting the DKKl protein; and

(c) a reagent for detecting the biological activity of the DKKl protein.

87. The kit of claim 86, wherein the reagent is an antibody against the DKKl protein.

88. The kit of claim 86, wherein the cancer is esophageal and lung cancer.